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Abstract 
 
 INTRODUCTION: A dysfunction in fatty acid beta-oxidation (β-oxidation), particularly medium chain 
acyl-CoA dehydrogenase (MCAD) dysfunction is a major cause of mortality and its diagnosis is usually 
achieved by measuring specific protein activities or metabolites in blood and/or urine samples. 
However, these methods do not account for secondary defects that accompany primary deficiency; 
such as where measures of disruption in fatty acid metabolism do not account for defects in the TCA 
cycle and oxidative phosphorylation. These metabolic pathways are connected and dysfunction in one 
pathway (primary) could lead to dysfunction in the other (secondary). We propose the use of methods 
that combines all aspects of the bioenergetics module (enzyme activity in substrate oxidation within 
each individual pathway, transfer of electrons through the electron transport system (ETS) and 
oxidative phosphorylation for ATP generation) may be a more effective assessment technique.  High 
resolution respirometry (HRR) is a recently developed technique that accounts for substrate oxidation, 
electron transfer via the ETS and oxidative phosphorylation.  It measures the rate of oxygen 
consumption or flux at different respiratory states when appropriate substrates, uncouplers and 
inhibitors (SUIT protocols) are used. With this method, two substrate combinations are commonly used 
to assess medium-chain fatty acid β-oxidation; a) Octanoylcarnitine and carnitine, which is partial to 
the β-oxidation cycle alone, and b) Octanoylcarnitine and malate, which assesses the influence of the 
TCA cycle. Additionally, a combination of pyruvate, glutamate and malate is used to assess oxidation 
within the TCA cycle. We investigated the sensitivity of commonly used substrate combinations in HRR 
assessment to detect changes in mitochondrial respiration and dysfunction induced by the inhibition 
of either β-oxidation or the TCA cycle in C2C12 myotubes. Furthermore, we assessed MCAD, citrate 
synthase and aconitase enzyme activities when β-oxidation or TCA cycle was inhibited in C2C12 
myotubes.  
 
METHODS: C2C12 myotubes were differentiated for 6 days and treated for 12 hours with a high or a 
low concentration of one of two inhibitors as follows; a) 2 mM or 8 mM 2-mercaptoacetate to inhibit 
medium chain acyl-CoA dehydrogenase (MCAD); b) 6 mM or 9 mM fluorocitrate to inhibit aconitase. 
Each treatment was compared to control myotubes grown for the same length of time without the 
addition of inhibitors. The activities of MCAD, aconitase and citrate synthase were determined. In 
addition, mitochondrial respiration measured as O2 flux at Routine, Leak, OXPHOS and ETS respiratory 
states were assessed in an Oxygraph-2K after inhibition or in control treatments using; i) 
Octanoylcarnitine and carnitine ii) Octanoylcarnitine and malate iii) pyruvate, malate and glutamate 
substrate combinations. For each assessment we corrected O2 flux recorded at each state to; a) 
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approximate number of cells (pmol O2/s/million cells) b) protein concentration (pmol O2/s/mg protein) 
c) Flux control ratio (FCR) of each state to the maximum ETS capacity; ETSFAO+CI+CII (convergent electron 
flow from Fatty acid oxidation (FAO), Complex I (CI) and CII) d) FCR to either FAO-linked ETS capacity; 
(ETSFAO) or CI-linked ETS capacity (ETSCI).  
 
RESULTS: Treatment of cells with either a low or high concentration of 2-mercaptoacetate to inhibit 
MCAD resulted in no significant difference in MCAD activity. Fluorocitrate treatment decreased 
aconitase activity with low treatment (p = 0.011) compared to control, and conversely it increased 
MCAD activity in high treatment compared to control (p = 0.024). Both 2-mercaptoacetate (p = 0.03) 
and fluorocitrate (p < 0.01) treatment at high concentrations resulted in increased citrate synthase 
activity, compared to low concentration and control.  
 
Mitochondrial respiration with octanoylcarnitine and carnitine substrate combination was not altered 
with MCAD or aconitase inhibition. Octanoylcarnitine and malate substrate combination showed a 
decrease in mitochondrial respiration at the following respiratory states with both MCAD and aconitase 
inhibition; Routine (p = 0.01), LeakFAO (p = 0.029), OXPHOSFAO (p = 0.006), ETSFAO (p = 0.008), ETSFAO+CI (p 
= 0.017). FCR of each state to the maximum capacity (ETSFAO+CI+CII) revealed a decrease with both MCAD 
and aconitase inhibition at the following states; routine (p = 0.001), OXPHOSFAO (p = 0.003), ETSFAO (p = 
0.018), ETSFAO+CAR (p = 0.008) and ETSFAO+CI (p = 0.027).  
 
Pyruvate, malate and glutamate substrate combination showed decreased mitochondrial respiration 
with MCAD inhibition at the following respiratory states; Routine (p = 0.004), LeakCI (p = 0.007), 
OXPHOSCI (p = 0.003), ETSCI (p = 0.003), ETSCI+FAO (p = 0.01) and ETSCI+FAO+CII (p = 0.003). FCR of each state 
to the maximum capacity (ETSCI+FAO+CII) decreased with both MCAD and aconitase inhibition at Routine 
(p = 0.024), OXPHOSCI (p = 0.024) and ETSCI (p = 0.035) states.  
 
DISCUSSION: The main finding of this study was related to two of the SUIT protocols 1) octanoylcarnitine 
and malate, and 2) pyruvate, malate and glutamate. These protocols were sensitive in showing 
decreased respiratory capacity and coupling control ratios and may be appropriate for assessing 
changes in oxidative metabolism when there is a defect in β-oxidation and/ or the TCA cycle. On the 
other hand, octanoylcarnitine and carnitine substrate combination is not sensitive to detect dysfunction 
induced by inhibition of either β-oxidation or TCA cycle. Irrespective of the enzyme inhibited, HRR 
detected dysfunction in complex I (CI), although, when aconitase was inhibited, reduced CI-linked 
respiration was more pronounced compared to MCAD inhibition. Furthermore, primary inhibition of 
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MCAD to inhibit β-oxidation may have caused secondary inhibition of TCA cycle via aconitase, shown in 
decreased TCA cycle CI-linked respiration where MCAD was inhibited. In contrast, primary inhibition of 
aconitase seemed to be compensated for by increased MCAD activity and mitochondrial respiration 
related to β-oxidation. Lastly, enzyme assays should not be used as standalone techniques for assessing 
metabolic dysfunction at the level of TCA, β-oxidation and the mitochondria since they are not sensitive 
to low level defects, nor do they account for secondary interactions that influence either TCA or beta-
oxidation. HRR is useful to assess mitochondrial respiration and dysfunction, when using an appropriate 
substrate combination and should be used in combination with the more traditional enzyme activity 
assays. 
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CHAPTER ONE 
Literature Review 
 
1.1 Introduction 
Skeletal muscle is highly dependent on oxidative metabolism via the tricarboxylic acid cycle (TCA) and 
beta-oxidation (β-oxidation). These systems collectively support oxidative phosphorylation (OXPHOS) 
to produce adenosine triphosphate (ATP) necessary for energy production, tissue function and 
thermogenesis (59). Diseases associated with the TCA cycle are rare and often related to dysfunction 
in certain TCA cycle enzymes (96, 126). Conversely, diseases associated with β-oxidation are common 
and relate to defects in proteins required for the transport of fatty acids (FA) into the mitochondrial 
matrix and/or with the chain shortening process itself (107, 170). Although there is a genetic 
component, the most common diseases that cause defects in oxidative metabolism are acquired 
conditions resulting from complications associated with ageing, neurodegenerative diseases, 
cardiovascular diseases, and metabolic syndrome (hypertension, dyslipidemia, insulin resistance, Type 
II diabetes, obesity) (12, 31, 67, 85, 105, 118, 176). These conditions cause a reduction in whole body 
and tissue specific metabolic flexibility, which compromises the ability to adapt to energy demands and 
nutrient availability; further exacerbating the disease and contributing to the development of co-
morbidities (67).  
 
Assessment of dysfunction in either β-oxidation or TCA cycle typically involves measurement of 
accumulating organic acids in blood or urine or the activity of defective enzymes in fibroblasts or muscle 
biopsies (171). However, because β-oxidation, TCA cycle and OXPHOS are connected, dysfunction in 
one pathway (primary) could lead to dysfunction in the other (secondary), which potentially 
complicates assessment (and ultimately treatment) of a primary dysfunction using any of the 
aforementioned methods (21, 47, 105, 107).  We propose that a method that combines all aspects of 
the bioenergetics module, which includes enzyme activity in substrate oxidation within each individual 
pathway, transfer of electrons through the electron transport system and oxidative phosphorylation 
for ATP generation may be a more effective assessment technique.  Correct assessment of dysfunction 
is important because advances in therapeutic treatment of dysfunctions in metabolism have resulted 
from understanding the functional impairment associated with disease pathogenesis (21).  
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This review will firstly provide an overview of oxidative metabolism via the TCA cycle and β-oxidation, 
highlighting existing literature on diseases associated with either pathway as well as the methods 
through which they are assessed. In doing so, we discuss the functional relationship between β-
oxidation, the TCA cycle and oxidative phosphorylation and the importance of a more inclusive method 
of assessment. Accordingly, we present a strategy to induce a dysfunction in β-oxidation and the TCA 
cycle and thus investigate the relationship between the TCA cycle, β-oxidation and oxidative 
phosphorylation in a defective sate. Lastly, we investigate the sensitivity of high resolution respirometry 
(HRR) in detecting alterations in mitochondrial respiration that reflect a dysfunction in β-oxidation 
and/or the TCA cycle.  
 
1.2 Overview of oxidative metabolism within the mitochondria (β-oxidation and TCA cycle and 
oxidative phosphorylation) 
The mitochondrion employs three main enzymatic pathways for energy generation; β-oxidation, the 
TCA cycle and OXPHOS; the connections between these are shown in figure 1.1. β-oxidation accounts 
for the oxidation of FAs of carbon chain-length, 20 or fewer in a series of four reactions that 
consecutively removes two carbon acetyl-CoA units. The complete cycle is illustrated in figure 1.2 (107). 
Briefly, free FAs of different chain lengths are activated to their respective acyl-CoA moieties in the 
cytosol, which allows them to cross the outer mitochondrial membrane into the intermembrane space. 
Acyl-CoAs are then converted into their corresponding acyl carnitine esters by carnitine 
palmitoyltransferase I (CPT I) that aids transport across the inner mitochondrial membrane into the 
matrix (172). Here, they are converted back into their CoA forms by CPT II; using up matrix CoA whilst 
releasing carnitine that is transferred out across the inner membrane by carnitine-acyl carnitine 
translocase (CACT), and acyl-CoA enters the β-oxidation pathway. Acyl-CoAs are degraded in a repeated 
series of four enzymatic reactions; dehydrogenation, hydration, a second dehydrogenation and 
thiolysis. The products being; reducing equivalents (NADH and FADH2) which enter OXPHOS, a 2- carbon 
shortened acyl-CoA that serves as the starting block for the next cycle of β-oxidation and acetyl-CoA 
which is oxidized in the TCA cycle (107). 
 
Acetyl-CoA in the TCA cycle undergoes a progressive sequence of oxidative decarboxylation reactions 
(126). Acetyl-CoA is additionally (mainly) supplied by the breakdown of glucose through glycolysis as 
well as other anaplerotic reactions that supply acetyl-CoA and carbon intermediates of the cycle. The 
TCA cycle consists of 8 enzyme-catalyzed biochemical reactions that generate reducing equivalents 
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NADH and FADH2 that are transferred to the electron transport system (ETS) (96, 126). The complete 
cycle is depicted in figure 1.3.  
 
 
Figure 1.1: Relationship between β-oxidation, TCA cycle and OXPHOS: Fatty acid β-oxidation (Purple) 
generates shortened acyl-CoAs, acetyl-CoA, NADH and FADH2 in four enzymatic reactions. The acetyl-CoA 
produced is utilized by the TCA cycle which also generates more NADH and FADH2. Electrons derived from NADH 
and FADH2 are used by the complexes of the Electron transport system (ETS) in OXPHOS to generate ATP. Flow of 
electrons in the ETS is governed by the increasing order of electronegativity of the complexes. The resulting 
membrane potential generated drives the synthesis of ATP from ADP and inorganic phosphate (Pi). Complex I (CI, 
NAD:ubiquinone oxidoreductase), Complex II (CII, succinate:ubiquinone oxidoreductase), Complex III (CIII, 
ubiquinol: ferricytochrome C oxidoreductase, Complex IV (CIV, cytochrome c oxidase), Complex V (ATP synthase) 
modified from (107) 
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Figure 1.2: Overview of mitochondrial β-oxidation pathway: Degradation of fatty acyl-CoA esters in the matrix 
of the mitochondrion comprises of four reactions (numbered 1-4 in black) that are catalyzed by chain-length 
specific enzymes (chain lengths shown in dark blue). (1) Oxidation of acyl-CoAs into enoyl-CoA by FAD-dependent 
acyl-CoA dehydrogenases: Short-chain (SCAD), medium-chain (MCAD), long-chain (LCAD) and very long-chain 
(VLCAD). (2) Hydration into 3-hydroxyl-CoA by enoyl-CoA hydratase (ECHS) or the single hetero-octamer protein, 
the mitochondrial trifunctional protein (MTP) (3) Dehydrogenation into 3-ketoacyl-CoA by medium/short chain 
hydroxyacyl-CoA dehydrogenase (HADH) or MTP (4) Thiolysis by ketoacyl-CoA thiolase (KAT) or (MTP) to produce 
a 2-carbon shortened acyl-CoA and acetyl-CoA (107). 
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Figure 1.3: Overview of the TCA cycle: Oxidative decarboxylation of acetyl-CoA, reducing equivalents are 
generated that transfer electrons to the ETS to generate ATP; modified from (126). 
 
 
OXPHOS results from coupling of a series of oxidation-reduction reactions within complexes (I-V) 
arranged on the inner mitochondrial membrane that facilitate phosphorylation of ADP to ATP (figure 
1.1). NADH and FADH2 from either β-oxidation or the TCA cycle transfer electrons sequentially to 
molecular oxygen, the final acceptor of electrons attached to the heme group of complex IV. The 
electron pair from FADH2 is transferred to electron transfer flavoprotein (ETF), the Q junction, complex 
III, cytochrome C and finally, complex IV. Moreover, NADH is transferred to the Q junction via complex 
I (49). The sequential transfer of electrons is enabled because complexes are arranged in increasing 
order of electronegativity. Oxygen has the highest electronegativity and is a primary driving force for 
electron flow, in its reduced form it reacts with H+ to form H2O, which detaches from the complex IV 
binding site to allow for another O2 to bind in its place. As electrons are transferred from one complex 
to the next, free energy generated is used to pump protons across the inner mitochondrial membrane 
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by complexes I, III and IV to create a proton motive force. This force is used by ATP synthase (complex 
V) to drive the phosphorylation of ADP and inorganic phosphate to produce ATP (111).  
 
 
 
1.3 Dysfunction of β-oxidation 
 
At least 22 disorders of β-oxidation have been implicated in human diseases, involving transport 
proteins or enzymes of the chain shortening process. (4, 124). Of these, a defect in medium chain acyl-
CoA dehydrogenase (MCAD is reported as the most common, which affects ~1 in every 10,000 births 
in a Caucasian population (120, 170). Disorders affecting β-oxidation typically become apparent during 
specific conditions that stress tissues to increase reliance on β-oxidation. This can occur during fasting, 
mild to moderate prolonged exercise, fever with infection or cold exposure (158). Thus, clinical 
presentation is attributed to energy deficiency in β-oxidation-dependent tissues such as heart, liver and 
skeletal muscle. They are characterized by a spectrum of clinical disorders including; skeletal myopathy, 
progressive lipid storage myopathy, myoglobinuria, neuropathy, progressive cardiomyopathy, 
hypotonia, coma, rhabdomyolysis, exercise intolerance, recurrent Reye-like syndrome alongside 
hypoglycemia, hypoketonemia, hepatic encephalopathy and microvesicular steatosis of the liver and 
other tissues (108, 145, 159, 170)  
 
Genetic abnormalities of β-oxidation normally present in infancy and early childhood; children are less 
able to cope with the high energy demands required during periods of stress (11). This is because they 
have low activity of many key enzymes involved in energy production, a larger brain compared to body 
size that is dependent on glucose metabolism, a larger surface area compared to body mass and hence 
a higher energy requirement to sustain body temperature, which relies on shivering thermogenesis 
provided primarily by fat oxidation(158). The severity of the disease symptom depends on the enzyme 
that is affected or the presence of residual activity (40, 94, 170). Thus some individuals are 
asymptomatic and are suddenly impacted later in life under aggravating conditions (35, 170). In all cases 
the oxidative capacity under challenging conditions is impaired (94).  
 
Interestingly, recent investigations into these disorders revealed complications not attributed to 
defects in the β-oxidation pathway alone. Case reports of patients have demonstrated a complex 
interrelationship between the ETS and the β-oxidation cycle (124). Accordingly, defects in specific β-
oxidation proteins can result in secondary OXPHOS defects (32, 128, 160, 165). Furthermore, 
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mitochondrial dysfunction (mitochondrial alterations and disruption of redox homeostasis) is a 
secondary complication of β-oxidation deficiency, which contributes to the pathophysiology of 
deficiency (36, 41, 104). Two hypotheses are proposed as the cause of secondary defects associated 
with primary β-oxidation defects;  
i) i) sequestration of CoA and the build-up of toxic intermediates resulting from a primary 
defect (47, 136–139, 161): Experimental data demonstrated that toxic metabolites that 
accumulated in FAO disorders caused disruption of mitochondrial homeostasis (deficient 
energy production, oxidative stress) (2, 47, 107, 130, 170). Scaini et al., (2012) investigated 
the in-vitro effects of octanoic acid and decanoic acids (metabolites that accumulate in 
MCAD deficiency) on various bioenergetics and oxidative stress markers, and found that 
these caused decreased activity of complexes I-IV in the liver and inhibited complex IV 
activity in skeletal muscle. Furthermore, they showed increased thiobabituric acid reactive 
substances (TBARS) levels and carbonyl content in both liver and skeletal muscle as well as 
decreased glutathione levels in rat skeletal muscle (47). Another study using blood samples 
from MCAD deficient patients found that parameters of lipid protein oxidative damage 
(sulfhydryl content) was increased and antioxidant defense system (glutathione, 
superoxide, dismutase, catalase activity) was decreased in these patients (36).  
 
 
ii) ii) physical interactions of fatty acid oxidation proteins and OXPHOS complexes, where loss 
of interactions may cause secondary defect and contribute to pathology of the disease (32, 
106, 128, 154, 157, 165). β-oxidation enzymes co-migrating with OXPHOS complexes 
present a physical association of β-oxidation enzymes with OXPHOS complexes. Wang et 
al. (2010) showed that in rat liver mitochondria, fatty acid proteins (VLCAD, ETF, LCHAD 
and MCAD) co-migrated with complex I and I/III/IV OXPHOS super complex with blue native 
polyacrylamide gel electrophoresis and by sucrose density gradients (174). They further 
showed that acyl-CoA substrates (for enzymes; VLCAD, LCAD and MCAD) were metabolized 
in fractions of purified OXPHOS supercomplexes (174). In another study where MCAD 
knockout was generated using 143B osteosarcoma cells, loss of MCAD function was shown 
to be associated with loss of stability of complex I and OXPHOS super complex (86).   
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Overall, a defect in energy efficiency seems to be the most important outcome of β-oxidation disorders, 
where oxidative stress and oxidative damage to proteins may worsen disease presentation, explaining 
why increased feeding or energetic substrate supply does not correct symptoms seen in some cases 
(149). Furthermore, the majority of these studies show the associations between β-oxidation, ETS and 
OXPHOS, and suggest that the function of the TCA cycle may be equally affected. Where β-oxidation is 
defective there is reduced supply of acetyl-CoA to the TCA, aggravating the decrease in reducing 
equivalents that are supplied to the ETS for OXPHOS and ultimately ATP generation (107). Accordingly, 
in β-oxidation defects, there is increased carbohydrate feeding and avoidance of fasting or any stressors 
that increase demand for fat catabolism. However, this does not explain the persistence of symptoms 
found in some cases (107, 149, 158). Notably, oxidative stress is particularly detrimental to Iron-sulphur 
cluster (Fe-S) containing proteins, one of which is aconitase of the TCA cycle (22).  Aconitase can be 
inactivated by oxidative stress limiting the TCA cycle (75, 85). In support of this, Shuck et al (2010), 
showed that in rat brain, cis-4-decenoic acid, a key MCAD deficiency metabolite decreased the activity 
of aconitase as well as TCA-cycle linked respiration (138). Dhami et al. (2018) also showed that aconitase 
knockout proved to be the most lethal deletion of any TCA cycle enzyme, limiting the functioning of the 
entire system (37). Others have also reported that inactivation of aconitase aggravates the negative 
impact of an oxidative environment (27, 37, 112, 177). When aconitase is oxidized, an iron atom is 
released from its active site which in turn catalyzes hemolysis of hydrogen peroxide (H2O2) that 
generate free radicals by the Fenton reaction (27). This further oxidizes mitochondrial proteins, DNA 
and lipids (37, 112, 177). Therefore, where β-oxidation is already defective, aconitase inactivation (or 
inhibition) would worsen the condition. Thus, secondary TCA cycle dysfunction may indeed play a role 
in the pathophysiology of some β-oxidation deficiencies.  However, the effect of direct MCAD inhibition 
or deficiency on the TCA cycle in other tissues such as skeletal muscle is unknown. In summary, primary 
β-oxidation defect may cause secondary, OXPHOS and TCA cycle defect leading to overall mitochondrial 
dysfunction and energy deficiency. 
 
Hence, the implication of secondary dysfunction is the worsening of symptoms where β-oxidation is 
defective (primary dysfunction). Thus, a secondary dysfunction may go undetected since diagnosis of 
disease is mostly associated with measuring characteristic fatty acids as well as their carnitine or glycine 
derivatives that accumulate in blood or urine or assessment of enzyme activity. Indeed, the appropriate 
management of many β-oxidation disorders is hindered by the failure to recognize clear biochemical 
abnormalities (107). Accordingly, correct investigative assessment may offer new perspectives for 
therapeutic intervention. For example, if the extent of oxidative damage to aconitase is a direct 
correlation of MCAD dysfunction, intervention that protects aconitase from oxidative inactivation could 
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improve disease symptoms. Therefore, the effect of MCAD dysfunction (or inhibition) on the TCA cycle 
and especially aconitase is worth further investigation. 
 
1.4 Dysfunction of the TCA cycle 
Unlike β-oxidation, genetic human diseases associated with the TCA cycle are rare (126). These diseases 
are connected with either the inability of pyruvate metabolism to supply acetyl-CoA to the TCA cycle 
for the complete oxidation of carbohydrate or inactivity of enzymes within the TCA cycle to metabolize 
acetyl-CoA (53, 96, 126). Diseases of  the TCA cycle involve deficiency of pyruvate dehydrogenase, 
phosphoenoylpyruvate carboxykinase, dihydrolipoamide dehydrogenase, 2-ketoglutarate 
dehydrogenase, fumarase, succinate dehydrogenase or a combined succinate dehydrogenase and 
aconitase deficiency (53, 57, 96, 126). These deficiencies are associated with altered functioning of the 
central nervous system and neuromuscular system as a result of impaired energy production (20, 96, 
126). The classical features include; encephalopathy, neonatal lactic acidosis, Leighs’s syndrome, 
progressive hypotonia, psychomotor retardation, Kearns-Sayre syndrome, growth retardation, 
pulmonary oedema, muscle weakness, and exercise intolerance to mention a few (20, 96, 126).  
 
1.4.1 The role of β-oxidation and anaplerotic reactions in maintaining energy production in 
primary TCA cycle dysfunction. 
The pattern of disease with TCA cycle dysfunction shows a characteristic organ specific impairment, 
which seems to exclude other organs or tissues (heart, liver or kidney) that are predominantly 
dependent on oxidative metabolism(126). Indeed, we know that β-oxidation is a major fuel source in 
many organs including the heart, liver and skeletal muscle (38, 45, 124) and could explain why patients 
with TCA cycle dysfunction survive or why defects are associated with specific organ/tissue impairment. 
The role of β-oxidation in TCA cycle-associated defects is exemplified in cases of pyruvate 
dehydrogenase deficiency where a ketogenic diet can improve symptoms (122, 146). Wexler et al. 
(1997), showed that the earlier the restriction of carbohydrates the better the outcome of mental 
development and survival (64). In contrast to the idea that β-oxidation may compensate for energy 
deficiency in TCA cycle associated defects, Yudoff et al. (1994) suggests that sustained life is due to the 
TCA cycle being made up of two ‘mini-cycles’ as follows; i) running from oxaloacetate, citrate, isocitrate, 
α-ketoglutarate and back to oxaloacetate, ii) from α-ketoglutarate, succinoyl-CoA, succinate, fumarate, 
malate, oxaloacetate and back to α-ketoglutarate (126). Accordingly, many of the defects that have 
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been found with the enzymes of the TCA cycle involve enzymes limited to either one part of the ‘mini-
cycle’, suggesting that the unaffected ‘mini-cycle’ is bypassed, in part metabolizing pyruvate and 
allowing for cell survival (126). According to the discussion in section 1.3 above, secondary defects in 
the TCA cycle arising from a primary defect in β-oxidation are associated with the ‘first mini cycle’, a 
path that connects reducing equivalents to complex I of the ETS. Where β-oxidation is defective, there 
is reduced acetyl-CoA supply to the TCA cycle as well as likely inhibition of aconitase. The implication 
would be the worsening of energy deficiency and reliance on the ‘second mini cycle’ for energy 
production. However, it remains to be seen what effect the second mini cycle would have on energy 
compensation where β-oxidation is already defective and may not compensate for energy production. 
It is likely that cell survival could result from anaplerotic reactions that supply carbon intermediates 
beyond the point of enzyme defect that allows for TCA cycle metabolism to continue (14). For example, 
in fumarase deficiency the blockade of the TCA cycle may be partially corrected by the transamination 
of α-ketoglutarate into oxaloacetate, thereby allowing pyruvate oxidation (14). To provide more insight 
into the potential supply of carbon intermediates where TCA cycle enzymes are defective, a schematic 
diagram is provided in figure 1.4 (126). Overall, in TCA cycle deficiencies, energy compensation may 
fuel cell survival, however the mechanism, as well as the organ/tissue specifications for compensation, 
is not clear and needs to be further investigated.  
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Figure 1.4 Reactions of the TCA cycle including exogenous supply of TCA cycle carbon intermediates (126) 
 
1.5 Summary: A strategy to investigate the relationship between β-oxidation, TCA cycle and 
OXPHOS by inhibiting key enzymes of β-oxidation or TCA cycle 
 
Conditions that affect energy efficiency and the supply of fuel would cause loss of organ/tissue function 
that would adversely impact the whole body (111). β-oxidation, TCA cycle and oxidative 
phosphorylation are key processes in maintaining energetic homeostasis. Although it is evident that 
defects in these pathways can cause devastating illnesses in humans, however, the relationship that 
exists in an attempt to maintain homeostasis when one pathway is defective is insufficient and requires 
further investigation. 
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MCAD deficiency can elicit devastating effects on the β-oxidation pathway (41, 107, 155, 170). A defect 
in longer chain acyl-CoA dehydrogenases causes an increased supply of medium chain fatty acids to 
bypass the defect, however, during MCAD deficiency there is no bypass. As such, toxic metabolites 
accumulate that exacerbate energy deficiency, cause oxidative stress leading to oxidative damage of 
proteins contributing to the pathology of disease (46, 147–149, 168). The unexplained characteristic in 
many β-oxidation defects including MCAD has led to investigations into the pathophysiology of the 
disease (4, 107, 110, 140). Several studies have shown the impact on energy machinery (including 
OXPHOS and TCA cycle) of toxic metabolites that accumulate where MCAD is deficient (36, 107, 128, 
138). However, to our knowledge no study has investigated the impact of directly inhibiting MCAD on 
β-oxidation, TCA cycle and OXPHOS; the assessment of which may contribute to understanding MCAD 
and β-oxidation dysfunction. To investigate this, 2-mercaptoacetate may be used to inhibit MCAD as it 
has been shown to directly inhibits acyl-CoA dehydrogenases including MCAD (9). Studies using 2-
mercaptoacetate report that inhibition of 2-mercaptoacetate was limited to the acyl-CoA 
dehydrogenase enzyme, but not electron transfer flavoprotein (ETF) or in the transport of fatty acids 
into the mitochondria (7–9). Therefore, the use of 2-mercaptoacetate may be an appropriate model of 
MCAD deficiency. 
 
With regards to the TCA cycle, genetic defects in the pathway are less common, with acquired defects 
being the most important contributors to the dysfunction of the pathway (21, 53, 105, 126). To this 
end, aconitase is suggested as an important enzyme affected under conditions of oxidative stress (5, 
27, 58, 85, 143). Furthermore, aconitase has been implicated in MCAD dysfunction, where its activation 
contributes to worsening energy deficiency (138). Moreover, clarity is lacking into the impact of a TCA 
cycle dysfunction on β-oxidation and OXPHOS. Aconitase may be directly inhibited using fluorocitrate, 
a toxic inhibitor of aconitase (43, 85). Fluorocitrate has been used in many studies to understand the 
impact of energy deficiency seen in some neurological diseases and also in understanding the impact 
of hypoxia on cell physiology (43, 83, 97, 162). Thus, fluorocitrate is ideal for investigating the 
relationship between β-oxidation, TCA cycle and OXPHOS in a TCA cycle defective state. 
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1.6 Commonly used methods for assessing β-oxidation and TCA cycle defects 
The assessment of TCA cycle dysfunction is similar to that of β-oxidation where accumulating organic 
acids in blood or urine samples as well as in fibroblast are assessed by biochemical evaluation, TMS or 
enzymatic analysis (53, 96). These are usually indicative of the point in the pathway where a defect is 
present. The methods used to assess β-oxidation dysfunction have already been extensively reviewed 
(10, 61) and a short summary is provided below: 
 
Enzymology: Classical enzymological determinations involve monitoring the transfer rate of electrons 
from appropriate fatty acyl-CoAs to electron acceptors by enzymes in mitochondrial preparations or 
total cell homogenates using spectrometry or fluorometry (65). For example, in determining the activity 
of acyl-CoA dehydrogenases (enzymes that catalyze the first step of β-oxidation) the rate of re-oxidation 
of the reduced enzyme is measured by monitoring the charge transfer to a suitable electron acceptor 
at a specific wavelength. During β-oxidation, acyl-CoA dehydrogenases are reduced by appropriate acyl-
CoAs and then re-oxidized by FAD+, which donates the electrons to electron transfer flavo protein (ETF) 
in a two-step one electron process. Experimentally, the rate of transfer of electrons to the ETF is a 
measure of the activity of the enzyme. In these reactions, the acyl-CoA dehydrogenases are incubated 
in a reaction mix containing hexafluorophosphate (a commercially available alternative to the ETF) and 
the addition of acyl-CoAs are used to determine the activity of the enzyme at a given wavelength using 
spectrophotometry (80, 172). However, enzyme assays alone may not explain the nature of β-oxidation 
dysfunction that is presented in some scenarios. For example, partial defect in the activity of one 
enzyme may not be reflected on such assays (10). Furthermore, additional steps are required for the 
interpretation and performance of these enzyme assays depending on the nature of the sample. This 
is because there is a distinct overlap between enzymes i.e. between MCAD and SCAD in disrupted cells 
(10). Additionally, measuring the enzyme activity excludes other contributing factors involved in β-
oxidation impairment such as defect in transport proteins or of mitochondrial dysfunction. Enzymology 
is thus used in combination with one or more detection technique/s. 
 
Metabolite method: The production rate of carbon dioxide (CO2) is the end product of complete β-
oxidation and monitored by use of appropriate carbon-radiolabeled fatty acid substrates (4, 63, 68). In 
this method, tissue homogenates or cultured cells are incubated in oxidation reaction medium together 
with 14C-labelled fatty acid, usually palmitate or oleate, for an amount of time at 370C. During 
incubation, the fatty acid is oxidized in the mitochondrion to generate acetyl-CoA, which can then enter 
the TCA cycle and be oxidized to CO2. In addition to CO2, acid soluble metabolites (ASM) such as; acetyl-
carnitine, acetyl-CoA, ketone bodies, glucogenic intermediates and short chain fatty acyl-CoAs (˂C6) 
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can be generated from incomplete oxidation (measured using a scintillation counter). The radioactive 
CO2 and ASMs are measures of fatty acid oxidation (63). Diagnosis of β-oxidation by this method 
assumes that there is an association between the accumulations of specific chain length intermediates 
(ASMs) with the deficiency of a distinct acyl-CoA dehydrogenase (10). This method only provides an 
indication of the presence of dysfunction, but no understanding as to the energy produced from the 
oxidative process or how efficiently oxidation is coupled to energy production. Accordingly, it may be 
used as a confirmation of an already suspected dysfunction.  
 
Tandem mass spectroscopy (TMS): TMS is used to measure the accumulation rate of β-oxidation 
intermediates, usually acyl-carnitines of various lengths. The acyl-carnitine profile obtained is analyzed 
and compared with profiles from samples of known β-oxidation defects (103, 142). However, two 
acylcarnitine compounds may have the same mass but are associated with different conditions, which 
cannot be differentiated using TMS (10). Analysis of urine organic acids may be used to differentiate 
species and identify disease by biochemical evaluation (123, 142). 
 
Biochemical evaluation: This method typically involves acidification of urine, addition of appropriate 
internal standards, extraction into an organic solvent and derivatization, and analysis by gas 
chromatography/electron impact mass spectrometry. It is used for investigating suspected metabolic 
disease in patients presenting a range of clinical symptoms (71). A broad range of metabolites in urine 
are detected using gas chromatography/mass spectrometry. For example, the detection of medium 
chain dicarboxylic acids, produced when flux through β-oxidation pathway is impaired at the level of 3-
hydroxyacyl CoA dehydrogenase or 3-ketoacyl CoA thiolase (10). The limitation of this method is that it 
does not detect longer chain-length dicarboxylic acids that are not found in urine and will hence be 
undetected in cases where these accumulate in disease. This method also relies on detecting 
acylcarnitine profiles by using isotope-labelled internal standards that are not commercially available 
for all acylcarnitine species. Again, this method is restricted to already suspected defects in β-oxidation. 
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1.7 The use of high resolution respirometry for assessing β-oxidation, TCA cycle and Oxidative 
phosphorylation 
 
1.7.1 Principle of respirometry  
Unlike the aforementioned methods which only measure one aspect of metabolism (by product of 
metabolism, intermediates, or enzyme activity), mitochondrial respirometry offers a dynamic 
measurement of metabolic flux rates (114). The principle of respirometry is based on the coupling of 
changes in metabolite levels, membrane permeability, and activity of individual enzymes to oxidative 
phosphorylation (114). As previously mentioned, oxidation of substrates in β-oxidation or TCA cycle 
produces electron carriers, NADH and FADH2 that donate their electrons to complexes of the electron 
transfer system (ETS) (see figure 1.1- 1.3). Oxygen is the major driving force for electron flow and is also 
the ultimate acceptor of electrons. As long as O2 supply is continuous, the flow of electrons along the 
ETS will be maintained. The flow of electrons through the ETS is coupled to the phosphorylation of ADP 
and inorganic phosphate into ATP (51). Hence, if the ADP and O2 are kept constant, the rate of oxygen 
consumption by the mitochondria will be restricted singularly by the rate at which NADH and FADH2 
are supplied from substrate oxidation (in β-oxidation or TCA cycle). This is the underlying principle of 
respirometry; a technique that measures the rate of O2 consumption (or O2 flux) by mitochondria from 
biological samples such as cells, isolated mitochondria and permeabilized tissues or biopsies (49) 
 
1.7.2 Assessment of mitochondrial respiration with high resolution respirometry, HRR 
Recent advancement in respirometry has led to the development of HRR that allows accurate 
measurement of oxygen consumption in very small samples at various respiratory states (e.g. leak, 
intrinsically coupled, pathologically dyscoupled or experimentally non-coupled respiratory states) in an 
Oxygraph (Oroboros-2k) (48, 50). This technology employs sensitive polagraphic oxygen sensors to 
accurately measure the rate of oxygen consumption under controlled conditions that mimic 
physiological conditions of temperature (370C), ionic concentration and substrates availability (15, 62). 
A carefully designed sequence of titrating substrates, uncouplers and inhibitors (SUIT protocols) makes 
possible assessment of rates of oxygen consumption for desired respiratory states (72, 119). For 
example, in intact cells (e.g blood cells, fibroblasts, stem cells, muscle cells etc), it is possible to 
determine routine respiration (physiological resting respiration), uncoupled respiration (when ATP 
synthase is inhibited), and experimentally noncoupled respiration (by titrating non-physiologic 
uncouplers) (166). These are the only respiratory states that can be measured in these cell types 
because the plasma membrane is impermeable to exogenously added ADP and mitochondrial 
substrates (114, 135). Routine respiration here is because of endogenous substrates; as such, the 
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capacity for oxidative phosphorylation cannot be measured (92). However controlled membrane 
permeabilization with an agent such as digitonin allows for entry of exogenous substrates (61, 112, 127, 
147, 149). This permeabilization leads to the loss of cytosolic molecules such as adenylates, substrates 
and cytosolic enzymes making it possible for exogenous substrates to gain access into the mitochondria. 
There is therefore a drop in oxygen consumption from routine state after the addition of digitonin (114). 
This drop is then rescued by the addition of exogenous substrate in leak state (49). 
 
In permeabilized fibers, cells and isolated mitochondria, leak respiration is usually determined at the 
start of the experiment after addition of substrate but not ADP (51, 75). Leak respiration is the non-
phosphorylating resting state of intrinsic uncoupled or dyscoupled respiration when oxygen flux is 
minimized by the back-pressure of a high chemiosmotic potential generated when ATP synthase is not 
active (49, 52). The addition of saturating concentration of ADP activates ATP synthase and stimulates 
oxygen consumption. This rate of oxygen consumption represents the maximum capacity of oxygen 
consumption when substrate oxidation is coupled to phosphorylation of ADP to generate ATP, which is 
referred to as OXPHOS capacity (49, 51). Another leak state of respiration may be induced by titrating 
an inhibitor of ATP synthase such as oligomycin. This leak state measures oxygen consumption due to 
proton leak, electron slip or cation recycling at a maximum membrane potential (51). A low oxygen flux 
at this state indicates that mitochondria maintain a sufficiently high protonmotive force, which restricts 
electron transport, whereas a high flux reflects proton leakiness of the mitochondria. This state is a 
measure of the coupling efficiency of the mitochondrial OXPHOS system. Addition of non-physiologic 
uncouplers at this state induces maximal oxygen consumption and is referred to as ETS capacity. 
Uncouplers, such as FCCP and CCP, are protonophores that allow the movement of protons down a 
concentration gradient (protons move from the intermembrane space into the matrix) and dissipate 
the membrane potential. Dissipation of the membrane potential in this way stimulates maximal activity 
of the ETS to pump H+ back to the intermembrane space, an activity that stimulates electron flow 
through the ETS thus consuming more O2 above OXPHOS. Inhibition of electron flow through the ETS 
by an appropriate inhibitor, allows measurement of residual O2 consumption (ROX). It accounts for O2 
consumed by reactions not associated with the ETS. ROX is used as a correction factor and subtracted 
from ROUTINE, LEAK, OXPHOS and ETS respiratory (50). 
 
The SUIT protocol provides insight into the effects of experimental treatments or disease conditions on 
specific components of the OXPHOS system. SUIT protocols allow for the evaluation of cell viability; 
membrane integrity (cytochrome c release), respiratory inhibition caused by defects in the ETS, 
including respiratory complexes and activities of enzymes and substrate transporters across the inner 
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mitochondrial membrane (49). For example, changes in ETS and OXPHOS capacities recorded after 
exercise training in muscle reflect changes in substrate oxidation and ATP synthesis (169). On the other 
hand, a change in LEAK indicates a change in proton conductance (18, 44, 117). The ratio of different 
respiratory states also yields valuable information regarding respiratory control. For example, the ratio 
of respiration in the coupled state to respiration in the leak state is referred to as the respiratory control 
ratio (RCR) (18, 50) and indicates the ability of the mitochondria to respond to ADP stimulation. A high 
RCR implies that the mitochondria have a high capacity for substrate oxidation and ATP production (51, 
114). HRR can detect small changes in RCR due to experimental treatments or mitochondrial 
dysfunction and hence it an excellent tool for revealing the effects of treatments, diseases or 
adaptations to physiological conditions or stressors.  
 
1.7.3 Sensitivity of substrates used for assessing β-oxidation and TCA cycle with HRR 
Pyruvate, glutamate, malate and succinate are commonly used to reconstitute the TCA cycle function 
in HRR assessment and is depicted in figure 1.5 (51). These substrates are anions that cannot cross the 
lipid membrane and hence their entrance into the inner mitochondria is aided by anion carriers in the 
inner mitochondria membrane (49). Pyruvate, glutamate and malate are NADH generating CI-linked 
substrates, while succinate is directly linked to CII. Together these substrates represent the convergent 
electron flow from CI and CII to the Q-junction and then to CIII and finally CIV of the ETS (51). Because 
pyruvate, glutamate and malate are CI-linked, they were used alone in the past to stimulate CI-linked 
respiration; i.e. either pyruvate, malate or glutamate and succinate for CII. However, the use of any 
substrates alone underestimate OXPHOS capacity. Irrespective, separating CI-linked substrates from 
that of CII or grouping CI-linked substrates allows testing of specific hypotheses in mitochondrial 
research, for example, where a defect in particular enzymes or complex of the ETS is suspected (114).  
 
However, unlike the TCA cycle, there are some uncertainties with assessing β-oxidation using HRR, and 
these issues are discussed below. 
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Figure 1.5: Reconstitution of the TCA cycle using exogenous supplied pyruvate, malate, glutamate and 
succinate (51).  
 
1.8.4 Commonly used substrate combinations for the assessment of β-oxidation by HRR 
Over the years different substrates have been used in assessing β-oxidation. Researchers initially used 
palmitoylcarnitine (long chain fatty acyl-carnitine) alone but there has been a gradual evolution to 
include either malate or carnitine along with palmitoylcarnitine (38, 60, 109, 164). Recently, use of 
octanoylcarnitine (medium chain fatty acyl-carnitine) instead of, or in addition to, palmitoylcarnitine 
has become popular (12, 77, 134). Oxidation of octanoylcarnitine has been found to have an 
approximately equal effect as using palmitoylcarnitine in respirometry determinations (134). 
Octanoylcarnitine and palmitoylcarnitine are active forms of FAs that are able to cross the 
mitochondrial membrane into the matrix where they are broken down to produce acetyl-CoAs, shorter 
chain acyl-CoAs, NADH and FADH2 (6). Acyl-CoAs are recycled back into the β-oxidation cycle for further 
degradation, while FADH2 and NADH feed into the ETS. The acetyl-CoA produced may build up in the 
mitochondrial matrix and inhibits the thiolase reaction of β-oxidation if not continually removed (79). 
Inclusion of malate or carnitine along with palmitoylcarnitine/octanoylcarnitine prevents accumulation 
of acetyl-CoA. Malate is easily transported into the mitochondrial matrix by the dicarboxylate carriers 
(51) and oxidized to oxaloacetate by malate dehydrogenase enzyme. Oxaloacetate reacts with acetyl-
CoA to form citrate which is metabolized in the TCA cycle. Alternatively, carnitine may also be used to 
prevent accumulation of acetyl-CoA when octanoylcarnitine or palmitoylcarnitine are metabolized in 
beta oxidation. Carnitine is transported into the mitochondrial matrix by carnitine - acyl carnitine 
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translocase where it reacts with acetyl-CoA to form acetyl-carnitine that is transported out of the matrix 
via carnitine-acetyl carnitine translocase (6).  
 
1.8.4.1 Palmitoylcarnitine or octanoylcarnitine 
Research conducted by Perevoschika et al. (2013) revealed that oxidation of palmitoylcarnitine alone is 
not sufficient to support respiration as shown by oxygen consumption (115). In this study, isolated rat 
muscle mitochondria were employed to determine the rate of oxygen consumption. Results showed 
that palmitoylcarnitine was unresponsive to ADP and uncoupler titrations. This response was attributed 
to a build-up of acetyl-CoA that inhibits the thiolase reaction in β-oxidation. Other research by Van 
Eunen et al. (2013) verifies that palmitoylcarnitine alone is not sufficient to support beta oxidation (40). 
Using both computational and experimental models involving palmitoylcarnitine oxidation, they 
revealed that the β-oxidation pathway is vulnerable to substrate overload (40). At high palmitoyl-CoA 
concentrations, the shorter CoA esters accumulate (since they are not being utilized in the TCA cycle), 
resulting in a depletion of the CoA pool and preventing further oxidation of acyl-carnitine (40). The 
above observations suggest that use of palmitoylcarnitine/octanoylcarnitine alone for assessing β-
oxidation is not viable and thus researchers have used carnitine or malate in addition to either 
palmitoylcarnitine or carnitine for β-oxidation assessment. 
 
1.8.4.2 Palmitoylcarnitine or octanoylcarnitine plus malate  
Octanoylcarnitine/ palmitoylcarnitine plus malate has been used often as substrate combinations in the 
assessment of β-oxidation. These substrate combinations have been used under a variety of 
physiological conditions. Perevoschika et al. (2013) showed that in mitochondria from skeletal muscle 
of healthy rats, leak respiration after the addition of palmitoylcarnitine and malate was 71 ± 10 nmol 
O/min/mg protein and addition of ADP increased oxygen consumption to 376 ± 28 nmol O/min/mg 
protein. OXPHOS capacity, measured in the presence of octanoylcarnitine and malate, increased from 
76.8 ± 15.6 to 86.3 ± 17.9 pmol/s/mg protein and Flux control ratio (FCR) increased from 1.9 ± 0.6 to 
2.8 ± 0.2 AU in permeabilized fibres from adults after endurance training (116). Bonnard et al. (2008) 
used respirometry to measure changes in mitochondrial function in mice fed a high fat and high sucrose 
(HFHSD) diet for 16 weeks (12). Their results indicated a reduction in OXPHOS capacity and FCR using 
both palmitoylcarnitine + malate and octanoylcarnitine and malate as substrates; indicating that a 
HFHSD diet supressed β-oxidation. Additionally, reduced β-oxidation was not linked to altered 
availability of substrates because genes involved in muscle fatty acid uptake (FAT/CD36) and entry into 
the mitochondria were remarkably increased in the skeletal muscle of the mice. The authors attributed 
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this to excessive reactive oxygen species (ROS) production; treatment with an antioxidant decreased 
ROS production and restored mitochondrial function (12).  
 
Palmitoylcarnitine + malate is favoured as a substrate combination in assessing β-oxidation. It is 
effective in determining changes in OXPHOS capacity that result from different physiologic conditions. 
However, it remains unclear whether the readings recorded are valid measures of β-oxidation, under 
all physiological conditions, due to metabolism of malate. Upon entry into the mitochondrial matrix, 
malate is oxidized to oxaloacetate by malate dehydrogenase in the TCA cycle.  Oxaloacetate condenses 
with acetyl CoA to produce citrate which is further metabolized in the TCA cycle. Thus, the complete 
oxidation of a fatty acid moiety could be calculated as the energy generated as a result of reducing 
equivalents from the β-oxidation pathway itself and from the complete oxidation of acetyl-CoA in the 
TCA cycle. It could therefore be suggested that the rate of β-oxidation (including removal of acetyl-CoA) 
is influenced in part by the TCA cycle.  
 
Remarkably, a computational model of β-oxidation predicts that decreased acetyl-CoA concentration 
should raise the concentration of free CoAs that facilitate continued β-oxidation (40). Conversely, a 
defect in enzymes of the TCA cycle such as, malate dehydrogenase, citrate synthase or aconitase may 
affect the rate of removal of acetyl-CoA contributing to a decline in the rate of β-oxidation (111); this 
however remains to be tested.  Interestingly, there are only a limited number of diseases that are 
associated with primary isolated or multiple defects in TCA cycle enzymes (126). However, as previously 
mentioned, secondary dysfunction in the TCA cycle and especially inactivation of aconitase in many 
primary deficiencies including MCAD dysfunction can inhibit aconitase. This inhibition is likely to reduce 
flux through the TCA cycle and decrease the rate of oxidation of octanoylcarnitine. 
 
Based on the above observations, it can be hypothesized that conditions that affect the metabolism of 
malate in the TCA cycle would reduce the measured oxygen flux, giving a false reading of the rate of β-
oxidation when malate is used as a co-substrate. For example, if a primary MCAD deficiency results in 
the inhibition of aconitase, it would be difficult to differentiate the effect of primary deficiency versus 
secondary. Therefore, it is necessary to evaluate the validity of using acylcarnitine + malate as 
substrates under conditions of mitochondrial dysfunction that arise from TCA cycle defects. 
 
1.8.4.3 Palmitoylcarnitine or octanoylcarnitine plus carnitine 
 It has long been established that long- or medium-chain FAs or their CoA derivatives are only oxidized 
by mitochondria if carnitine is present, whereas their corresponding carnitine esters are excellent 
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substrates by themselves (29, 87). Recent research verified this observation polarographically using 
human muscle mitochondria and myoblasts. They showed that oxidation of palmitoyl-CoA was 
dependent on the presence of carnitine whereas palmitoylcarnitine oxidation occurred in its absence. 
As mentioned earlier, carnitine is needed for transportation of fatty acids into the mitochondrial matrix. 
Inside the mitochondrial matrix, palmitoylcarnitine is converted to palmitoyl-CoA by CPT II. Use of 
optimal concentrations of palmitoyl-CoA and carnitine in these experiments ensure that both 
palmitoylcarnitine and carnitine are present to drive β-oxidation.   
 
Inclusion of carnitine has been shown by several studies to increase palmitoylcarnitine oxidation. The 
effects of carnitine on the metabolism of palmitoylcarnitine was studied by using isolated healthy rat 
liver mitochondria (19). They found that carnitine concentrations less than 1.25 mM resulted in an 
increased production of acetylcarnitine and increased palmitoylcarnitine oxidation. Recently 
Perevoshchikova et al. (2013) measured the rate of oxygen consumption with carnitine + 
palmitoylcarnitine as substrates (167). Oxygen consumption using a polarographic Clark electrode was 
measured from skeletal muscle mitochondria of female Wistar rats. The addition of carnitine (2 mM) 
to palmitoylcarnitine (15 µM) resulted in an increase in basal respiration from an 11 ± 1 to 57 ± 6 nmol 
O/min/mg protein and OXPHOS capacity from 11 ± 1 to 96 ± 15 nmol O/min/mg protein  (115). It has 
been explained that carnitine increases respiration by preventing acetyl-CoA accumulation during 
palmitoylcarnitine oxidation. Carnitine reacts with acetyl-CoA to form acetylcarnitine in a reaction 
catalysed by carnitine acetyltransferase (124). Further research showed that the addition of 2 mM 
carnitine had no significant effect on the oxidation pyruvate/malate and glutamate/malate (TCA cycle 
substrates) but increased oxygen consumption with palmitoylcarnitine. Carnitine increased 
NAD(P)H/NAD(P)+ autofluorescence during palmitoylcarnitine oxidation (141). An increase in NADH 
implies a greater capacity for electrons transfer into the electron transport system, oxygen utilization, 
and ATP production. 
 
Although palmitoylcarnitine (or octanoylcarnitine) plus carnitine is a common substrate used for β-
oxidation assessments, a critical analysis of this substrate combination leads to reservations whether it 
is a true representation of β-oxidation in-vivo. Firstly, β-oxidation produces NADH and FADH2 directly 
and indirectly through acetyl-CoA oxidation by the TCA cycle. Hence the rate of oxygen consumption 
recorded during beta oxidation reflects oxidation of electron carries from both the TCA cycle and β-
oxidation. However, use of palmitoylcarnitine plus carnitine (or octanoylcarnitine) does not account for 
FADH and NADH from acetyl-CoA since carnitine transports the acetyl CoA from β-oxidation out of the 
mitochondria. Therefore, oxygen flux obtained by using the substrate combination is lower than 
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expected from in-vivo assessments. Secondly, the oxidation of palmitoylcarnitine (or octanoylcarnitine) 
requires that there be an existing CoA pool to drive β-oxidation. It is not known whether the rate of 
removal of acetyl-CoA by carnitine sufficiently restores the CoA pool for optimal oxidation of 
palmitoylcarnitine (or octanoylcarnitine). Failure to restore the CoA pool would result in diminished 
oxidation of palmitoylcarnitine and manifest as a decrease in oxygen consumption and would be 
erroneously interpreted as a decreased capacity of the mitochondria to oxidize fatty acids. Therefore, 
the validity of this substrate combination in assessing β-oxidation needs to be further evaluated. 
 
1.9 Aims 
The primary aim of this study was to investigate the sensitivity of commonly used substrate 
combinations in HRR to detect changes in mitochondrial respiration and dysfunction, induced by the 
inhibition of either MCAD or aconitase to limit β-oxidation and the TCA cycle, respectively, in C2C12 
myotubes. 
 
The secondary aim was to investigate the activity of MCAD, citrate synthase and aconitase enzymes 
when MCAD or aconitase is inhibited in C2C12 myotubes and how it relates to β-oxidation and/ or the 
TCA cycle 
 
1.10 Objectives 
To evaluate the effects of low and high concentration inhibition of MCAD (using 2-mercaptoacetate) 
and aconitase (using fluorocitrate) on; 
i. Mitochondrial respiration (β-oxidation & TCA cycle) using HRR, and employing either of 
the following commonly used substrate combinations: 
a) Pyruvate, malate and glutamate 
b) Octanoylcarnitine and malate 
c) Octanoylcarnitine and carnitine 
 
ii. Activity of enzymes; MCAD, aconitase and citrate synthase.  
 
1.11 Hypothesis 
1) MCAD inhibition would reduce MCAD activity and limit β-oxidation, as well as decrease aconitase 
activity whilst increasing citrate synthase activity. Furthermore, MCAD inhibition will reduce 
mitochondrial respiration of the ETS capacity linked to complex I. This would be most significantly 
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shown in the complex I specific substrate combination; pyruvate, malate and glutamate and in the β-
oxidation substrate combination; octanoylcarnitine and malate.   
2) Aconitase inhibition would reduce aconitase activity and limit the TCA cycle, as well as increase 
citrate synthase enzyme activity. Furthermore, aconitase inhibition will reduce mitochondrial 
respiration of the ETS capacity linked to complex I. This would be most significantly shown in the 
complex I specific substrate combination (pyruvate, malate and glutamate) and to a lesser extent in the 
substrate combination that most closely links beta-oxidation and the TCA cycle (octanoylcarnitine and 
malate).  
3) The substrate combination octanoylcarnitine and carnitine will have limited sensitivity in MCAD and 
aconitase inhibition.  
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CHAPTER TWO 
 Materials and Methods 
 
2.1. Justification for the use of a cell culture model  
C2C12 cells, a sub clone of the mouse myoblast cell line is widely used in various studies (24, 26, 42, 89, 
98, 144).These cells readily proliferate in high-serum conditions and differentiate at low-serum 
conditions into extensive contracting muscle-like myotubes that express characteristic skeletal muscle 
proteins and properties. The ability to differentiate into myotubes is an important characteristic of 
C2C12 cells as an in-vitro model of skeletal muscle, and it is appropriate for investigating complex 
biochemical, molecular or pathological adaptations that occur in skeletal muscle (82, 100, 144, 178). 
The cells were obtained from the American Type Culture collection (Manassas VA, USA). 
 
2.2 Experimental logistics and design 
An overview of the experimental logistics and design is provided in figure 2.2 with detailed description 
provided below. 
 
2.3 Experimental Protocols 
2.3.1 Cell culture  
All tissue culture was performed under BIOflow II Labotec laminar flow (Midrand, South Africa). C2C12 
adherent myoblasts were grown on 50 ml tissue culture flasks with filtered caps (Greiner Bio-one, 
GMBH, Frickenhausen, Germany) containing growth medium. The growth medium comprised of 7 ml 
Dulbecco’s Modified Eagles Medium (DMEM++) (Sigma-Aldrich, St. Louis, MO) containing 25 mM 
glucose and supplemented with 1% antibiotic (10000 U/ml penicillin, 100000 μg/ml streptomycin) 
(Gibco, Paisley, Scotland) and 10% Fetal Bovine Serum (FBS) (Life technologies, Carlsbad, Canada). The 
cultures were maintained in a humidified incubator (Labotec, USA) at 370C and 5% CO2. Growth medium 
was changed every 2 days. Myoblasts were routinely passaged once 70-80% confluency was reached 
and were sub cultured in a 1:4 split ratio. The cells were observed at critical time intervals, such as the 
undifferentiated stage and at day 2, 4, 6, 7 and 10 of differentiation (figure 2.1) with a Zeiss Stemi 305 
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stereo microscope and photographed with a digital camera, Zeiss, AuxioCam ERc5s (Zeiss, Oslo, 
Norway). 
 
2.3.2. Trypsinization 
Trypsin-EDTA, 0.25% (Gibco, Paisley, Scotland) was used to dislodge anchorage-dependent cells once 
cells reached 70 – 80% confluency. Trypsinization was performed as follows: 
DMEM++ was aspirated from the adherent cells. Thereafter, cells were washed with 5 ml of Phosphate-
Buffered Saline (0.01 M Phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium chloride, pH 
7.4 at 250C) (Sigma-Aldrich, St. Louis, MO) and 1 ml of concentrated Trypsin-EDTA was added to 
trypsinize the cells. The cells were immediately incubated for ~2 min at 370C and fresh DMEM++ was 
added to inactivate trypsin action. The cell suspension was transferred to a 15 ml falcon tube and 
centrifuged (1500 g, 250C for 4 min) using a micro centrifuge (Heraeus instruments, Newton, CT USA) 
to obtain pellets.  
 
2.3.3 Cell Passage 
The pellets obtained after trypsinization were carefully re-suspended in DMEM++. To achieve a split 
ratio of 1:4, a pellet from a single flask was re-suspended in 4 ml DMEM++ and 1 ml of cell suspension 
was added to 4 flasks each containing 6 ml of DMEM++. For all experiments, cells were maintained at a 
passage number of 7. 
 
2.3.4. Differentiation 
To induce differentiation to form multinucleated myotubes, cultured cells were allowed to reach ≥90% 
confluence in the growth medium. The growth medium was then replaced with a differentiation 
medium (DMEM with supplemented 2% Horse serum, 1% antibiotic-10000 unit/ml penicillin and 10000 
µg/ml streptomycin) and changed every 48 hours for seven days prior to treatment. From day 8 post 
differentiation we observed gradual increase in cell death and hence all treatment was done at day 7 
post differentiation (figure 2.1).    
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2.3.5. Mycoplasma Test 
Mycoplasma tests (30) were routinely performed to verify that cells were not contaminated. Cells were 
cultured in DMEM++ until 70-80% confluence was reached and thereafter trypsinized (section 2.3.2). 
The resulting pellets were re-suspended in penicillin and streptomycin free media and plated onto a 
cover slip in a 30 mm tissue culture dish. These cells were maintained in the antibiotic free medium for 
3-5 days (humidified incubator at 370C and 5% CO2). On the day of the test, cells that had been growing 
on coverslips were washed with PBS and fixed with glacial acetic acid: methanol (1:3) for 5 min. 
Thereafter, the fixative was removed and the coverslip air dried for 3 min, followed by staining with 0.5 
μg/ml Hoechst solution (Hoechst 33342, trihydrochloride, trihydrate) in the dark for 10 min. Stained 
cells were then washed three times with PBS. The cover slip was mounted with Mowiol 4-88 
(Calbiochem, San Diego, USA) onto a glass slide, and visualized on the phase contrast microscope, 
Axiovert 200 M microscope (Zeiss, Oslo, Norway). Images were taken using an AxioCamHR camera with 
Axiovision software (Version 4.7, Zeiss, Oslo, Norway). Stained nuclei appeared blue and spots around 
the nuclei indicated mycoplasma contamination. Further experiments were only performed upon 
confirmation that the cells were mycoplasma negative.  
 
       
      
 Figure 2.1: Changes in cell morphology in response to myogenic differentiation in control C2C12 cells. 
Light microscope images of C2C12 cells before and after induction of differentiation at 70% confluency with DMEM 
containing 2% horse serum. Cells reach 70% confluency approximately 24 hours after seeding cells onto a tissue 
70% confluency Day 2 Day 4 
Day 6 Day 7 Day 10 
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culture flask. The cells are spindle-shaped, replication increases with time till the tissue culture flasks is fully 
saturated with cells at Day 2. Cells fuse together to form elongated and branched multi-nucleated myotubes; 
increasing with number of days till after the 8th day, where they start to gradually die off (Day 10). Cells were 
treated with inhibitors on the 7th day after differentiation was initiated. 
 
2.3.6 Treatment regime 
A defect in β-oxidation was induced by selective inhibition of MCAD using 2-mercaptoacetate (7, 16, 
81), while fluorocitrate was used to inhibit aconitase of the TCA cycle (43, 78, 83, 175).  
 
2-mercaptoacetate (Thioglycolic acid; Sigma-Aldrich, St. Louis, MO) was reconstituted in water up to a 
final concentration of 1 M at pH 7. DL-Fluorocitric acid barium salt (Fluorocitrate; Sigma-Aldrich, St. 
Louis, MO, USA) was activated and corrected to the purity of the powder according to a protocol by 
Tremblay et al. (2005) (163) Barium fluorocitrate (82.86 mg) was dispersed in 1 ml deionised water to 
which 50.2 μl of 37% HCl was added to dissolve the powder. Thereafter, 42.6 mg sodium sulphate and 
31.8 mg anhydrous sodium carbonate were added to the barium solution. The insoluble barium 
sulphate was removed by centrifugation (2000 g, 5 min) and the test solution was prepared to a 
concentration of 0.1 M in water at 7 pH. Both inhibitors were further re-diluted in differentiation media 
(DMEM supplemented with 2% horse serum and 1% antibiotic) to their final concentrations. 
 
2.3.7. MTT Proliferation Assay 
This assay was used to determine effective concentrations and treatment times of inhibitors. Initially, 
2-mercaptoacetate was reconstituted in DMEM to a final concentration of 0.25, 0.5, 1, 2, 4, 6, 8, 10 and 
20 mM and fluorocitric acid to 0.025, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1 and 2 mM. Concurrently, other cells 
(controls) were grown without the addition of the inhibitors to DMEM. All cells were plated at a density 
of 3 x 103 cells/well in a 96 well plate (90 μl cell suspension in DMEM++ per well) and incubated at 37°C 
in a 5% CO2 incubator. Cell proliferation and differentiation was initiated as previously described 
(section 2.3.4). On day 7 of differentiation, sample wells containing myotubes were treated with 10 μl 
of the respective concentration of either 2-mercaptoacetate or fluorocitric acid for either 4, 12 or 24 
h. After treatment, 10 μl of MTT reagent (100 mg/20 ml 1 XPBS) was added to both sample and blank 
wells for 4 h before adding the solubilizing reagent (25 g sodium lauryl sulphate, 250 ml distilled water, 
76.6 μl 37% HCL) for overnight incubation (Appendix 1).  
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Absorbance was measured at 595 nm using a micro plate reader (Biotek® instruments Inc. Winooski, 
USA) in conjunction with the Gen 5 Data analysis software (version 2.01, Biotek® instruments Inc. town, 
USA). The dose response curve was determined using Graph Pad-Prism software (version 5, Los 
Angeles, USA).  Inhibition was achieved after 12 h of treatment and was used for subsequent 
experiments. To determine the optimum inhibitory concentration cells were incubated with increasing 
concentrations of the inhibitors for 12 h treatment. The cells were inhibited by 2-mercaptoacetate 
treatment from 1 – 10 mM. Fluorocitric acid treatment resulted in decreased proliferation from 2 mM 
and above. We further examined the effect of an increase in the concentration of fluorocitric acid on 
cell proliferation. There was a decrease in proliferation from 2 – 10 mM of fluorocitric acid. Hence, we 
chose to treat with a low or high concentration of either inhibitor as follow; 2 mM and 8 mM of 2-
mercaptoacetate, and 6 mM and 9 mM of fluorocitric acid for 12 h in all subsequent experiments. 
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Day 1-5: Passage 5-7; seeding, growing and passaging cells. 
 
Day 6: Passage 7: cells are ≥ 90% confluent; initiation of differentiation 
 
Day 7 – 13: cells have differentiated for 7 days 
 
Day 13: Treatment: 12 hours 
 
 
                                
 
 
 
 
 
 
Figure 2.2: Experimental design. C2C12 cells were grown till a passage number of 7 (1x106 cells), after which 
they were differentiated into myotubes for 7 days. On the 7th day, myotubes were treated with a low or high 
concentration of either inhibitor for MCAD or aconitase versus vehicle for 12 hours. Thereafter flasks were pooled 
together and separated for use in either high resolution respirometry (HRR) or for protein extraction. For all 
experiments, 2 technical repeats and 3 biological repeats was employed. Octanoylcarnitine (Oct), malate (Mal), 
carnitine (Car), pyruvate (Pyr), glutamate (Glut) 
 
Inhibition of MCAD using 2-
mercaptoacetate 
(Versus control) 
Inhibition of Aconitase using 
fluorocitric acid 
(Versus control) 
OR 
Day 14: Experiments 
 
HRR HRR PROTEIN EXTRACTION PROTEIN EXTRACTION 
(Frozen at -800C) 
 
(Frozen at -800C) 
 
c 
Bradford 
Aconitase activity assay 
MCAD activity assay 
Citrate synthase activity assay 
Bradford 
Aconitase activity assay 
MCAD activity assay 
Citrate synthase activity assay 
c 
Oct + Mal 
Oct + Car 
Pyr+Mal+Glut 
c c 
Oct + Mal 
Oct + Car 
Pyr+Mal+Glut 
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2.3.8 Protein assays 
2.3.8.1 Protein extraction 
Protein was extracted from each flask containing myotubes. They were first washed with PBS, scrapped 
off the bottom of the flask using a NuncTM cell scraper (ThermoFischer Scientific) into another 5 ml PBS. 
The suspension containing myotubes was transferred to a clean 15 ml falcon tube which was 
centrifuged at 1500 g, for 3 mins at 250C. Thereafter, the supernatant was discarded and pellets 
obtained. The pellets were re-suspended in 150 μl of ice cold extraction buffer (containing 0.1 M Tris-
HCL, 15 mM tricarballylic acid, final pH 7.8) (173), transferred to a clean 1.5 ml microfuge tube and 
homogenised on ice. Homogenisation was achieved by sonicating at 80 HZ for 3 x 10 s bursts (Qsonica 
sonicator, Newton, CT, USA). The homogenates were left on ice for 20 min followed by centrifugation 
(13000 g 40C and 20 min). The supernatant containing lysate was collected and stored at -800C until 
further analyses. 
 
2.3.8.2 Protein determination 
The protein concentration of all previously frozen lysates was measured using the Bradford protocol 
(17). Briefly, lysates were re-diluted (1:1) in extraction buffer; 10 ul of diluent was added to 250 ul of 
Bradford reagent (Bradford reagent was purchased from Sigma-Aldrich Co®. St. Loius, USA) and the 
absorbance measured at 595 nm using a microplate reader (Biotek® instruments Inc. Winooski, USA). 
BSA was used to make standards of known concentration and the protein concentration was 
determined from BSA standard curve. The unknown protein concentration (mg) was calculated using 
the formula; 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑢𝑛𝑘𝑛𝑜𝑤𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 𝑋 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛
𝑆𝑙𝑜𝑝𝑒 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑐𝑢𝑟𝑣𝑒
 
 
 
2.3.8.3 MCAD activity 
The assay was performed according to modifications to a procedure (173). Briefly, MCAD activity was 
determined spectrophotometrically by monitoring the decrease in ferrocenium ion absorbance at 300 
nm using an extinction coefficient of 4300 M-1. The reaction medium (0.24 ml final volume, 7.4 pH) 
contained: 100 mM potassium phosphate (KH2PO4), 1mM EDTA, 0.5mM sodium tetrathionate, 0.0716 
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mM ferrocenium hexafluorophosphate (Sigma-Aldrich Co®. St. Loius, USA) and 10 µl C2C12 homogenate 
(1.2-3.6 mg/ml protein). The reaction was started by addition of 104.2 mM octanoyl-CoA. Absorbance 
measurements were made on a microplate reader (Biotek® instruments Inc. USA) for ~30 min with 
absorbance read every 5 min (Appendix 4). Microsoft Excel (2012) was used to draw a standard curve 
of known ferrocenium hexafluorophosphate concentrations. Reaction rates were calculated from the 
linear portions of the absorbance versus time plots and the following formula applied to get the specific 
activity (µmol/min/mg Protein) of MCAD in each sample; 
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑋 𝑠𝑙𝑜𝑝𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
𝑠𝑙𝑜𝑝𝑒 𝑜𝑓 𝑆𝑇𝐷 𝑐𝑢𝑟𝑣𝑒 𝑋 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
 
 
In initial experiments with controls, we used the acyl-CoA dehydrogenase reaction medium as 
described by Wang et al. (2013) (173) which followed modifications to a method by Lehman and co-
workers (80). This included, 10 µl of sample homogenate, 500 µl of reaction mix containing 100 mM 
KH2PO4, 1 mM EDTA, 0.5 mM sodium tetrathionate and 200 µM ferrocenium hexafluorophosphate, pH 
7.4 to which 50 µl of 0.5 mM octanoyl-CoA was added. The decrease in absorbance at 300 nm was 
measured over 5 min in a UV/vis spectrophotometer (Beckman Coulter, Fullerton, CA, USA) and activity 
was then determined by multiplying the slope to the molar concentration constant for ferrocenium 
hexafluorophosphate (4300 M-1). Under these conditions the rate of reduction in our C2C12 myotubes 
were found to follow no trend after 5 min. We then switched to determining the activity of MCAD in a 
microplate reader (Biotek® instruments Inc. Vermont, USA), after first determining the absorbance of 
standards of known ferrocenium hexafluorophosphate concentrations. A trend towards linearity in 
MCAD activity was observed at a lower concentration of 71.6 µM of ferrocenium hexafluorophosphate. 
We therefore decided to study the effect of increasing the concentration of octanoyl-CoA on the 
linearity of the enzyme assay with time, at 71.6 µM of ferrocenium hexafluorophosphate. Linearity was 
optimal at higher octanoyl-CoA concentrations for ~30 min (figure 2.3). Our results showed that MCAD 
activity with octanoyl-CoA as substrate was best measured at an acyl-CoA concentration of 104.2 mM 
(based on the concentration of acyl-CoA that resulted both in the highest activity of MCAD as well as 
sample volume with the least standard error). We measured MCAD activities in C2C12 myotubes of all 
treated and control samples using these optimized conditions. 
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Figure 2.3. The activity of Medium chain acyl-CoA dehydrogenase (MCAD) in control C2C12 myotubes 
relative to Octanoyl-CoA concentrations (104.2, 160.7, 106.4, 163.6 and 86.2 mM). 
 
2.3.8.4 Aconitase activity 
Protocol was adapted from Gardener et al. (1992) (43). Briefly, aconitase activity was measured by 
monitoring the increase in absorbance at 340 nm, 250C. The reaction medium (total volume 0.25 ml, 
7.4 pH) contained: 50 mM Tris-Buffer, 2 mM Tri-sodium citrate, 0.5 mM MgCl2, 0.2 mM β-NADP+, 1.5 
U/ml isocitrate dehydrogenase. The reaction started by adding 15 µl of sample homogenate containing 
protein. Absorbance measurements were made on a microplate reader (Biotek® instruments, Vermont, 
USA) every 60 s for at least 1 h (Appendix 3). Reaction rates were calculated from the linear portions of 
the absorbance versus time plots. Microsoft excel was used to draw a standard curve of known NADPH 
concentrations and the following formula applied to get the specific activity (µmol/min/mg protein) of 
aconitase in each sample; 
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑋 𝑠𝑙𝑜𝑝𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
𝑠𝑙𝑜𝑝𝑒 𝑜𝑓 𝑆𝑇𝐷 𝑐𝑢𝑟𝑣𝑒 𝑋 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
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To determine the best assay conditions, we initially studied the effect of altered concentration of the 
sample on the linearity of aconitase activity over 2 h in control cells. Increasing sample concentrations 
resulted in a proportional increase in linearity with time. Linearity reduced after ~ 1 h (figure 2.4) and a 
mid-point was identified (15 µl sample in a total reaction volume of 250 µl, measured over 1 h). These 
optimized conditions (based on both sample economy and sample volume that resulted in the highest 
aconitase activity) were used to determine aconitase activity for all control and treated myotubes. 
 
 
Figure 2.4: The activity of aconitase in control C2C12 myotubes relative to sample volume 
 
2.3.8.5 Citrate synthase  
This was completed according to a modified protocol by Kohn et al. (2007) (69). The activity of citrate 
synthase was determined by monitoring the increase in fluorescence of NADH at 250C, every 30 s for 5 
min. The reaction mix (total volume 0.26 ml, pH 8) contained 0.1 M Tris-buffer, 2.5 mM EDTA, 0.5 mM 
NAD+, 1 mM L-malate and 8 μg/ml malate dehydrogenase was added to 10 μl sample and 5 μl acetyl-
CoA (Appendix 5). Reaction rates were calculated from the linear portions of the absorbance versus 
time plots. Microsoft Excel (2012) was used to draw a standard curve of known NADH concentrations 
and the following formula applied to get the specific activity (µmol/min/mg protein) of citrate synthase 
in each sample; 
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𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑋 𝑠𝑙𝑜𝑝𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
𝑠𝑙𝑜𝑝𝑒 𝑜𝑓 𝑆𝑇𝐷 𝑐𝑢𝑟𝑣𝑒 𝑋 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
 
 
 
2.3.9 Respirometry 
The rate of mitochondrial respiration in C2C12 myotubes was measured using Oxygraph-2K High 
resolution respirometry (Oroboros® instruments, Innsbruck, Austria). A substrate-uncoupler-inhibitor 
titration (SUIT) protocols was applied as previously described (102). This oxygraph has two chambers, 
equipped with a Peltier thermostat, electromagnetic stirrers and a gas-tight stopper ensuring minimum 
oxygen diffusion between the chamber solution and surroundings. Oxygen concentration (μmol/L) in 
the chamber and oxygen flux (pmol O2/s/million cells) were recorded using DatLab software (Version 
7.3, Oroboros instruments, Innsbruck, Austria). Standard instrumental calibrations were performed 
timeously (≥ 3 months) to correct for instrumental background oxygen flux, which accounts for the 
back-diffusion of oxygen into the chamber from the various components; leak from the exterior, the 
chemical medium and sensor (48). Air calibration of the oxygen sensors was performed daily and before 
each experiment to account for the partial pressure of air and the medium (51)  
 
On each day of experiment, cells were scrapped into 5 ml PBS and pellets obtained after centrifugation 
(1500 g, 250C, 3 mins) The pellets were then re-suspended in 2.3 ml of respiration buffer, MIR05 
(containing 0.5 mM EGTA, 3 mM MgCl2, 20 mM taurine, 10 mM KHPO4, 20 mM HEPES, 200 mM sucrose, 
0.1% BSA, final pH 7.1) (114). Two millilitres of the cell suspension was added to an oxygraph chamber 
(1x106 cells). Immediately, the chamber was hyper-oxygenated to a concentration of 450-500 μmol/L 
and the oxygen flux allowed to stabilize. Once oxygen levels were stabilised a state of routine respiration 
(physiological resting respiration) was recorded. The cell membrane was then permeabilized with 2 μl 
of digitonin (final concentration of 10 mg/ml DMSO; Appendix 2). This concentration was evaluated in 
optimization experiments to achieve full permeabilization of cells to allow for easy access of substrates 
and ADP into the mitochondria without compromising the membrane integrity and mitochondrial 
function. A sequence of defined respiratory states  (oxygen flux resulting from titration of specific 
substrates) were induced experimentally by stepwise titration according to the following SUIT protocols 
(51): 
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2.3.9.1 SUIT Protocol 1: Respiration with octanoylcarnitine + malate 
Octanoylcarnitine and malate (0.2 mM and 0.5 mM, respectively) were added to initiate leak respiration 
(non-phosphorylating resting state as a result of proton leak or slip). Thereafter, maximum oxidative 
phosphorylation (OXPHOS) was induced by addition of ADP (5 mM). Cytochrome C (10 μM) was added 
to check the integrity (<10% change in oxygen flux) of the outer mitochondrial membrane (72). The 
contribution of β-oxidation to the maximum capacity of the ETS was determined by titrating 1 μL (0.05 
μM) of chemical uncoupler, CCCP (carbonyl cyanide m-chlorophenyl hydrazine) in stepwise additions 
until no further increase in respiration was observed. This was closely followed by addition of pyruvate 
(5 mM) and glutamate (10 mM) to obtain the contribution of complex I to the maximum capacity and 
afterwards 10 mM of succinate for a convergent Complex I and II linked respiration. Lastly, 2.5 μM of 
antimycin A, an inhibitor of complex III was added to produce a state of residual oxygen consumption 
(ROX) to estimate oxidative side reactions. During the course of the experiment oxygen was added to 
the chambers where necessary to maintain a concentration of 450-250 μmol/l.  
 
2.3.9.2 SUIT Protocol 2: Respiration with octanoylcarnitine + carnitine 
In separate experiments, all steps of the suit protocol 1 (presented above) was administered. However, 
leak respiration was initiated with octanoylcarnitine (0.2 mM) and carnitine (2 mM).  Maximum 
Complex I-linked ETS capacity was measured by titrating 5 mM of pyruvate, 0.5 mM of malate and 
10mM of glutamate in succession. 
 
2.3.9.3 SUIT Protocol 3: Mitochondrial respiration with pyruvate +malate 
TCA cycle-linked leak respiration was initiated by titrating 2 mM of pyruvate, 0.5 mM of malate and 10 
mM of glutamate. This was followed by ADP (2 mM), cytochrome C (5 μM), and 0.05 μM steps of CCCP 
for maximum capacity of the Complex I-linked ETS. To determine the contribution of β-oxidation-linked 
substrate to ETS, octanoylcarnitine and carnitine (0.2 mM and 2 mM, respectively) was added. This was 
followed by 10 mM succinate for Complex II-linked ETS and 2.5 μM of antimycin A for ROX. 
 
On completion of each respirometry assessment, the most stable portion of the oxygen flux/slope was 
selected at each respiratory state. Experiments that did not meet the criteria for stability of oxygen flux 
across respiratory states, cell viability and membrane integrity (cytochrome c release) were excluded 
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from statistical analysis. Thereafter, oxygen flux was corrected for ROX and normalized to protein 
concentration (mg) and approximate cell number (million cells; number of cells present in cell culture 
dish before differentiation into myotubes; as it is not possible to obtain cell number after they have 
fused into myotubes). Flux control ratios (FCR) were calculated as the ratio of each respiratory state to 
the maximum capacity as well as to maximum FA-linked or Complex I-linked respiration. (50). Lastly, 
the ratio of LEAK state to OXPHOS states were calculated.  
 
2.4 Statistical analysis 
Three biological repeats and two technical repeats were employed for each experimental 
determination. Statistical analysis was performed using IBM SPSS statistics software (Version 25) and 
graphical representation was made using GraphPad Prism (version 8.0.2, GraphPad Software inc., La 
Jolla, Ca, US). Data were first checked for normality using the Shapiro-Wilks test. Normally distributed 
data are presented as mean ± standard deviation. Statistical differences between control and treatment 
groups within each protocol were determined using repeated measures ANOVA using group and 
treatment concentration as main effects and interaction. Paired t-test were used to explore differences 
within each group. Statistical significance was accepted as p<0.05.  
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CHAPTER THREE 
Results 
3.1 The effect of inhibition on enzyme activities  
We determined the effect of specific enzyme inhibition on the activities of MCAD, aconitase and citrate 
synthase. Where MCAD was inhibited, it was firstly important to evaluate the effect of inhibition on the 
targeted enzyme and additionally to investigate the effect of β-oxidation inhibition on the activity of 
TCA cycle enzymes. We equally measured the activity of aconitase, MCAD and citrate synthase where 
MCAD or aconitase was respectively inhibited. 
 
3.1.1 MCAD activity  
MCAD activity for MCAD and aconitase inhibition are shown in figure 3.1 A and B, respectively. No 
significant alteration in MCAD activity was observed with either high or low concentration of MCAD 
inhibitor (p > 0.05; figure 3.1A). However, MCAD activity was increased with high concentration of 
aconitase inhibitor compared to control (p = 0.024; figure 3.1B). 
 
3.1.2 Aconitase activity assay 
Aconitase activity for MCAD and aconitase inhibition are shown in figure 3.1 C and D, respectively. We 
observed a trend towards a main effect of concentration (p = 0.059) where aconitase was inhibited. 
Post hoc analysis revealed a significant decrease in aconitase activity with aconitase inhibition in the 
low treatment compared to control (p = 0.011). No significant change in aconitase activity was observed 
where MCAD was inhibited. 
 
3.1.3 Citrate synthase activity assay 
Citrate synthase activity where MCAD or aconitase was inhibited is shown in figure 3.1 E and F, 
respectively. MCAD inhibition showed a significant increase in citrate synthase activity with high 
concentration treatment compared to control (p = 0.03) and low treatment (p = 0.015). Similarly, 
aconitase inhibition showed an increase in citrate synthase activity with both low (p = 0.001) and high 
(p < 0.001) concentration treatment groups, compared to control. Additionally, a trend towards 
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increased citrate synthase activity was observed in high compared to low treatment with aconitase 
inhibitor (p = 0.053). 
 
 
FIGURE 3.1: The effect of MCAD and aconitase inhibition on MCAD, aconitase and citrate synthase 
activities respectively. A, C, E are enzyme assays where MCAD was inhibited while B, D, F are enzyme assays 
where aconitase was inhibited. All data reported as mean ± standard deviation. * P < 0.05, ** P < 0.01*** P < 
0.001. 
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3.2 The effect of enzyme inhibition on mitochondrial respiration 
 
3.2.1 The effect of enzyme inhibition on mitochondrial respiration using octanoylcarnitine and 
malate as substrates. 
 
Figure 3.2. Representative trace for a high resolution respirometry protocol with octanoylcarnitine and 
malate substrate combination. Graph represents oxygen (O2) concentration (blue line [µM] and changes in 
Oxygen flux (red line; [pmol/(s*million cells)]) with time (h: min) in a single oxygraph chamber (oroboros-2K; 
Oroboros instruments; Austria). ADP (Adenosine di phosphate), CCCP (carbonyl cyanide m-chlorophenyl 
hydrazone), OXPHOS (oxidative phosphorylation), ETS (electron transport system), ROX (residual oxygen 
consumption). 
 
3.2.1.1 The effect of MCAD inhibition 
Mitochondrial respiration was normalised to the approximate number of cells (pmol O2/s/million cells) 
and results are shown in figure 3.3A. There was a main effect of concentration at all respiratory states 
except ROX as follows:  Routine (p = 0.01), LeakFAO (p = 0.029), OXPHOSFAO (p = 0.006), ETSFAO (p = 0.008), 
ETSFAO+CAR (p = 0.009), ETSFAO+CI (p = 0.017), ETSFAO+CI+CII (p = 0.012). At routine respiration, O2 flux 
decreased in low treatment compared to control (p = 0.023). OXPHOSFAO significantly decreased in the 
high treatment compared to control (p = 0.048) with a trend to decrease in the low treatment group 
compared to control (p = 0.056). Likewise, there was a trend towards decreased at ETSFAO in low 
treatment compared to control (p = 0.067). ETSFAO+CI+CII significantly decreased in high treatment 
compared to control (p = 0.044) and low treatment (p = 0.009).  
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Oxygen flux normalised to protein concentration (pmol O2/s/mg protein) are shown in figure 3.3B. This 
provided a more accurate estimation of mitochondrial respiration, accounting for cell loss through 
enzyme inhibition. There was a main effect of concentration at routine state alone, however, post hoc 
analysis revealed no significant difference in O2 flux with increased inhibition. There was no main effect 
or interaction effect for all other respiratory states (p > 0.05). 
 
Flux control ratios (FCR) at all respiratory states relative to ETSFAO+CI+CII or ETSFAO are shown in figure 3.4A 
and B, respectively. There was a main effect of concentration at routine, OXPHOSFAO, ETSFAO, ETSFAO+CAR 
and ETSFAO+CI FCR. FCR for routine respiration decreased in low treatment compared to control (p = 
0.002) and increased in high treatment compared to both control (p = 0.006) and low treatment (p = 
0.003). OXPHOSFAO FCR decreased in both low (p = 0.013) and high (p = 0.023) treatment compared to 
control. Lastly, FCR decreased in low treatment compared to control for both ETSFAO (p = 0.028) and 
ETSFAO+CAR (p = 0.037). FCR of all respiratory states relative to ETSFAO showed no significant main effect, 
however, a trend at ETSFAO+CI was observed (p = 0.052). Finally, we measured the coupling control ratio 
of LeakFAO to OXPHOSFAO; no significant main effect with MCAD inhibition was observed (figure 3.5) 
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Figure 3.3: The effect of MCAD inhibition on O2 flux with octanoylcarnitine and malate as substrates. A) O2 
flux corrected to approximate number of cells (pmol O2/s/million cells). B) O2 flux corrected to protein concentration 
(pmol O2/s/mg protein). FAO (fatty acid oxidation), OXPHOS (Oxidative phosphorylation), ETS (Electron transport 
system), CI (Complex I), CII (Complex II), car (Carnitine), ROX (Residual oxygen consumption). All data reported as 
mean ± standard deviation; N= 3; *p ˂ 0.05, **p ˂ 0.01. 
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Figure 3.4: The effect of MCAD inhibition on flux control ratio (FCR) with octanoylcarnitine and malate as 
substrates. Diagram shows flux control ratios (FCR) normalized relative to A) maximum ETS capacity (ETSFAO+CI+CII) 
as a result of convergent electron flow from fatty acid oxidation (FAO), Complex I (CI) and complex II (CI) B) ETS 
capacity as a result of FAO (ETSFAO). ETS (Electron transport system), OXPHOS (Oxidative phosphorylation). All data 
reported as mean ± standard deviation; n = 3; *p ˂ 0.05, **p ˂ 0.01. 
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Figure 3.5: The effect of MCAD inhibition on LeakFAO/OXPHOSFAO coupling control ratio with 
octanoylcarnitine and malate as substrates. All data reported as mean ± standard deviation; n = 3. 
 
3.2.1.2 The effect of aconitase inhibition 
Respiration normalised to approximate number of cells (pmol O2/s/million cells) and protein 
concentration (pmol O2/s/mg protein) are shown in figure 3.6 A and B, respectively. There was a main 
effect of concentration in O2 flux (pmol O2/s/million cells) at the following respiratory states; Routine 
(p = 0.01), LeakFAO (p = 0.029), OXPHOSFAO (p = 0.006), ETSFAO (p = 0.008). Routine respiration significantly 
decreased in the high treatment compared to control (p = 0.032), however, the decrease in the low 
treatment compared to control (p = 0.088) and in the high compared to low treatment (p = 0.074) was 
not significant. LeakFAO decreased in high treatment compared to control (p = 0.047). Similarly, 
OXPHOSFAO decrease in high treatment compared to both control (p = 0.042) and low treatment (p = 
0.037). Although not significant, there was a trend towards decreased O2 flux at ETSFAO in high compared 
to low treatment (p = 0.066). Routine respiration (pmol O2/s/mg protein) revealed a main effect of 
concentration (p = 0.037). There was a decreased flux in the high treatment compared to low treatment 
(p = 0.042), but there was a trend towards a decrease in the low treatment compared to control without 
reaching significance (p = 0.058).  
 
 The FCR relative to maximum capacity of the ETS (ETSFAO+CI+CII) or ETSFAO are shown in figure 3.7 A and 
B, respectively. There was a main effect of concentration at routine (p = 0.001), OXPHOSFAO (p = 0.003), 
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ETSFAO (p = 0.018), ETSFAO+CAR (p = 0.008) and ETSFAO+CI (p = 0.027). Routine FCR was significantly 
decreased in both low (p = 0.009) and high (p = 0.004) treatment compared to control; however, there 
was a trend to decrease in the high compared to low treatment (p = 0.055).  OXPHOSFAO FCR decreased 
in the high treatment compared to control (p = 0.006) and low treatment (p = 0.046). Additionally, 
ETSFAO showed a trend to decrease in the low (p = 0.054) and high (p = 0.05) treatment compared to 
control. Post hoc analysis revealed no significant change in FCR at ETSFAO+CAR and ETSFAO+CI. Finally, we 
measured the coupling control ratio of LEAKFAO to OXPHOSFAO. No significant main effects (p = 0.121 
concentration; p = 0.703 treatment) or interaction (p = 0.699) was shown with aconitase inhibition 
(figure 3.8). 
 
3.2.1.3 Differences between aconitase inhibition and MCAD inhibition 
There was an interaction effect between aconitase inhibitor treatment and MCAD inhibitor treatment 
at Routine respiration (pmol O2/s/million cells; p = 0.037), however, this interaction was driven by a 
significant effect of concentration within groups and no difference between treatment groups (p > 
0.05). Furthermore, O2 flux normalised to protein concentration (pmol O2/s/mg protein) showed a main 
effect of treatment at Routine respiration (p = 0.037). Post hoc analysis did not reveal any significant 
difference with inhibitor treatment. The FCR calculated to ETSFAO+CI+CII showed interaction effects of 
routine (p < 0.001), LeakFAO (p = 0.013) and OXPHOSFAO (p = 0.015). Routine respiration showed a 
difference between aconitase treatment and MCAD treatment at high concentration (p = 0.040). 
LeakFAO and OXPHOSFAO showed no difference between aconitase and MCAD treatment concentrations 
(all p > 0.05). Therefore, the interactions were driven by significant changes within each treatment 
group. Lastly, there was an interaction effect in ETSFAO+CI to ETSFAO ratio (p = 0.017). Similarly, the 
interaction effects were driven by the significant effect of concentration within the groups. 
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Figure 3.6: The effect of aconitase inhibition on O2 flux with octanoylcarnitine and malate as substrates. 
A) O2 flux corrected to approximate number of cells per oxygraph chamber (pmol O2/s/million cells) B) O2 flux 
corrected to protein concentration (pmol O2/s/mg protein). FAO (fatty acid oxidation), OXPHOS (Oxidative 
phosphorylation), ETS (Electron transport system), CI (Complex I), CII (Complex II), ROX (Residual oxygen 
consumption). All data reported as mean ± standard deviation; n= 3; *p ˂ 0.05. 
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Figure 3.7: The effect of aconitase inhibition on flux control ratio (FCR) with octanoylcarnitine and malate 
as substrates. Diagram shows flux control ratios (FCR) normalized relative to A) maximum ETS capacity 
(ETSFAO+CI+CII) as a result of convergent electron flow from fatty acid oxidation (FAO), Complex I (CI) and complex II 
(CI) B) ETS capacity as a result of FAO (ETSFAO). ETS (Electron transport system), OXPHOS (Oxidative 
phosphorylation). All data reported as mean ± standard deviation; n = 3; *p ˂ 0.05, **p ˂ 0.01. 
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Figure 3.8. The effect of aconitase inhibition on LeakFAO/OXPHOSFAO coupling control ratio with 
octanoylcarnitine and malate as substrates. All data reported as mean ± standard deviation; n = 3 
 
 
3.2.2 The effect of enzyme inhibition on mitochondrial respiration using octanoylcarnitine and 
carnitine as substrates. 
 
Figure 3.9. Representative trace for a high resolution respirometry protocol with octanoylcarnitine and 
carnitine substrate combination. Graph represents oxygen (O2) concentration (blue line [µM] and changes in 
Oxygen flux (red line; [pmol/(s*million cells)]) with time in a single oxygraph chamber (oroboros-2K; Oroboros 
instruments; Austria). ADP (Adenosine di phosphate), CCCP (carbonyl cyanide m-chlorophenyl hydrazone), OXPHOS 
(oxidative phosphorylation), ETS (electron transport system), ROX (residual oxygen consumption). 
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3.2.2.1 The effect of MCAD and aconitase inhibition 
Mitochondrial respiration using octanoylcarnitine and carnitine substrate combination are shown in 
figures 3.10-3.15. MCAD and aconitase inhibition showed no main effect or interaction (p>0.05) for 
most respiratory states when respiration was normalised to cell number (pmol O2/s/million cells), 
protein concentration (pmol O2/s/mg protein), and FCR. The only observed change was a main effect 
of concentration when FCR was calculated to maximum ETS capacity for FAO alone (ETSFAO; p = 0.04) at 
LeakFAO state. There was a significant increase in the low treatment compared to control when MCAD 
(p = 0.017; figure 3.11B) and aconitase were inhibited (p = 0.001; figure 3.15 B).  
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Figure 3.10: The effect of MCAD inhibition on O2 flux with octanoylcarnitine and carnitine as substrates. 
A) O2 flux corrected to approximate number of cells per oxygraph chamber (pmol O2/s/million cells) B) O2 flux 
corrected to protein concentration (pmol O2/s/mg protein). FAO (fatty acid oxidation), OXPHOS (oxidative 
phosphorylation), ETS (Electron transport system), CI (Complex I), CII (Complex II), ROX (Residual oxygen 
consumption). All data reported as mean ± standard deviation; n= 3. 
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Figure 3.11: The effect of MCAD inhibition on Flux control ratio (FCR) with octanoylcarnitine and carnitine 
as substrates. Diagram shows flux control ratios (FCR) normalized relative to A) maximum ETS capacity 
(ETSFAO+CI+CII) as a result of convergent electron flow from fatty acid oxidation (FAO), Complex I (CI) and complex II 
(CI) B) ETS capacity as a result of FAO (ETSFAO). ETS (Electron transport system), OXPHOS (Oxidative 
phosphorylation). All data reported as mean ± standard deviation; n = 3; *p ˂ 0.05. 
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Figure 3.12: The effect of MCAD inhibition on LeakFAO/OXPHOSFAO coupling control ratio with 
octanoylcarnitine and carnitine as substrates. All data reported as mean ± standard deviation; n = 3. 
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Figure 3.13: The effect of aconitase inhibition on O2 flux with octanoylcarnitine and carnitine as substrates. 
A) O2 flux corrected to approximate number of cells per oxygraph chamber (pmol O2/s/million cells) B) O2 flux 
corrected to protein concentration (pmol O2/s/mg protein). FAO (fatty acid oxidation), OXPHOS (oxidative 
phosphorylation), ETS (Electron transport system), CI (Complex I), CII (Complex II), ROX (Residual oxygen 
consumption). All data reported as mean ± standard deviation; n= 3. 
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Figure 3.14: The effect of aconitase inhibition on flux control ratio (FCR) with octanoylcarnitine and 
carnitine as substrates. Diagram shows flux control ratios (FCR) normalized relative A) maximum ETS capacity 
(ETSFAO+CI+CII) as a result of convergent electron flow from fatty acid oxidation (FAO), Complex I (CI) and complex II 
(CI) B) ETS capacity as a result of FAO (ETSFAO). ETS (Electron transport system), OXPHOS (Oxidative 
phosphorylation). All data reported as mean ± standard deviation; n = 3; **p ˂ 0.005. 
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Figure 3.15: The effect of aconitase inhibition on LeakFAO/OXPHOSFAO coupling control ratio with 
octanoylcarnitine and carnitine as substrates.  All data reported as mean ± standard deviation; n = 3. 
 
3.2.3 The effect of enzyme inhibition on mitochondrial respiration using pyruvate, 
malate and glutamate as substrates. 
 
 
Figure 3.16. Representative trace for a high resolution respirometry protocol with pyruvate, malate and 
glutamate substrate combination. Graph represents oxygen (O2) concentration (blue line [µM] and changes in 
Oxygen flux (red line; [pmol/(s*million cells)]) with time in a single oxygraph chamber (oroboros-2K; Oroboros 
instruments; Austria). ADP (Adenosine di phosphate), CCCP (carbonyl cyanide m-chlorophenyl hydrazone), OXPHOS 
(oxidative phosphorylation), ETS (electron transport system), ROX (residual oxygen consumption). 
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3.2.3.1 The effect of MCAD inhibition 
Oxygen flux normalised to the approximate amount of cells (pmol O2/s/million cells) are reported in 
figure 3.17 A. A main effect of concentration at all respiration states are as follows: Routine (p = 0.004), 
LeakCI (p = 0.007), OXPHOSCI (p = 0.003), ETSCI (p = 0.003), ETSCI+FAO (p = 0.01) and ETSCI+FAO+CII (p = 0.003). 
LeakCI (p < 0.001), OXPHOSCI (p = 0.002), ETSCI (p = 0.022) and ETSCI+FAO (p = 0.022) decreased in high 
compared to low treatment. Lastly, ETSCI+FAO+CII decreased in high treatment compared to both control 
(p = 0.028) and low treatment (p = 0.008). Oxygen flux adjusted to protein concentration (pmol O2/s/mg 
protein) are reported in figure 3.17 B. There was a main effect of concentration at Routine (p = 0.005), 
ETSCI (p = 0.006) and ETSCI+FAO (p = 0.022). ETSCI (p = 0.024) and ETSCI+FAO (p = 0.037) significantly 
decreased in the low treatment compared to control. 
 
The flux control ratios of each respiratory state to ETSCI+FAO+CII or ETSCI are shown in figure 3.18 A and B, 
respectively. There was a main effect of concentration at Routine (p = 0.024) and OXPHOSCI (p = 0.024) 
to ETSCI+FAO+CII. We observed a trend for decreased routine FCR with high compared to low treatment (p 
= 0.06), while OXPHOSCI decreased in the high compared to low treatment (p = 0.022). Lastly, LeakCI to 
OXPHOSCI ratio indicated a main effect of concentration (p = 0.036), however, post-hoc analysis showed 
no significant difference with increasing inhibitor concentration (figure 3.19). 
 
 
 
 
 
 
74 
 
      
Figure 3.17: The effect of MCAD inhibition on O2 flux with pyruvate, malate and glutamate as substrates. 
A) O2 flux corrected to approximate number of cells per oxygraph chamber (pmol O2/s/million cells) B) O2 flux 
corrected to protein concentration (pmol O2/s/mg protein). FAO (fatty acid oxidation), OXPHOS (Oxidative 
phosphorylation), ETS (Electron transport system), CI (Complex I), CII (Complex II), ROX (Residual oxygen 
consumption). All data reported as mean ± standard deviation; n = 3; *p ˂ 0.05, **p ˂ 0.01, ***p ˂ 0.001. 
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Figure 3.18: The effect of MCAD inhibition on flux control ratio (FCR) with pyruvate, malate and glutamate 
as substrates. Diagram shows flux control ratios (FCR) normalized relative to A) maximum ETS capacity 
(ETSCI+FAO+CII) as a result of convergent electron flow from Complex I (CI), fatty acid oxidation (FAO) and complex II 
(CI) B) ETS capacity as a result of CI (ETSCI). All data reported as mean ± standard deviation; n = 3; *p ˂ 0.05. 
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Figure 3.19: The effect of MCAD inhibition on LeakCI/OXPHOSCI coupling control ratio with pyruvate, malate 
and glutamate as substrates.  All data reported as mean ± standard deviation; n = 3. 
 
3.2.3.2 The effect of aconitase inhibition 
Respiration normalised to the million cells (pmol O2/s/million cells) are displayed in figure 3.20 A. There 
was a main effect of concentration at all respiration states except ROX as follows: Routine (p = 0.004), 
LEAKCI (p = 0.007), OXPHOSCI (p = 0.003), ETSCI (p = 0.003), ETSCI+FAO (p = 0.01) and ETSCI+FAO+CII (p = 0.003).  
Routine respiration was significantly decreased in both low (p = 0.022) and high (p = 0.009) treatment 
compared to control. Likewise, LEAKCI and OXPHOSCI decreased in high treatment compared to control 
(p < 0.05) and low treatment (p < 0.05). ETSCI decreased in high (p = 0.024) and low (p = 0.013) treatment 
compared to control. ETSCI+FAO decreased in the low treatment compared to control (p = 0.015), and, a 
trend towards decreased flux was observed in high treatment compared to controls (p = 0.065). 
Additionally, a trend towards decreased flux was also observed in the high compared to low treatment 
at ETSCI+FAO+CII (p = 0.054). 
 
Oxygen flux at each respiratory state corrected to protein concentration (pmol O2/s/mg protein) are 
shown in figure 3.20 B. Results show a main effect of concentration at Routine (p = 0.005), ETSCI (p = 
0.006) and ETSCI+FAO (p = 0.022). Routine respiration was significantly decreased in low treatment 
compared to control (p = 0.045) but only a trend towards decrease in the high treatment compared to 
control (p = 0.057). ETSCI, decreased in low treatment compared to control (p = 0.036). There was a 
trend towards decreased flux at ETSCI+FAO in low treatment compared to controls (p = 0.063) 
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The FCR of each respiratory state to the maximum capacity of the ETS (ETSCI+FAO+CII) are shown in figure 
3.21 A. There was a main effect of concentration at Routine (p = 0.024), OXPHOSCI (p = 0.024) and ETSCI 
(p = 0.035). Routine FCR decreased in the low treatment compared to control (p = 0.01), however, only 
a trend towards a decrease was observed in the high compared to low treatment (p = 0.068). OXPHOSCI 
decreased in the high treatment compared to control (p = 0.045) and low treatment (p = 0.005). 
Similarly, ETSCI decreased in both low (p = 0.009) and high (p = 0.03) treatment, compared to control. 
 
The FCR of each respiratory state to the maximum capacity of the ETS due to CI contribution alone 
(ETSCI) are displayed in figure 3.21 B. There was a main effect of concentration at ETSCI+FAO+CII. There was 
a significant increase in both the low (p = 0.008) and high (p = 0.035) treatment compared to control. 
There was a trend towards an increase in the high compared to low treatment (p = 0.06). Finally, there 
was a main effect of concentration in the LEAKCI to OXPHOSCI ratio, however, there was no significant 
effect of treatment concentration (figure 3.22). 
 
3.2.3.3 Differences between aconitase inhibition and MCAD inhibition 
There was a main effect of treatment when respiration was corrected to millions of cells (pmol 
O2/s/million cells) at ETSCI (p = 0.026). At low inhibitor concentration, O2 flux was decreased with MCAD 
compared to aconitase inhibition (p = 0.015), however only a trend towards a decrease between groups 
was observed at high concentration (p = 0.055). When FCR was calculated to the maximum capacity of 
the ETS, ETSCI+FAO+CII; we observed an interaction effect for LeakCI FCR (p = 0.018) and ETSCI FCR (p = 
0.046); conversely there was a main effect of treatment for OXPHOSCI (p = 0.046), ETSCI (p = 0.003) and 
ETSCI+FAO (p = 0.008). ETSCI FCR was decreased in MCAD compared to aconitase inhibition at both low (p 
= 0.008) and high (p = 0.012) concentration. Similarly, ETSCI+FAO FCR was decreased with MCAD inhibition 
compared to aconitase inhibition at both low (p = 0.005) and high (p = 0.02) concentration. Lastly, FCR 
calculated to the maximum capacity for complex I alone (ETSCI) showed a main effect of treatment for 
LeakCI (p = 0.032), OXPHOSCI (p = 0.027) and ETSCI+FAO+CII (p = 0.041). There was a decreased FCR in MCAD 
compared to aconitase inhibition at low concentration for LeakCI (p = 0.025), OXPHOSCI (p = 0.002) and 
ETSCI+FAO+CII (p = 0.01). 
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Figure 3.20: The effect of Aconitase inhibition on O2 flux with pyruvate, malate and glutamate as 
substrates.  A) O2 flux corrected to approximate number of cells per oxygraph chamber (pmol O2/s/million cells) 
B) O2 flux corrected to protein concentration (pmol O2/s/mg protein). FAO (fatty acid oxidation), OXPHOS (Oxidative 
phosphorylation), ETS (Electron transport system), CI (Complex I), CII (Complex II), ROX (Residual oxygen 
consumption). All data reported as mean ± standard deviation; n = 3; *p ˂ 0.05, **p ˂ 0.01. 
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Figure 3.21: The effect of aconitase inhibition on flux control ratio (FCR) with pyruvate, malate and 
glutamate as substrates. Diagram shows flux control ratios (FCR) normalized relative to  A) maximum ETS 
capacity (ETSCI+FAO+CII) as a result of convergent electron flow from Complex I (CI), fatty acid oxidation (FAO) and 
complex II (CI) B) ETS capacity as a result of CI (ETSCI). All data reported as mean ± standard deviation; n = 3; *p ˂ 
0.05, **p ˂ 0.01. 
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Figure 3.22: The effect of aconitase inhibition on LeakCI/OXPHOSCI coupling control ratio with pyruvate, 
malate and glutamate as substrates. All data reported as mean ± standard deviation; n = 3. 
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CHAPTER FOUR 
Discussion 
This thesis investigated alterations in the activity of specific enzymes and in mitochondrial respiration 
during the selective inhibition of rate limiting enzymes of either β-oxidation or the TCA cycle. 
Furthermore, we assessed the sensitivity of three different HRR protocols in detecting β-oxidation and 
TCA cycle dysfunction when the rate limiting enzymes were inhibited. The main finding of this study 
was related to two of the SUIT protocols 1) octanoylcarnitine and malate, and 2) pyruvate, malate and 
glutamate. These protocols were sensitive in showing decreases in mitochondrial respiration and 
dysfunction and may be appropriate for assessing changes in oxidative metabolism when there is a 
defect in β-oxidation and the TCA cycle. Secondly, enzyme assays may not be used as a standalone 
technique for assessing mitochondrial dysfunction and should be used to complement the results 
obtained from HRR, when using an appropriate substrate combination. Additionally, octanoylcarnitine 
and carnitine substrate combination is not a sensitive SUIT protocol to assess alterations in 
mitochondrial respiration when rate limiting enzymes are inhibited. Irrespective of the enzyme 
inhibited, HRR detected dysfunction in complex I (CI). Although, when aconitase was inhibited reduced 
CI-linked respiration was more pronounced when compared to MCAD inhibition. Lastly, primary 
inhibition of MCAD to inhibit β-oxidation may have caused secondary inhibition of TCA cycle via 
aconitase, shown in decreased TCA cycle, CI-linked respiration where MCAD was inhibited. In contrast, 
primary inhibition of aconitase seemed to be compensated for by increased MCAD activity and 
mitochondrial respiration related to FAO oxidation. These results are novel as they explore the effect 
of β-oxidation dysfunction on the TCA and vice versa in C2C12 myotubes using HRR. 
 
4.1 Effect of MCAD inhibition on enzyme activity determined by spectrophotometric assay 
In this study, treatment of C2C12 myotubes with either a low (2 mM) or high (8 mM) concentration of 
2-mercaptoacetate to inhibit MCAD did not significantly alter MCAD activity assessed using the classic 
spectrophotometric assay that employed ferrocenium ion as electron acceptor (figure 3.1A). Other 
studies have shown that 2-mercaptoacetate does indeed reduce the activity of acyl-CoA 
dehydrogenases (ACAD) including MCAD (7–9, 16, 81, 95). Previously, Bauchѐ et al. (1983) found a 16%, 
36% and 63% inhibition of palmitoyl-CoA, butryl-CoA and isovaleryl-CoA with 25 µM of 2-
mercaptoacetate, respectively (9). More recently, 2 mM and 4 mM of 2-mercaptoacetate inhibited acyl-
CoA dehydrogenase shown by reduction in CO2 produced from [1-14C] oleate in lung adenocarcinoma 
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cells (81). To our knowledge, the present study is the first to assess the effect of 2-mercaptoacetate on 
MCAD activity in skeletal muscle. One critical observation made with this study was the effect of high 
inhibitor concentration on cell viability. We observed that cells lifted off the tissue culture dish and were 
lost in the washing process when myotubes were treated for 12 hours. Thus, the results obtained here 
may be a reflection of partial inhibition in the remaining surviving myotubes. Nevertheless, it has been 
reported that measurement of MCAD activity via this method may be confounded by residual activity 
that produce false results even where MCAD is clearly deficient. For example, where genetic testing has 
revealed anomalies in enzymes of β-oxidation or where specific circulating metabolites of incomplete 
β-oxidation have been found (65, 133, 156). Residual activity is as a result of compounds such as free 
CoA that contain a free SH-group that can reduce ferricenium ion directly resulting in artificial high rates 
of reaction (80). To solve this problem, some researchers have added N-ethylmaleimide to their 
incubation medium; N-ethylmaleimide reacts with SH-group competing with free CoA, balancing out 
the unusual high rates of reaction when MCAD activity is assessed (65). However, addition of N-
ethylmaleimide to mitochondrial matrix pre-exposed to 2-mercaptoacetate resulted in the reversion of 
inhibitions of palmitoyl-CoA, isovaryl-CoA and butryl-CoA dehydrogenations (7). Accordingly, its 
addition was omitted in our protocol, which may have caused increased variability in the results through 
an artificial amplification of MCAD activity. These results highlight the limitation of using the classic 
spectrophotometric enzyme assay in assessing MCAD activity. 
 
Despite the unaltered MCAD activity with inhibition obtained in the spectrophotometric assay, we were 
able to confirm that 2-mercaptoacetate indeed influenced the C2C12 myotubes, as we found increased 
activity of citrate synthase with both low and high concentration treatment of MCAD inhibitor (figure 
3.1E). In this study it was essential to measure the activity of citrate synthase as it is an important 
marker of mitochondrial function, biogenesis and a key enzyme of the TCA cycle (73, 75). However, 
increased citrate synthase activity was not accompanied by changes in aconitase activity, which may 
have indicated upregulation of the TCA cycle. We may therefore conclude that increased citrate 
synthase activity was not due to increased oxidative metabolism within the TCA cycle. In fact, we 
hypothesise that MCAD inhibition may result in partial loss of TCA cycle function from the simultaneous 
inhibition of aconitase. One effect of MCAD inhibition (or deficiency) is the accumulation of toxic β-
oxidation metabolites (varied chain length of free fatty acids and their acyl-CoA and acyl-carnitines 
derivatives) that are significant contributors to oxidative stress. Aconitase is very sensitive to oxidative 
stress and can be inhibited when oxidative stress is induced in the mitochondria. In view of this, Schuk 
et al. (2010) showed that aconitase is inactivated by cis-4-decenoic acid, a representative toxic MCAD 
metabolite resulting from MCAD deficiency (138). Even though, we recorded no change in aconitase 
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activity where MCAD was inhibited using the enzymatic spectrophotometric assay, we show reduced 
TCA cycle CI-linked respiration where MCAD is inhibited (Section 3.2.3.1, figure 3.17), which may have 
been due to attenuation of aconitase activity. In support of this, where aconitase was directly inhibited 
we show similar pattern of decreased TCA cycle CI-linked respiration (Section 3.2.3.2, figure 3.20). Thus 
the reflected lack of significant change in aconitase activity where MCAD was inhibited may be as a 
result of the limitation of the sensitivity of the spectrophotometric assay. Overall, primary inhibition of 
MCAD to limit β-oxidation may have caused secondary inhibition of the TCA cycle via aconitase. 
 
Citrate produced from increased citrate synthase activity would largely exit the mitochondria into the 
cytosol and cause a decrease in aconitase activity (75). To our knowledge no study has shown a 
concurrent increase in citrate synthase activity with β-oxidation inhibition. A possible consequence of 
decreased oxidative metabolism (inhibition of β-oxidation and possibly TCA cycle) may be increased 
activation of glycolysis, which may in part account for increased citrate synthase activity because of 
increased substrate supply from glycolysis. In fact, glycolytic and oxidative metabolic pathways are 
tightly coupled and function to maintain the cellular energetic balance (25). Many studies have shown 
that glycolysis is inhibited by oxidation of fatty acids and particularly by medium chain fatty acids in 
muscle and other tissues where it constitutes a glucose sparing process (99, 153). Therefore, when 
oxidation of medium chain fatty acid is inhibited (and the resultant inactivation of the TCA cycle), 
glycolysis may be activated as an alternative fuel source.  Although, the glycolytic pathway is less energy 
efficient, it has been shown that glycolysis is enhanced to compensate for energy production where an 
oxidative pathway is weakened (179). Indeed, we showed that both β-oxidation and TCA cycle linked 
respiration are attenuated with 2-mercaptoacetate treatment to inhibit MCAD. Accordingly, 
compromised oxidative metabolism (catabolic reaction of β-oxidation and TCA cycle) may have resulted 
in increased involvement of the glycolytic pathway to restore homeostasis. Assessing the effect of 
MCAD inhibition on glycolytic enzymes or on the pathway itself was beyond the scope of this study and 
future research is required to test this hypothesis. 
 
Regardless of the potential shift to support more glycolysis to restore energy balance, it seems this is 
not sufficient energy to support body/organ function, which is indicated by the extreme clinical 
manifestation particularly with MCAD deficiency (34, 41, 158, 159). Perhaps an important consideration 
to the consequence of dysfunction maybe tissue specific, as tissue or organs have different energy 
requirements. However, where β-oxidation is defective, the level of contribution from the glycolytic 
pathway to restore energy homeostasis is unknown. Interestingly, it has been shown that in certain 
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cancer cells where aerobic glycolysis is preferred over oxidative metabolism, increased glycolysis is not 
an attempt to increase energy production but rather to support biosynthesis of bio molecules and 
increased proliferation (70, 90). In contrast, enhanced glycolysis in some cancers is due to impairment 
of mitochondrial function including diminished expression of mitochondrial oxidative enzymes, 
respiratory chain and TCA cycle (28, 88, 113); this effect is equally comparable to that seen in normal 
cells where mitochondrial dysfunction and reduced respiration sways metabolism towards glycolysis 
(25). Overall, inhibition of MCAD seemed to have caused a significant reduction in oxidative metabolism 
where glycolysis may be up regulated to restore energetic homeostasis. 
 
4.2 Effect of aconitase inhibition on enzyme activity 
Our treatment of C2C12 myotubes with either low (2 mM) or high (9 mM) concentration of fluorocitrate 
to inhibit aconitase showed a trend towards a main effect of concentration. Post hoc analysis revealed 
a significant decrease in aconitase activity with low concentration of the inhibitor. The current study 
determined the total aconitase activity in our cell lysate which included both cytosolic and 
mitochondrial aconitase (56). Previous studies have shown that cytosolic aconitase remains unaffected 
by inhibition with fluorocitrate (85), which may suggest that the abundance of unaffected cytosolic 
aconitase in our cell lysate may have contributed to the results. Since mitochondrial, and not cytosolic, 
aconitase activity contributes to energy metabolism and where aconitase activity becomes rate limiting, 
there should be an expected deleterious effect on oxidative phosphorylation. Accordingly, we found 
decreased TCA cycle-linked respiration with both low and high concentration of aconitase inhibitor. 
Although we are the first to use fluorocitrate to inhibit aconitase in C2C12 myotubes, previous studies 
have shown decreased activity of aconitase on various sample types (39, 43, 78, 83, 84, 91, 93, 163, 
175). In an earlier study, Gardener and colleagues treated cultured human epithelial-like lung cells 
(A549) with 10 mM sodium fluoroacetate or 0.1 mM sodium (±)-fluorocitrate for 24 hours. They found 
that the effect of fluorocitrate on aconitase inactivation mimicked the inhibitory effects of sub lethal or 
lethal hyperoxia induced in rat lungs. In their study, fluorocitrate caused cell swelling that was observed 
with hyperoxia and like the present study, treatment of fluorocitrate did not cause visible cell death 
(43). Another study showed that fluorocitrate acted on glial cells as a ‘suicide’ substrate for the enzyme 
aconitase, overall inhibiting the TCA cycle and temporarily depressing glial function (84). They treated 
the cortex of adult male Sprague-Dawley rats with 0.01, 0.02, 0.05 or 0.5 mM of fluorocitrate. Overall, 
our study supports previous reports that inhibition of aconitase with fluorocitrate limits the TCA cycle 
and oxidative phosphorylation (39, 43, 78, 83, 84, 91, 93, 163, 175). 
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Additionally, we have shown that where aconitase is inhibited, the activity of citrate synthase was 
increased; reflected in increased activity with both low and high concentration of aconitase inhibitor 
(figure 3.1F). This finding was similar to the study by Larsen et al. (2016); where inactivation of aconitase 
by oxidative stress, induced by high intensity exercise in human m. Vastus Lateralis, lead to increased 
citrate synthase activity (75). Similarly, Gardener et al (1994) showed that inhibition of aconitase with 
fluorocitrate or  hyperoxia in lung cells lead to increased citrate levels (43). One explanation for 
increased activity of citrate synthase was offered by Larsen et al. (2016) where they showed that the 
concurrent increased citrate offers cytoprotective effects from oxidative stress (75). To test this, they 
added 10 mM of sodium citrate to cultured primary myotubes pre-exposed to 50-200 μM H2O2 and 
showed that addition of citrate fully abolished mitochondrial dysfunction (75). Thus, we could 
hypothesise that inhibition of aconitase contributed to the loss of homeostasis in the cell and increasing 
citrate may have contributed to restoring this balance. 
 
Furthermore, since aconitase is a key regulator of the TCA cycle, its inhibition would lead to diminished 
oxidative metabolism and ATP production.  Accordingly, Dhami et al. (2018), using mammalian CHO-K1 
cells established that knockdown of aconitase was the most lethal amongst TCA cycle genes; its deletion 
impaired the entire cycle (37). As citrate cannot be metabolised further in the TCA cycle, it leaves the 
mitochondria and enters the cytosol where it is recruited for fatty acid synthesis (37, 75). Thus, 
deactivation of aconitase and resulting impairment of the TCA cycle was reported to increase fatty acid 
synthesis and glycolysis (37). In agreement, we found increased MCAD activity when high concentration 
of aconitase inhibitor was used (figure 3.1B), which may be an indication of increased substrate supply 
for β-oxidation. Collectively, the increase in citrate and accompanying increase in MCAD activity may 
reflect the conversion of glucose to lipids supported by increased glycolysis. This association of 
increased citrate synthase activity as well as enzymes of fatty acid oxidation is comparable to what is 
seen in some cancers, where decreased oxidative metabolism and increased citrate production directs 
substrates towards biosynthesis rather than toward oxidation to CO2 and H2O (132). Indeed the rate of 
glycolysis has been reported to increase in fluorocitrate poisoned frog and mammalian muscles, as well 
as in hyperoxia (43). Furthermore, others have found increased activity of lactate dehydrogenase and 
glucose 6-phosphate dehydrogenase, which are important enzymes involved in glycolysis, with 
increased activity of citrate synthase (43, 76, 132). It is worth noting that C2C12 myotubes in this study 
were grown in a high glucose medium, which would mean that the cells had enough substrates to 
support glucose metabolism via glycolysis. However, as this was beyond the scope of this study, we 
were unable to determine whether the inhibition of the TCA cycle leads to increased glycolysis. Overall 
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it seems that inhibition of aconitase resulted in oxidative imbalance, which may have up regulated β-
oxidation and glycolysis as a mechanism to restore homeostasis  
 
4.3 The combined effect of MCAD and aconitase inhibition  
This study aimed to explore the relationship between a defect in β-oxidation and the TCA cycle. We 
have shown that where MCAD activity was inhibited, the increase in citrate synthase was not due to 
increased metabolism within the TCA cycle, shown by the lack of concurrent increase in aconitase 
activity. Indeed, where aconitase was inhibited and its activity was shown to decrease, citrate synthase 
as well as MCAD activity increased. This is the first study to show these enzyme interactions, although 
understanding/exploring the mechanism by which this occur was beyond the scope of this study. We 
suspect that in both cases of inhibition, increase in citrate synthase activity was an attempt by the cell 
to restore the redox balance (58, 75). This loss of homeostasis was more pronounced with inhibition of 
aconitase reflected by the higher degree of increase in citrate synthase activity (figure 3.1 F). We can 
therefore hypothesize that where MCAD is deficient, the TCA cycle may not compensate for decreased 
oxidative metabolism but is rather negatively impacted by loss of β-oxidation, leading to overall 
dysfunction in the mitochondrial energetic machinery. Furthermore, where aconitase is inhibited, the 
cell attempts to improve redox balance partially through increased activity in β-oxidation. The 
relationship between β-oxidation and the TCA cycle and the impact of inhibition of each pathway on 
mitochondrial function was further investigated by assessing mitochondrial respiration with HRR. 
 
4.4 The effect of enzyme inhibition on mitochondrial respiration 
Recently, it has been reported that energy deficiency and/or disruption is involved in the 
pathophysiology of some FAO defects including MCAD (86, 107). We show here that MCAD inhibition 
with 2-mercaptoacetate decreases mitochondrial respiration assessed by HRR using both β-oxidation 
linked substrates (octanoylcarnitine and malate) and TCA cycle linked substrates (pyruvate, malate and 
glutamate). This confirms that β-oxidation inhibition affects overall mitochondrial energetic machinery 
irrespective of the substrates oxidized. Additionally, we investigated the impact of aconitase inhibition 
on mitochondrial respiration when adding TCA cycle linked substrates. We showed that aconitase is a 
key regulator of the TCA cycle and resulted in a decrease in respiratory capacity as well as energetic 
efficiency of the mitochondria when using a pyruvate, malate and glutamate substrate combination. 
Furthermore, β-oxidation with octanoylcarnitine and malate combination was also decreased with 
aconitase inhibition but the pyruvate, malate and glutamate substrate combination was most sensitive 
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to the inhibition. The use of octanoylcarnitine and carnitine seemed to have inhibited multiple 
respiratory states at the concentrations used in this study, affecting both control and inhibited 
myotubes. We suspect that there was an imbalance in the rate of octanoylcarnitine oxidation and the 
removal of its intermediate by carnitine thereby causing a metabolic block. Accordingly, careful 
consideration of the optimum concentration of both octanoylcarnitine and carnitine should be taken 
into account when using this substrate combination in the future. Overall, SUIT protocols using 
octanoylcarnitine and malate or pyruvate, malate and glutamate showed to be effective in detecting a 
dysfunction resulting from inhibition of rate limiting enzymes beyond classic enzymatic assays. 
 
4.4.1 The effect of MCAD inhibition on mitochondrial respiration 
 
4.4.1.1 The effect of MCAD Inhibition on mitochondrial respiration using octanoylcarnitine and malate 
substrate combination 
The use of octanoylcarnitine and malate has been demonstrated as an effective method for assessing 
β-oxidation by respirometry (12, 101, 115, 116). In agreement, we have shown that in healthy C2C12 
myotubes, respiration measured as oxygen flux increased in response to the addition of substrates, ADP 
and uncoupler titrations (figure 3.2). Following MCAD inhibition, this substrate combination resulted in 
decreased respiratory capacity at routine, OXPHOSFAO, ETSFAO and ETSFAO+CI+CII with high and low 
concentration inhibitor treatment (section 3.2.1.1; figure 3.3). This indicated that metabolism using 
octanoylcarnitine and malate substrate combination was efficient in responding to altered substrate 
oxidation, membrane potential and ATP demands. However, altered respiratory capacity with inhibition 
was only observed when oxygen flux was corrected to the approximate number of cells placed in the 
respiration chamber; correction of data to protein concentration did not reveal any significant change 
with inhibition. As mentioned previously, a high concentration of 2-mercaptoacetate resulted in a loss 
of cells and would be responsible in part for decreased flux at this concentration, since there would be 
fewer respiring mitochondria. Nevertheless, the additional decrease in oxygen flux with low inhibition 
concentration validates the use of octanoylcarnitine and malate substrate combination for detecting 
an MCAD specific β-oxidation dysfunction.  
 
With the use of octanoylcarnitine and malate where MCAD was inhibited, our most significant finding 
was the decreased respiratory capacity at; a) routine state with low inhibitor concentration; b) 
OXPHOSFAO  with both low and high inhibitor concentration; c) ETSFAO with low inhibition; c) maximum 
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capacity (ETSFAO+CI+CII) with both low and high inhibitor concentration. At OXPHOSFAO, the oxidation of 
substrates accounts for the partial stimulation of the ETS and decreased respiration would mean 
decreased substrate oxidation (49, 51). Increased stimulation, after the addition of a protonophore 
(CCCP), indicates that both substrate oxidation, and electron transfer across the respiratory chain 
(including the working of complexes), would influence the rate of respiration at ETSFAO and ETSFAO+CI+CII 
(49, 51). Results obtained reflect decreased respiratory capacity due to; a) blockage of 
octanoylcarnitine oxidation, and b) decreased reducing equivalents for the ETS where MCAD was 
inhibited (36, 107, 124). Reasons for this include; the MCAD catalysed step is rate limiting, it’s partial or 
total inhibition would cause the accumulation of medium chain fatty acyl esters, and a reduction of the 
CoA pool. It was important for us to first measure the FAO contribution to OXPHOS and ETS capacities. 
This will assess the direct effect of MCAD inhibition on β-oxidation and resulting oxidative 
phosphorylation. After this state, the inclusion of pyruvate and glutamate at ETSFAO+CI and succinate at 
ETSFAO+CI+CII allows the assessment of the maximum capacity of the mitochondrial for both β-oxidation 
and TCA cycle. Thus, the decreased respiration observed at ETSFAO+CI+CII is an indication that not only was 
β-oxidation impaired, but also the maximum respiratory capacity of the mitochondria, including TCA 
cycle-linked metabolism. 
 
Importantly, we found that aside from respiratory capacity, the degree of coupling of substrate 
oxidation to ATP generation was decreased with MCAD inhibition (section 3.2.1.1; figure 3.4). The 
degree of coupling is a measure of energy efficiency, which is an index of dysfunction.  It is sensitive to 
changes in all bioenergetics modules (substrate oxidation, electron transfer and oxidative 
phosphorylation) (51, 114). The degree of coupling of the mitochondria was assessed by calculating the 
ratio of each respiratory state to the maximum capacity, ETSFAO+CI+CII (represents convergent electron 
flow from FAO+CI+CII) or ETSFAO. This ratio is not limited by error prone approximations of cell number 
or protein concentration. We found decreased coupling at routine, OXPHOSFAO, ETSFAO and ETSFAO+CI 
respiratory states (Section 3.2.1a; Figure 3.4A). The decreased coupling after the addition of CI-linked 
substrate, shows that CI activity is altered with MCAD inhibition. The result of decreased coupling 
control indicates that where MCAD is inhibited (or in deficiency), and in the presence of maximum 
energetic substrate supply, the mitochondria is not efficient in converting this to energy. To our 
knowledge, this study is the first to show that MCAD inhibition affects the efficiency of the mitochondria 
to produce energy in skeletal muscle cells. Increased uncoupling proteins has been shown to be 
associated with free fatty acids in the failing heart where uncoupled respiration was associated with 
mitochondrial uncoupling and decreased cardiac efficiency (101). Interestingly, in many FAO defects 
and especially in MCAD deficiency, energetic substrate supplementation is unable to reverse or prevent 
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the symptom observed in some patients (170). These reports have shown that the disruption of 
mitochondrial homeostasis is compounded by deficient energy production and oxidative stress in β-
oxidation defects (47, 131, 136, 161). The decreased energy efficiency reported here is not reflected in 
enzymatic determinations, contributing to the validation of HRR as an important technique for 
assessing mitochondrial dysfunction when MCAD specific β-oxidation is impaired.  
 
A well-known causal effect of MCAD deficiency is the accumulation of toxic metabolites that fuel the 
production of reactive oxygen species (ROS), leading to oxidative stress (136, 138, 139).  Oxidative stress 
further impairs mitochondrial function and contributes to the pathology of MCAD dysfunction (36, 104). 
Our study shows that MCAD inhibition increased citrate synthase activity (section 3.1.1, figure 3.1 E), 
which may be a consequence to increased citrate to combat oxidative stress and restore redox balance 
(75, 143). Mitochondrial alterations and disruption of redox homeostasis has been commonly observed 
in mouse models of fatty acid oxidation disorders (107, 140). In addition to disrupting mitochondrial 
function, increased oxidative stress contributes to the inactivation of sensitive aconitase and hence a 
limitation of the TCA cycle (75). Limitation of the TCA cycle would further impair the oxidation of 
octanoylcarnitine assessed when octanoylcarnitine and malate are used as substrates, since the 
metabolism of malate in the TCA cycle would be affected. Consequently, the supply of NADH to the ETS 
would be further decreased. Overall, oxidative phosphorylation and respiratory capacity especially 
complex I-linked contribution would be further attenuated contributing to mitochondrial dysfunction 
with MCAD inhibition. 
 
4.4.1.2 The effect of MCAD inhibition on mitochondrial respiration using pyruvate, malate and 
glutamate substrate combination. 
To support the hypothesis that MCAD inhibition resulted in decreased metabolism in the TCA cycle 
(especially CI-linked), we assessed respirometry separately with pyruvate, malate and glutamate 
substrate combination where MCAD was inhibited. The use of this substrate combination partially 
reconstitutes metabolism within the TCA cycle in assessment of HRR and their metabolism produces 
NADH that supplies electrons directly to CI and ultimately to CIV of the ETS with coupling sites at the 
ubiquinone pool and CIII, whilst only partially stimulating CII (49, 51). Thus, OXPHOS and ETS respiratory 
states were first assessed with the addition of only CI-linked substrates (at OXPHOSCI and ETSCI), which 
was followed by addition of FAO substrates (ETSCI+FAO) and then CII-linked substrate to give maximum 
capacity (ETSCI+FAO+CII) (section 3.2.3, figure 3.16). Similar to octanoylcarnitine and malate substrate 
combination, pyruvate, malate and glutamate substrate combination were responsive to the SUIT 
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protocol in healthy C2C12 myotubes, additionally, reflecting altered respiration in response to 
inhibition. When respiration was corrected to the approximate number of cells we found decreased 
respiration with high MCAD inhibitor concentration at leakCI, OXPHOSCI, ETSCI, ETSCI+FAO and ETSCI+FAO+CII 
(figure 3.18A). Furthermore, for respiration corrected to protein concentration (figure 3.18B), we 
showed a decrease in respiration with low inhibitor concentration at ETSCI and ETSCI+FAO. Importantly, 
the decrease in respiratory capacity with MCAD inhibition were more pronounced here (with the use 
of pyruvate, malate and glutamate) than when substrates specific to FAO (octanoylcarnitine and 
malate) were used. Accordingly, pyruvate, malate and glutamate substrate combination proved to be 
the most sensitive for detecting MCAD inhibition. Our results confirm that MCAD inhibition indeed 
alters metabolism within the TCA cycle, thus showing that a primary β-oxidation inhibition caused a 
secondary TCA cycle inhibition. 
 
Similar to our findings of decreased respiratory capacity with pyruvate, malate and glutamate, others 
have also found decreased ADP stimulated respiration with treatment with 2-mercaptoacetate (5) or 
in MCAD deficiency (2, 8). Our study showed that FCR was largely unaffected by MCAD inhibition when 
we used pyruvate, malate and glutamate substrate combination (figure 3.19). It appears there may be 
a mechanism that restores the uncoupling of substrate oxidation to oxidative phosphorylation that was 
observed when β-oxidation substrates (octanoylcarnitine and malate) were used. One possible 
mechanism for the observed intact coupling efficiency with CI-linked TCA cycle substrates may be the 
involvement of CI stability. It has been reported that CI reversibly alternates between an active and 
deactivated conformation that most likely depends on the cell respiratory status (13, 54, 55). For 
example, Grivennikova et al. (2003), found that in mitochondria where CI was inactivated by inhibition, 
exposure to malate/glutamate, NAD(+) and cytochrome C induced reactivation of the enzyme (54). On 
the other hand, loss of MCAD function has been shown to affects CI stability as well as the stability of 
OXPHOS super complexes (CI, CII and CIV). This may be an explanation for the uncoupling of respiration 
seen with MCAD inhibition with the use of octanoylcarnitine and malate. Thus, using pyruvate, malate 
and glutamate may have reactivated CI with the stability in turn affecting the other respiratory 
complexes. The arrangement of the mitochondrial respiratory chain complexes into super complexes 
is well established in different organisms (131), others have also found a physical association between 
CI and CIII (23, 74, 127). Hence although respiratory capacity was decreased, the coupling of respiration 
persisted. Therefore, the decreased respiratory capacity observed with the use of pyruvate, malate and 
glutamate substrate combination is limited to their impaired oxidation within the TCA cycle where 
MCAD is inhibited. This agrees with the earlier statement that a primary defect in MCAD (as well as 
resulting dysfunction in β-oxidation) results in secondary TCA cycle dysfunction. 
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The mechanism of decreased respiratory capacity from metabolism within the TCA cycle is not fully 
understood. As previously stated, we suspect that MCAD inhibition impairs aconitase activity, which 
was partly confirmed by reduced CI-linked respiration. Inhibition of aconitase would further limit the 
TCA cycle since aconitase functions as a regulator of the TCA cycle (5, 75, 85). The role of oxidative 
stress is very popular in the pathology of MCAD deficiency (107), indeed many researchers have 
investigated the role of accumulating toxic metabolites in MCAD deficiency on redox homeostasis (36, 
104, 121, 130, 136, 138, 139). These studies have shown that toxic metabolites in MCAD deficiency 
cause oxidative stress leading to oxidative damage of proteins, inhibition of oxidative phosphorylation 
as well as diminished capacity of the anti-oxidant defence mechanism leading to overall mitochondrial 
bioenergetics dysfunction (3, 130, 136, 138, 161). This lends support to our hypothesis that the increase 
in citrate synthase activity with MCAD inhibition was not an indication of increased oxidative capacity, 
but rather a sign of oxidative stress and the cells machinery to restore homeostasis. In our study, TCA 
cycle-linked respiration associated with CI was decreased where MCAD was inhibited. Although no 
change in aconitase activity  was reflected with spectrophotometric enzymatic analysis, other studies 
have shown that medium chain free fatty acids (from MCAD defect) decrease aconitase activity (137, 
138). To our knowledge, the focus of secondary dysfunction with primary MCAD deficiency has been 
on oxidative phosphorylation even though different studies have shown that respiration in the presence 
of pyruvate, malate or glutamate is decreased as a result of the detrimental effects of MCAD 
dysfunction (3, 86, 121, 130, 137, 141). However, β-oxidation, the TCA cycle and OXPHOS are tightly 
linked, with OXPHOS being the ultimate outcome of substrate oxidation within either β-oxidation or the 
TCA cycle. We have proposed that a primary defect of either pathway would contribute to secondary 
dysfunction of the other. This is reflected in decreased TCA cycle-linked respiration where we have 
shown that MCAD was the primary defect.  
 
4.4.1.3 The effect of MCAD inhibition on mitochondrial respiration using octanoylcarnitine and 
carnitine substrate combination 
The use of octanoylcarnitine and carnitine substrate combination offers a similar support to FAO-linked 
respiration that octanoylcarnitine and malate provides. Inclusion of carnitine functions to lower the 
matrix level of catabolic intermediates. It regulates matrix acyl-CoA/CoA by exchange of cytosolic 
carnitine with matrix acylcarnitine catalysed by carnitine transferase (151). Our study shows that the 
addition of octanoylcarnitine and carnitine to control myotubes had minimal effect on oxygen 
consumption measured at LEAK, OXPHOS and ETSFAO; the rates of respiration was only significantly 
increased after the addition of CI-linked (pyruvate, malate, glutamate) and CII-linked (succinate) 
substrates to uncoupled respiration in the presence of maximum amounts of protonophore (CCCP) 
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(figure 3.9). Similar patterns in respiratory capacity was observed when respiration was assessed in 
MCAD inhibited myotubes. Inhibition did not significantly decrease oxygen flux when corrected for 
either cell number or protein concentration (figure 3.10). The pattern of respiration we observed here 
questions the use of octanoylcarnitine and carnitine substrate combination.  
 
Many studies using acylcarnitine and carnitine in assessing β-oxidation involve palmitoylcarnitine, a 
long chain acyl-carnitine. These studies have assessed respiration in isolated mitochondria from muscle, 
liver or brain tissue whereas we have used permeabilized skeletal muscle. Movement of substrates in 
and out of the inner mitochondrial matrix is different in intact cells versus isolated mitochondria and 
may have influenced the oxidation of octanoylcarnitine in our study perhaps accounting for disparity 
with other studies (1, 115, 141). For example, Seifert et al. (2010) using isolated mitochondria from 
male mice showed that increasing the concentration of palmitoylcarnitine from 4.5 μM to 18 μM did 
not increase respiration, and addition of 2 mM carnitine to 18 μM palmitoylcarnitine resulted in 
increased respiration (141). This indicates that addition of carnitine facilitates the oxidation of 
palmitoylcarnitine. However, in comparison, our study utilised a higher concentration of acylcarnitine 
(0.2 mM of octanoylcarnitine with 2 mM carnitine). Perhaps, the rate of oxidation of octanoylcarnitine 
and the resulting production of intermediates exceeds the rate of removal facilitated by carnitine 
leading to feed-back inhibition. Indeed, it has been shown that the ETS flux in skeletal muscle 
mitochondria can be inhibited with concentrations of palmitoylcarnitine above 5 μM (1). Although we 
have used octanoylcarnitine in our study this explanation may equally follow true. Regardless, the 
absence of further attenuation in respiration where MCAD is inhibited is questionable. We suspect that 
the use of octanoylcarnitine and carnitine at the concentrations used in this study in addition to 
functioning to inhibit flux, may produce a threshold effect, where up-regulating or down-regulating β-
oxidation may not significantly cause further changes in oxygen flux.  
 
Furthermore, this study explored the relationship between β-oxidation and the TCA cycle, and so we 
included pyruvate, malate and glutamate to octanoylcarnitine and carnitine after FAO-linked ETS 
(ETSFAO+CI; figure 3.9); and in the reverse scenario, octanoylcarnitine and carnitine was added to 
pyruvate, malate and glutamate after CI-linked ETS (ETSCI+FAO; figure 3.16). This expressed convergent 
electron flow from CI and β-oxidation in either instance. It is established that CI-linked substrates highly 
reduce the ETS compared to FAO-linked substrates (2, 141) and the addition of CI-linked substrates was 
expected to stimulate the ETS beyond FAO leading to increased respiration at ETSFAO+CI. However, 
before now it was not known whether the inclusion of octanoylcarnitine and carnitine after CI-linked 
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substrates would increase respiration. As expected, oxygen consumption increased when CI-linked 
substrates were added to octanoylcarnitine and carnitine although, there was no significant change 
with MCAD inhibition (figure 3.10). This is in agreement with studies by Amaral et al. (2016) and Sauer 
et al. (2008), who reported that carnitine derivatives of toxic β-oxidation metabolites including 
octanoylcarnitine were unable to alter the activities of isolated respiratory chain complexes, membrane 
potential, oxidation within the TCA cycle and NAD(P)H/NAD(P)+ ratio (2, 130). Interestingly, in the 
reverse scenario, we found that oxygen consumption decreased after the addition of octanoylcarnitine 
and carnitine to CI-linked substrates in both control and MCAD inhibited myotubes (figure 3.18). It 
seemed that octanoylcarnitine and carnitine acted as an inhibitor of oxidative phosphorylation in line 
with our earlier observations. Thus, the significant decrease observed with high inhibition compared to 
low at ETSCI+FAO is most likely due to initial decrease in respiration at ETSCI. Over all it seems that aspects 
of respiration involving the use of this substrate combination are unresolved and need to be explored 
further, especially with respect to the correct concentration of either octanoylcarnitine or carnitine for 
a specific sample type.  
 
4.4.2 The effect of aconitase inhibition on mitochondrial respiration 
 
4.4.2.1 The effect of aconitase inhibition on mitochondrial respiration using pyruvate, malate 
and glutamate substrate combination 
The use of pyruvate, malate and glutamate substrate combination was the most sensitive combination 
for assessing the TCA cycle functioning where aconitase was inhibited. Previously, others have shown 
reduced mitochondrial respiration with both pyruvate and glutamate linked respiration. In isolated 
skeletal muscle mitochondria from fluorocitrate poisoned hearts, pyruvate linked mitochondrial 
respiration was ~80% inhibited (93). Gardener et al. (1994) also showed that basal, uncoupled and total 
respiration with malate was diminished in human epithelial A549 cells treated with either 10 mM 
sodium fluoroacetate or 0.1 mM sodium citrate when respiration was assessed using a Gilson oxygraph 
with a Clark electrode (43). In agreement with previous papers, we have shown that inhibition of 
aconitase significantly decreased all states of respiration (section 3.2.2.2; figure 3.21) with both 
correction to cell number and to protein concentration. Respiratory capacity at routine, LeakCI, 
OXPHOSCI, ETSCI, ETSCI+FAO and ETSCI+FAO+CII was significantly decreased with both high and low inhibition 
treatment. Firstly, the evidence of decreased respiratory capacity in response to aconitase inhibition 
adds validity to the use of HRR and pyruvate, malate and glutamate substrate combination for assessing 
dysfunction since we had only found trends for decreased aconitase activity with spectrophotometric 
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enzyme assays. Furthermore, these results rationalise our earlier discussions where CI-linked 
respiratory was implicated with aconitase inhibition indirectly from MCAD inhibition and we show with 
pyruvate, malate and glutamate substrate combination that direct inhibition of aconitase is reflected 
in decreased CI-linked respiration.  
 
Even though we have inhibited aconitase in an attempt to limit the TCA cycle, it is known that where 
there is a defect in the cycle, its substrates may be generated from other anaplerotic reactions that 
allow for its partial continuation (51). Such supply can be generated from the oxidative decarboxylation 
of pyruvate catalysed by pyruvate dehydrogenase as well as oxidation of glutamate by glutamate 
dehydrogenase into 2-oxoglutarate. With both pyruvate and glutamate, extra support to oxidative 
phosphorylation from TCA cycle is supplied from the additional NADH produced. Notably, it has been 
shown that the reaction of pyruvate and glutamate are inhibited by fluorocitrate, and we have been 
able to limit the TCA cycle further by using this inhibitor. Furthermore, one of the mechanisms of 
reduced respiratory capacity with inhibition using fluorocitrate involves the transport of substrates into 
the mitochondrion. Decreased concentrations of aspartate and glutamate have been found in heart 
and skeletal muscle of fluorocitrate poisoned heart (93). In our study, the decrease in respiration may 
be explained by a limitation of the glutamate-aspartate carrier with the inclusion of glutamate. The 
glutamate-aspartate carrier catalyses the electrogenic antiport of glutamate and hydrogen in the ionic 
state for aspartate. It is also an important part of the malate-aspartate shuttle in many mitochondria 
(51), implicating not only the transport of glutamate but also malate with fluorocitrate poisoning. In 
addition, the 2-oxoglutarate carrier exchanges malate for 2-oxoglutarate in the ionic state (51).This 
transport may be further limited where the concentration of glutamate is decreased; glutamate 
oxidation supplies 2-oxoglutarate. In addition to limiting anaplerotic reactions, the direct inhibition of 
aconitase by fluorocitrate contributes to limiting downstream flux of the TCA cycle, exacerbating the 
impact of inhibition on the TCA cycle metabolism. By and large, oxidation of TCA cycle substrates are 
reduced leading to substantially decreased NADH production and ETS capacity.  
 
An important mechanism for decreased respiratory capacity from TCA cycle metabolism is the effect of 
inhibition directly on aconitase. Its deactivation releases Fe2+ associated with subsequent production of 
free hydroxyl radicals via the Fenton reaction, which further oxidises mitochondrial proteins, DNA and 
lipids (27, 33, 66). Indeed, Dhami et al (2018) reported a marked increase in H2O2 production after 
aconitase knockdown in CHO mammalian cells (37). Likewise, Fe-S- cluster containing subunits of 
mitochondrial proteins are remarkably sensitive to free radical (includes complex I-III) (125), this may 
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further worsen the effect of inhibition of aconitase leading to not only impaired respiratory capacity 
but also contributing to uncoupling of respiration. In light of this, we showed that coupling efficiency 
was decreased with aconitase inhibition (figure 3.22). We first calculated the FCR to the maximum 
respiration, ETSCI+FAO+CII; we showed that this ratio was significantly decreased at routine, OXPHOSCI, 
ETSCI and ETSCI+FAO with both high and low inhibition (figure 3.22A). Remarkably, the reverse was the 
case when FCR was calculated as the ratio of each state to ETSCI (figure 3.22B), this may indicate the CI 
exerts the most influence on the detrimental effects of decreased efficiency of the mitochondrial with 
aconitase inhibition. Collectively, aconitase inhibition lead to decreased respiratory capacity and 
decreased energetic efficiency of the mitochondria, causing overall mitochondrial dysfunction. 
 
It has been reported that there is no known disease that is caused by a single deficiency of aconitase 
(53), although Friedrich’s ataxia is characterised by combined aconitase and succinate dehydrogenase 
deficiency (125). However, several acquired conditions are characterised by alterations in electron 
transport respiratory chain proteins, compromised mitochondrial calcium handling and impaired TCA 
cycle enzymes (53). After pinpointing aconitase as a critical target where MCAD is inhibited (or in MCAD 
deficiency), we have shown that in direct inhibition of aconitase, respiratory capacity as well as 
energetic efficiency of the mitochondria is compromised. Therefore, reflecting that aconitase is key to 
TCA regulation and in the absence of primary aconitase deficiency, acquired defects that severely alter 
aconitase activity may be very detrimental to energy metabolism. Thus, aconitase may be a critical 
target for therapeutic interventions in diseases that affect oxidative metabolism.  
 
4.4.2.2 The effect of aconitase inhibition on mitochondrial respiration using octanoylcarnitine 
and malate 
Assessment of respiration with octanoylcarnitine and malate substrate combination involves the 
influence of the TCA cycle in addition to β-oxidation. Conditions affecting/limiting the TCA cycle would 
reduce oxygen flux, giving a false reading of the rate of β-oxidation when malate is used as a co-
substrate (111). As previously mentioned, aconitase is a key regulator of the TCA cycle, its inactivation 
has been shown to inhibit mitochondrial respiration by inhibiting the TCA cycle (75). In this study, 
assessment of respiration after inhibition of aconitase lead to decreased oxygen flux at routine, leakFAO, 
and OXPHOSFAO respiratory states when respiration was corrected to cell number (figure 3.7). The 
observations here is a fraction of what was observed with aconitase inhibition using pyruvate, malate 
and glutamate substrate combination. Although we recorded decreased respiratory capacities, this 
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decrease may have been related to decreased metabolism of malate in the TCA cycle, with β-oxidation 
minimising the effect of aconitase inhibition. Previously (section 4.1), we have shown increased MCAD 
activity in spectrophotometric analysis, which may have been an indication of increased β-oxidation in 
response to limitation of oxidative metabolism within the TCA cycle. As a result, there may be decreased 
burden of oxidative damage with this substrate combination since there is fewer reducing equivalents 
produced as a result of oxidation of octanoylcarnitine. In line with this, we only recorded significant 
changes in the FCR for each state to the maximum capacity (ETSFAO+CI+CII) at routine and OXPHOSFAO 
states with both high and low inhibition (Figure 3.8). This may suggest that decreased respiratory 
capacity is mainly as a result of decreased substrate oxidation within the TCA cycle. Thus, our 
observation with this substrate combination may be mainly attributed to decreased flux through the 
TCA cycle. 
 
4.4.2.3 The effect of aconitase inhibition on mitochondrial respiration using octanoylcarnitine 
and carnitine 
Similar to the use of this substrate combination where MCAD was inhibited, there was no significant 
change in respiratory capacity with either high or low inhibition of aconitase when respiration was 
corrected for both cell number and protein concentration. As with MCAD inhibition, we added TCA 
cycle CI-linked substrates after FAO-linked ETS (ETSFAO+CI; figure 3.9) and no significant change was 
observed. However, we observed a different pattern in contrast to where MCAD was inhibited. It 
appears that respiratory capacity was tending towards an increase at LeakFAO, OXPHOSFAO, ETSFAO and 
ETSFAO+CI+CII; the opposite pattern was noticed at ETSFAO+CI with both high and low inhibitor 
concentrations (figure 3.14).  Indeed, we know that the effect of aconitase inhibition is largely reflected 
in diminished CI-linked respiration, which explains the reversed graph indicating ‘decrease’ in 
respiration observed only after the addition of CI-linked substrates. This may be in agreement to the 
increased MCAD activity we found with aconitase inhibition in spectrophotometric analysis. In section 
1.4.1.3 it was mentioned that the use of this substrate combination requires further optimization, 
perhaps this explains why the results here were not significant. It seems that β-oxidation may be 
enhanced to compensate for the loss of oxidative metabolism via the TCA cycle. Furthermore, we 
observed a significant increase in the flux control ratio of Leak to ETSFAO (figure 3.15B) with low 
inhibition, contributing to the argument that beta-oxidative metabolism appears to be compensating 
for a limitation in the TCA cycle.  
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Additionally, we added octanoylcarnitine and carnitine after ETS respiratory state with CI-linked 
pyruvate, malate and glutamate to assess ETSCI+FAO (figure 3.16). This assesses the convergent electron 
flow from both TCA cycle and FAO-linked oxidation. Respiratory capacity at this state was significantly 
decreased with low inhibitor concentration when respiration was corrected to number of cells (figure 
3.21 A). This observation contrasts with the preceding paragraph where a role for increased β-oxidation 
when aconitase is inhibited was identified. However, because stimulation of the ETS from β-oxidation-
linked substrates are a smaller fraction compared to that from TCA cycle-linked substrates, this 
decrease is most likely a carryover of that initially observed after the addition of pyruvate, malate and 
glutamate. Remarkably, addition of octanoylcarnitine and carnitine appears to have contributed to a 
loss in significant decreased observed initially at ETSCI (figure 3.21B and 3.22A), which may support the 
hypothesis of increased β-oxidation where aconitase is inhibited. To our knowledge no other studies 
have measured the effect of aconitase inhibition (or deficiency) on β-oxidation. Here we show that 
where oxidation linked to the TCA cycle is compromised, β-oxidation is a likely alternative pathway to 
sustain fuel maintenance.  
 
Despite these intriguing observations, we are unable to draw conclusions and it seems that the validity 
of octanoylcarnitine and carnitine substrate combination remains questionable. Further investigation 
is required to clarify reasons for inhibited respiration when this substrate combination is used. In our 
attempts to characterize the use of this substrate combination, we initially tested the effect of 
increasing octanoylcarnitine or carnitine and found that respiration remained the same. However, a 
follow up study is required to investigate the effect of decreasing the concentration of either 
octanoylcarnitine or carnitine on respiration.  
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4.5 Conclusion and future considerations 
We investigated the effect of either MCAD or aconitase inhibition on the sensitivity of commonly used 
substrate combinations in HRR as well as the effect of inhibition on MCAD, aconitase and citrate 
synthase enzyme activities. We hypothesized that MCAD inhibition would lead to both a decrease in 
MCAD and aconitase activity while increasing citrate synthase activity. On the other hand inhibition of 
aconitase was predicted to decrease aconitase activity and increase citrate synthase activity. 
Furthermore, we predicted that this inhibition would be reflected by decreased mitochondrial 
respiration assessed with pyruvate, malate and glutamate as well as octanoylcarnitine and carnitine 
substrate combinations but not octanoylcarnitine and carnitine. To the knowledge of the author of this 
thesis, this is the first study to evaluate the sensitivity of commonly used HRR substrates in a β-oxidation 
or TCA cycle defective state. The major findings of this study are: 
1. MCAD inhibition resulted in mitochondrial dysfunction reflected by decreased mitochondrial 
respiration and coupling control of respiration when pyruvate, malate and glutamate as well as 
octanoylcarnitine and malate substrate combinations were used in HRR assessment. 
Furthermore, with enzymatic spectrophotometric assay, MCAD inhibition increased citrate 
synthase activity. Contrary to the hypothesis, MCAD and aconitase activity remained 
unchanged with MCAD inhibition. 
2. Aconitase inhibition resulted in mitochondrial dysfunction reflected by decreased 
mitochondrial respiration and coupling control of respiration when pyruvate, malate and 
glutamate as well as octanoylcarnitine and malate substrate combinations were used in HRR 
assessment. Furthermore, with enzymatic spectrophotometric assay, aconitase inhibition 
decreased aconitase activity, increased citrate synthase and unexpectedly increased MCAD 
activity. 
3. Octanoylcarnitine and carnitine substrate combination was not sensitive to inhibition of either 
MCAD or aconitase  
 
Overall, inhibition of either MCAD or aconitase was more apparent with pyruvate, malate and 
glutamate substrate combination, indicating a role for decreased CI-linked respiration and thus CI- 
activity where either of these enzymes are defective. Accordingly, pyruvate, malate and glutamate 
substrate combination may be the best choice for assessing a defect in either β-oxidation or the TCA 
cycle. HRR was sensitive to dysfunction that was undetected where spectrophotometric enzyme activity 
was measured, indicative of the effectiveness of HRR for assessing MCAD or TCA cycle dysfunction.  
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4.5.2 Future Considerations 
The results of this study has demonstrated the importance of using HRR where there is a defect in either 
β-oxidation or the TCA cycle. However, HRR relies on fresh tissue from muscle biopsies, which limits its 
clinical applicability compared to other techniques that utilise less invasive samples such as blood or 
urine. It would be important in the future to explore the possibility of assessing mitochondrial 
respiration in blood samples of patients or animals where β-oxidation is defective. Completing HRR on 
blood samples would be less invasive and more cost effective. Furthermore, the use of 
octanoylcarnitine and carnitine substrate combination may prove useful in assessing defects in β-
oxidation (or the effect of TCA cycle defect on β-oxidation) if the correct concentrations are used. To 
this effect, future studies may consider exploring the effect of using concentrations of octanoylcarnitine 
lower than 0.2 mM.  
 
It is worth mentioning that the correction factor used in interpreting the results from HRR would be 
affected by the sample type and also by the treatment regime. This study discussed data normalised to 
approximate number of cells, protein concentration as well as flux control ratio. A limitation of using 
approximate number of cells here (since it was impossible to count fused myotubes) was that cell loss 
especially with inhibiting MCAD could not be accounted for. Thus correcting to protein concentration 
was more appropriate. However even better is the flux control ratio that acts as an internal control 
factor regardless of cell number or treatment used. 
 
Lastly, this study has indicated that a primary defect in either β-oxidation or the TCA cycle could lead 
to a secondary defect in the other; a finding that has important therapeutic implications. However, 
future studies may benefit from exploring the exact mechanism through which this occurs, particularly 
assessing and investigating the role of  oxidative stress and/or glycolysis under the conditions induced 
in this study 
 
 
 
 
 
100 
 
References 
1.  Abdul-Ghani MA, Muller FL, Liu Y, Chavez AO, Balas B, Zuo P, Chang Z, Tripathy D, Jani R, Molina-
Carrion M, Monroy A, Folli F, Van Remmen H, Defronzo RA. Deleterious action of FA 
metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, 
and insulin resistance 266. A J Physiol Endocrinol Metab 295: E678–E685, 2008. 
2.  Amaral AU, Cecatto C, Da Silva JC, Wajner A, Godoy KDS, Ribeiro RT, Wajner M. Cis-4-Decenoic 
and decanoic acids impair mitochondrial energy, redox and Ca2 + homeostasis and induce 
mitochondrial permeability transition pore opening in rat brain and liver: Possible implications 
for the pathogenesis of MCAD deficiency. Biochim Biophys Acta - Bioenerg 1857: 1363–1372, 
2016. 
3.  Amaral AU, Cecatto C, Da Silva JC, Wajner A, Godoy KDS, Ribeiro RT, Wajner M. Cis-4-Decenoic 
and decanoic acids impair mitochondrial energy, redox and Ca2 + homeostasis and induce 
mitochondrial permeability transition pore opening in rat brain and liver: Possible implications 
for the pathogenesis of MCAD deficiency. Biochim Biophys Acta - Bioenerg 1857: 1363–1372, 
2016. 
4.  Andresen BS, Bross P, Udvari S, Kirk J, Gray G, Kmoch S, Chamoles N, Knudsen I, Winter V, 
Wilcken B, Yokota I, Hart K, Packman S, Harpey JP, Saudubray JM, Hale DE, Bolund L, Kølvraa S, 
Gregersen N. The molecular basis of medium-chain acyl-CoA dehydrogenase (MCAD) 
deficiency in compound heterozygous patients: Is there correlation between genotype and 
phenotype? Hum Mol Genet 6: 695–707, 1997. 
5.  Armstrong JS, Whiteman M, Yang H, Jones DP. The redox regulation of intermediary 
metabolism by a superoxide-aconitase rheostat. BioEssays 26: 894–900, 2004. 
6.  Bartlett K, Eaton S. Mitochondrial β-oxidation. Eur J Biochem 271: 462–469, 2004. 
7.  Bauche F, Sabourault D, Giudicelli Y, Nordmann J, Nordmann R. Effects of 2-mercaptoacetate in 
isolated liver mitochondria in vitro. Biochem J 206: 53–59, 1982. 
8.  Bauché F, Sabourault D, Giudicelli Y, Nordmann J, Nordmann R. 2-Mercaptoacetate 
administration depresses the beta-oxidation pathway through an inhibition of long-chain acyl-
CoA dehydrogenase activity. Biochem J 196: 803–809, 1981. 
9.  Bauché F, Sabourault D, Giudicelli Y, Nordmann J, Nordmann R. Inhibition in vitro of acyl-CoA 
dehydrogenases by 2-mercaptoacetate in rat liver mitochondria. Biochem J 215: 457–64, 1983. 
101 
 
10.  Bennett MJ. Assays of fatty acid beta-oxidation activity. Methods Cell Biol 80: 179–197, 2007. 
11.  Bier DM, Leake RD, Haymond MW, Arnold KJ, Gruenke LD, Sperling MA, Kipnis DM. 
Measurement of “true” glucose production rates in infancy and childhood with 6,6-
dideuteroglucose. Diabetes 26: 1016–1023, 1977. 
12.  Bonnard C, Durand D, Peyrol S, Chanseaume E, Chauvin M a, Morio B, Vidal H, Rieusset J. 
Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced 
insulin resistant mice. J Clin Invest 118: 789–800, 2008. 
13.  Böttcher B, Scheide D, Hesterberg M, Nagel-Steger L, Friedrich T. A novel, enzymatically active 
conformation of the Escherichia coli NADH:ubiquinone oxidoreductase (complex I). J Biol Chem 
277: 17970–17977, 2002. 
14.  Bourgeron T, Chretien D, Poggi-Bach J, Doonan S, Rabier D, Letouze P, Munnich IA, Rotig A, 
Landneu P, Rustin P. Mutation of the Fumarase Gene in Two Siblings with Progressive 
Encephalopathy and Fumarase Deficiency. J Clin Invest 93: 2514–2518, 1994. 
15.  Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsøe R, Dela F. Patients with type 2 diabetes 
have normal mitochondrial function in skeletal muscle. Diabetologia 50: 790–796, 2007. 
16.  Boutellier S, Lutz TA, Volkert M, Scharrer E. 2-Mercaptoacetate, an inhibitor of fatty acid 
oxidation, decreases the membrane potential in rat liver in vivo. Am J Physiol Integr Comp 
Physiol 277: R301–R305, 1999. 
17.  Bradford MM. Determinacion De Proteinas: Metodo De Bradford. Anal Biochem 72: 248–254, 
1976. 
18.  Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J 435: 297–312, 
2011. 
19.  Brass EP, Hoppel CL. Effect of carnitine on mitochondrial oxidation of palmitoylearnitine. 
Biochem J 188: 451–458, 1980. 
20.  Brie J, Favier J, Rustin P. Tricarboxylic acid cycle dysfunction as a cause of human diseases and 
tumor formation. AJP Cell Physiol 291: C1114–C1120, 2006. 
21.  Brière J-J, Favier J, Gimenez-Roqueplo A-P, Rustin P. Tricarboxylic acid cycle dysfunction as a 
cause of human diseases and tumor formation. Am J Physiol Physiol 291: C1114–C1120, 2006. 
22.  Brzóska K, Mȩczyńska S, Kruszewski M. Iron-sulfur cluster proteins: Electron transfer and 
beyond. Acta Biochim Pol 53: 685–691, 2006. 
102 
 
23.  Budde SMS, Van Den Heuvel LPWJ, Janssen AJ, Smeets RJP, Buskens CAF, DeMeirleir L, Van 
Coster R, Baethmann M, Voit T, Trijbels JMF, Smeitink JAM. Combined enzymatic complex I and 
III deficiency associated with mutations in the nuclear encoded NDUFS4 gene. Biochem 
Biophys Res Commun 275: 63–68, 2000. 
24.  Burattini S, Ferri R, Battistelli M, Curci R, Luchetti F, Falcieri E. C2C12 murine myoblasts as a 
model of skeletal muscle development: Morpho-functional characterization. Eur J Histochem 
48: 223–233, 2004. 
25.  Burns J, Manda G. Metabolic Pathways of the Warburg Effect in Health and Disease: 
Perspectives of Choice, Chain or Chance. Int J Mol Sci 18: 2755, 2017. 
26.  Cabrero À, Alegret M, Sánchez RM, Adzet T, Laguna JC, Carrera MV. Increased reactive oxygen 
species production down-regulates peroxisome proliferator-activated α pathway in C2C12 
skeletal muscle cells. J Biol Chem 277: 10100–10107, 2002. 
27.  Cantu D, Schaack J, Patel M. Oxidative inactivation of mitochondrial aconitase results in iron 
and H2O2-mediated neurotoxicity in rat primary mesencephalic cultures. PLoS One 4: e7095, 
2009. 
28.  Chandra D, Singh KK. Genetic insights into OXPHOS defect and its role in cancer. Biochim 
Biophys Acta - Bioenerg 1807: 620–625, 2011. 
29.  Chase JFA, Tubbs PK. Specific Inhibition of Mitochondrial Fatty Acid Oxidation by 2-
Bromopalmitate and its Coenzyme A and Carnitine Esters. Biochem. J. . 
30.  Chen TR. In situ detection of mycoplasma contamination in cell cultures by fluorescent 
Hoechst 33258 stain. Exp Cell Res 104: 255–262, 1977. 
31.  Dai L, Xu S, Choi SK, Ha CM, Thoudam T, Cha SK, Wiederkehr A, Wollheim CB, Lee IK, Park KS. 
Oxidative stress and calcium dysregulation by palmitate in type 2 diabetes. Exp Mol Med 49: 
e291-12, 2017. 
32.  Das AM, Fingerhut R, Wanders RJA, Ullrich K. Secondary respiratory chain defect in a boy with 
long-chain 3- hydroxyacyl-CoA dehydrogenase deficiency: Possible diagnostic pitfalls. Eur J 
Pediatr 159: 243–246, 2000. 
33.  David Cantu, Ruth E. Fulton, Derek A. Drechsel MP. Mitochondrial aconitase knockdown 
attenuates paraquat- induced dopaminergic cell death via decreased cellular metabolism and 
release of iron and H2O2. J Neurochem 118: 79–92, 2011. 
103 
 
34.  Derks TGJ, Boer TS, Assen A, Bos T, Ruiter J, Waterham HR, Niezen-Koning KE, Wanders RJA, 
Rondeel JMM, Loeber JG, Te Kate LP, Smit GPA, Reijngoud DJ. Neonatal screening for medium-
chain acyl-CoA dehydrogenase (MCAD) deficiency in The Netherlands: The importance of 
enzyme analysis to ascertain true MCAD deficiency. J Inherit Metab Dis 31: 88–96, 2008. 
35.  Derks TGJ, Reijngoud DJ, Waterham HR, Gerver WJM, van den Berg MP, Sauer PJJ, Smit GPA. 
The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: 
Clinical presentation and outcome. J Pediatr 148: 665–670, 2006. 
36.  Derks TGJ, Touw CML, Ribas GS, Biancini GB, Vanzin CS, Negretto G, Mescka CP, Reijngoud DJ, 
Smit GPA, Wajner M, Vargas CR. Experimental evidence for protein oxidative damage and 
altered antioxidant defense in patients with medium-chain acyl-CoA dehydrogenase 
deficiency. J Inherit Metab Dis 37: 783–789, 2014. 
37.  Dhami N, Trivedi DK, Goodacre R, Mainwaring D, Humphreys DP. Mitochondrial aconitase is a 
key regulator of energy production for growth and protein expression in Chinese hamster 
ovary cells. Metabolomics 14: 136, 2018. 
38.  Djouadi F, Bonnefont JP, Munnich A, Bastin J. Characterization of fatty acid oxidation in human 
muscle mitochondria and myoblasts. Mol Genet Metab 78: 112–118, 2003. 
39.  Dummel RJ, Kun E. Studies with Specific Enzyme Inhibitors. J Biol Chem 244: 2966–2969, 1969. 
40.  van Eunen K, Simons SMJ, Gerding A, Bleeker A, den Besten G, Touw CML, Houten SM, Groen 
BK, Krab K, Reijngoud DJ, Bakker BM. Biochemical Competition Makes Fatty-Acid β-Oxidation 
Vulnerable to Substrate Overload. PLoS Comput Biol 9: 2–9, 2013. 
41.  F. Feillet, G Steinmann, C. Vianey-Saban, C. de Chillou, N. Sadoul , E. Lefebvre, M. Vidailhet PEB. 
Adult presentation of MCAD deficiency revealed by coma and severe arrythmias. Intensive 
Care Med 29: 1594–1597, 2003. 
42.  Flandin P, Donati Y, Barazzone-Argiroffo C, Muzzin P. Hyperoxia-mediated oxidative stress 
increases expression of UCP3 mRNA and protein in skeletal muscle. FEBS Lett 579: 3411–3415, 
2005. 
43.  Gardner PR, Nguyen DH, White CW. Aconitase is a Sensitive and Critical Target of Oxygen 
Poisoning in Cultured Mammalian Cells and in Rat Lungs. Proc Natl Acad Sci 91: 12248–12252, 
1994. 
44.  Garedew A, Hütter E, Haffner B, Gradl P, Gradl L. High-resolution Respirometry for the Study of 
Mitochondrial Function in Health and Disease . The OROBOROS Oxygraph-2k. In: 11th Congress 
104 
 
Eu. Shock Soc. 2005, p. 107–111. 
45.  Ghosh S, Kruger C, Wicks S, Simon J, Kumar KG, Johnson WD, Mynatt RL, Noland RC, Richards BK. 
Short chain acyl-CoA dehydrogenase deficiency and short-term high-fat diet perturb 
mitochondrial energy metabolism and transcriptional control of lipid-handling in liver. Nutr 
Metab 13: 1–17, 2016. 
46.  Gillingham MB, Scott B, Elliott D, Harding CO. Metabolic control during exercise with and 
without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA 
dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 89: 58–63, 
2006. 
47.  Giselli Scaini, Kellen R. Simon AMT, Schuck, Estela N. B. Busanello, Alana P. Moura, Gustavo C. 
Ferreira, Moacir Wajner , Emilio L. Streck PF. Toxicity of octanoate and decanoate in rat 
peripheral tissues: evidence of bioenergetic dysfunction and oxidative damage induction in 
liver and skeletal muscle. Mol Cell Biochem 361: 329–335, 2012. 
48.  Gnaiger E. Bioenergetics at low oxygen: Dependence of respiration and phosphorylation on 
oxygen and adenosine diphosphate supply. Respir Physiol 128: 277–297, 2001. 
49.  Gnaiger E. Capacity of oxidative phosphorylation in human skeletal muscle. New perspectives 
of mitochondrial physiology. Int J Biochem Cell Biol 41: 1837–1845, 2009. 
50.  Gnaiger E. Mitochondrial Pathways and Respiratory control. OROBOROS MiPNet Publ 2: 43–53, 
2009. 
51.  Gnaiger E. Mitochondrial Pathways and Respiratory Control An Introduction to OXPHOS 
Analysis. 2014. 
52.  Gnaiger E, Boushel R, Søndergaard H, Munch-Andersen T, Damsgaard R, Hagen C, Díez-Sánchez 
C, Ara I, Wright-Paradis C, Schrauwen P, Hesselink M, Calbet JAL, Christiansen M, Helge JW, 
Saltin B. Mitochondrial coupling and capacity of oxidative phosphorylation in skeletal muscle of 
Inuit and Caucasians in the arctic winter. Scand J Med Sci Sport 25: 126–134, 2015. 
53.  Goncalves S, Paupe V, Dassa EP, Brière J-J, Favier J, Gimenez-Roqueplo A-P, Bénit P, Rustin P. 
Rapid determination of tricarboxylic acid cycle enzyme activities in biological samples. BMC 
Biochem 17: 5, 2010. 
54.  Grivennikova VG, Kapustin AN, Vinogradov AD. Catalytic activity of NADH-ubiquinone 
oxidoreductase (Complex I) in intact mitochondria: Evidence for the slow active/inactive 
transition. J Biol Chem 276: 9038–9044, 2001. 
105 
 
55.  Grivennikova VG, Serebryanaya D V, Isakova EP, Belozerskaya TA, Vinogradov AD. The transition 
between active and de-activated forms of NADH: ubiquinone oxidoreductase (Complex I) in 
the mitochondrial membrane of Neurospora crassa. Biochem J 369: 619–626, 2003. 
56.  Hailer RG, Henrikason KG, Jorfeldt L, Hultman E, Wibom R, Sahlin K, Areskog N, Gunder M, Ayyad 
K, Blomqvist CG, Hall RE, Thuillier P, Kennaway NG, Lewis SF. Deficiency of Skeletal Muscle 
Succinate Dehydrogenase and Aconitase. J Clin Invest 88: 1197–1206, 1991. 
57.  Haller RG, Henriksson KG, Jorfeldt L, Hultman E, Wibom R, Sahlin K, Areskog NH, Gunder M, 
Ayyad K, Blomqvist CG, Hall RE, Thuillier P, Kennaway NG, Lewis SF. Deficiency of skeletal 
muscle succinate dehydrogenase and aconitase. Pathophysiology of exercise in a novel human 
muscle oxidative defect. J Clin Invest 88: 1197–1206, 1991. 
58.  Han D, Canali R, Garcia J, Aguilera R, Gallaher TK, Cadenas E. Sites and Mechanisms of Aconitase 
Inactivation by Peroxynitrite : Modulation by. Biochemistry 44: 11986–11996, 2005. 
59.  Hocquette JF, Ortigues-Marty I, Pethick D, Herpin P, Fernandez X. Nutritional and hormonal 
regulation of energy metabolism in skeletal muscles of meat-producing animals. Livest Prod Sci 
56: 115–143, 1998. 
60.  Hoeks J, Briedé JJ, de Vogel J, Schaart G, Nabben M, Moonen-Kornips E, Hesselink MKC, 
Schrauwen P. Mitochondrial function, content and ROS production in rat skeletal muscle: 
Effect of high-fat feeding. FEBS Lett 582: 510–516, 2008. 
61.  Houten SM, Violante S, Ventura F V., Wanders RJA. The Biochemistry and Physiology of 
Mitochondrial Fatty Acid β-Oxidation and Its Genetic Disorders. Annu Rev Physiol 78: 23–44, 
2016. 
62.  Hutter E, Renner K, Pfister G, Ockl PS, Jansen-Urr P, Gnaiger E. Senescence-associated changes 
in respiration and oxidative phosphorylation in primary human fibroblasts. Biochem J 380: 
919–928, 2004. 
63.  Huynh FK, Green MF, Koves TR, Hirschey MD. Measurement of fatty acid oxidation rates in 
animal tissues and cell lines. 2014. 
64.  I.D. Wexler, S.G. Hemalatha, J. McConnell, N.R.M. Buist, H-H.M. Dahl, S.A. Berry, S.D. 
Cederbaum, M.S. Patel  and DSK. Outcome of pyruvate dehydrogenase deficiency treated with 
ketogenic diets: Studies in patients with identical mutations. Neurology 49: 1655–1661, 1997. 
65.  Ijlst L, Wanders RJ. A simple spectrophotometric assay for long-chain acyl-CoA dehydrogenase 
activity measurements in human skin fibroblasts. Ann Clin Biochem 30 ( Pt 3): 293–297, 1993. 
106 
 
66.  Kalyanaraman B, Claire M. Mitochondrial Aconitase Is a Source of Hydroxyl Radical. J Biol Chem 
275: 14064–14069, 2000. 
67.  Kelley DE, Mandarin LJ, Mandarino LJ. Fuel selection in human skeletal muscle in insulin 
resistance: a reexamination. Diabetes 49: 677–683, 2000. 
68.  Kim JY, Hickner RC, Cortright RL, Dohm GL, Houmard J a. Lipid oxidation is reduced in obese 
human skeletal muscle. Am J Physiol Endocrinol Metab 279: E1039–E1044, 2000. 
69.  Kohn TA, Myburgh KH. Regional specialization of rat quadriceps myosin heavy chain isoforms 
occurring in distal to proximal parts of middle and deep regions is not mirrored by citrate 
synthase activity. J Anat 210: 8–18, 2007. 
70.  Kroemer G, Pouyssegur J. Tumor Cell Metabolism: Cancer’s Achilles’ Heel. Cancer Cell 13: 472–
482, 2008. 
71.  Kumps A, Duez P, Mardens Y. Metabolic, nutritional, iatrogenic, and artifactual sources of 
urinary organic acids: A comprehensive table. Clin Chem 48: 708–717, 2002. 
72.  Kuznetsov A V, Schneeberger S, Seiler R, Brandacher G, Mark W, Steurer W, Saks V, Usson Y, 
Margreiter R, Gnaiger E. Mitochondrial defects and heterogeneous cytochrome c release after 
cardiac cold ischemia and reperfusion. Am J Physiol Heart Circ Physiol 286: H1633-41, 2004. 
73.  Lacobazzi V, Infantino V. Citrate-new functions for an old metabolite. Biol Chem 395: 387–399, 
2014. 
74.  Lamantea E, Carrara F, Mariotti C, Morandi L, Tiranti V, Zeviani M. A novel nonsense mutation 
(Q352X) in the mitochondrial cytochrome b gene associated with a combined deficiency of 
complexes I and III. Neuromuscul Disord 12: 49–52, 2002. 
75.  Larsen FJ, Schiffer TA, Ørtenblad N, Zinner C, Morales-Alamo D, Willis SJ, Calbet JA, Holmberg 
HC, Boushel R. High-intensity sprint training inhibits mitochondrial respiration through 
aconitase inactivation. FASEB J 30: 417–427, 2016. 
76.  Larsen S, Danielsen JH, Søndergård SD, Søgaard D, Vigelsoe A, Dybboe R, Skaaby S, Dela F, Helge 
JW. The effect of high-intensity training on mitochondrial fat oxidation in skeletal muscle and 
subcutaneous adipose tissue. Scand J Med Sci Sport 25: e59–e69, 2015. 
77.  Larsen S, Kraunsøe R, Gram M, Gnaiger E, Helge JW, Dela F. The best approach: 
Homogenization or manual permeabilization of human skeletal muscle fibers for 
respirometry? Anal Biochem 446: 64–68, 2014. 
107 
 
78.  Lauble H, Kennedy MC, Emptage MH, Beinert H, Stout CD. The reaction of fluorocitrate with 
aconitase and the crystal structure of the enzyme-inhibitor complex. Proc Natl Acad Sci U S A 
93: 13699–13703, 1996. 
79.  Le W, Abbas AS, Sprecher H, Vockley J, Schulz H. Long-chain acyl-CoA dehydrogenase is a key 
enzyme in the mitochondrial β-oxidation of unsaturated fatty acids. Biochim Biophys Acta - 
Mol Cell Biol Lipids 1485: 121–128, 2000. 
80.  Lehman TC, Thorpe C. Alternate Electron Acceptors for Medium-Chain Acyl-CoA 
Dehydrogenase: Use of Ferricenium Salts. Biochemistry 29: 10594–10602, 1990. 
81.  Li J, Zhao S, Zhou X, Zhang T, Zhao L, Miao P, Song S, Sun X, Liu J, Zhao X, Huang G. Inhibition of 
lipolysis by mercaptoacetate and etomoxir specifically sensitize drug-resistant lung 
adenocarcinoma cell to paclitaxel. PLoS One 8: e746323, 2013. 
82.  Li W, Hu Z-F, Chen B, Ni G-X. Response of C2C12 Myoblasts to Hypoxia: The Relative Roles of 
Glucose and Oxygen in Adaptive Cellular Metabolism. Biomed Res Int 2013, 2013. 
83.  Lian XY, Stringer JL. Inhibition of aconitase in astrocytes increases the sensitivity to chemical 
convulsants. Epilepsy Res 60: 41–52, 2004. 
84.  Lian XY, Stringer JL. Astrocytes contribute to regulation of extracellular calcium and potassium 
in the rat cerebral cortex during spreading depression. Brain Res 1012: 177–184, 2004. 
85.  Liang-Jun Yan RLL and RSS. Oxidative damage during aging targets mitochondrial aconitase. 
Proc Natl Acad Sci 94: 11168–11172, 1997. 
86.  Lim SC, Tajika M, Shimura M, Carey KT, Stroud DA, Murayama K, Ohtake A, McKenzie M. Loss of 
the Mitochondrial Fatty Acid β-Oxidation Protein Medium-Chain Acyl-Coenzyme A 
Dehydrogenase Disrupts Oxidative Phosphorylation Protein Complex Stability and Function. Sci 
Rep 8: 1–17, 2018. 
87.  Lippel K, Beattie DS. The submitochondrial distribution of acid:CoA ligase (AMP) and acid:CoA 
ligase (GDP) in rat liver mitochondria. Biochim Biophys Acta (BBA)/Lipids Lipid Metab 218: 227–
232, 1970. 
88.  López-Ríos F, Sánchez-Aragó M, García-Garía E, Ortega ÁD, Berrendero JR, Pozo-Rodríguez F, 
López-Encuentra Á, Ballestín C, Cuezva JM. Loss of the mitochondrial bioenergetic capacity 
underlies the glucose avidity of carcinomas. Cancer Res 67: 9013–9017, 2007. 
89.  Lu Z, Sack MN. ATF-1 is a hypoxia-responsive transcriptional activator of skeletal muscle 
108 
 
mitochondrial-uncoupling protein 3. J Biol Chem 283: 23410–23418, 2008. 
90.  Lunt SY, Vander Heiden MG. Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell 
Proliferation. Annu Rev Cell Dev Biol 27: 441–464, 2011. 
91.  M. D. Brand, Susan M. Evans JM-M and JBC. Fluorocitrate Inhibition. Biochem J 134: 217–224, 
1973. 
92.  Makrecka-Kuka M, Krumschnabel G, Gnaiger E. High-resolution respirometry for simultaneous 
measurement of oxygen and hydrogen peroxide fluxes in permeabilized cells, tissue 
homogenate and isolated mitochondria. Biomolecules 5: 1319–1338, 2015. 
93.  Margreth A, Azzone GF. A study of respiration in fluoroacetate-poisoned muscle preparations. 
Biochem J 92: 73–82, 1964. 
94.  Martines ACMF, van Eunen K, Reijngoud DJ, Bakker BM. The promiscuous enzyme medium-
chain 3-keto-acyl-CoA thiolase triggers a vicious cycle in fatty-acid beta-oxidation. PLoS 
Comput Biol 13: e1005461, 2017. 
95.  Matsumura S, Saitou K, Miyaki T, Yoneda T, Mizushige T, Eguchi A, Shibakusa T, Manabe Y, 
Tsuzuki S, Inoue K, Fushiki T. Mercaptoacetate inhibition of fatty acid beta-oxidation attenuates 
the oral acceptance of fat in BALB/c mice. Am J Physiol Regul Integr Comp Physiol 295: R82-91, 
2008. 
96.  De Meirleir LJ, Van Coster R, Lissens W. Disorders of pyruvate metabolism and the tricarboxylic 
acid cycle. 2006. 
97.  Mirsattari SM, Shen B, Leung LS, Rajakumar N. A gliotoxin model of occipital seizures in rats. 
Seizure 17: 483–489, 2008. 
98.  Mookerjee SA, Gerencser AA, Nicholls DG, Brand MD. Quantifying intracellular rates of 
glycolytic and oxidative ATP production and consumption using extracellular flux 
measurements. J Biol Chem 292: 7189–7207, 2017. 
99.  Morand C, Besson C, Demigne C, Remesy C. Importance of the Modulation of Glycolysis in the 
Control of Lactate Metabolism by Fatty Acids in Isolated Hepatocytes from Fed Rats. Arch. 
Biochem. Biophys. 309: 254–260, 1994. 
100.  Murphy SM, Jakeman PM, Kiely PA, Kiely M, Carson BP. Optimization of an in vitro bioassay to 
monitor growth and formation of myotubes in real time. Biosci Rep 36: e00330–e00330, 2016. 
101.  Murray AJ, Cole MA, Lygate CA, Carr CA, Stuckey DJ, Little SE, Neubauer S, Clarke K. Increased 
109 
 
mitochondrial uncoupling proteins, respiratory uncoupling and decreased efficiency in the 
chronically infarcted rat heart. J Mol Cell Cardiol 44: 694–700, 2008. 
102.  Nabben M, Hoeks J, Briedé JJ, Glatz JFC, Moonen-Kornips E, Hesselink MKC, Schrauwen P. The 
effect of UCP3 overexpression on mitochondrial ROS production in skeletal muscle of young 
versus aged mice. FEBS Lett 582: 4147–4152, 2008. 
103.  Nada MA, Chace DH, Sprecher H, Roe CR. Investigation of β-oxidation intermediates in normal 
and MCAD-deficient human fibroblasts using tandem mass spectrometry. Biochem Mol Med 
54: 59–66, 1995. 
104.  Najdekr L, Gardlo A, Mádrová L, Friedecký D, Janečková H, Correa ES, Goodacre R, Adam T. 
Oxidized phosphatidylcholines suggest oxidative stress in patients with medium-chain acyl-CoA 
dehydrogenase deficiency. Talanta 139: 62–66, 2015. 
105.  Nima N. Naseri, Hui Xu, Joseph Bonica, Jean Paul G. Vonsattel, Etty P. Cortes, Larry C. Park, 
Jamshid Arjomand  and GEG. Abnormalities in the Tricarboxylic Acid Cycle in Huntington 
Disease and in a Huntington Disease Mouse Model. J Neuropathol Exp Neurol 74: 527–537, 
2016. 
106.  Nouws J, Te brinke H, Nijtmans LG, Houten SM. ACAD9, a complex I assembly factor with a 
moonlighting function in fatty acid oxidation deficiencies. Hum Mol Genet 23: 1311–1319, 
2014. 
107.  Nsiah-Sefaa A, McKenzie M. Combined defects in oxidative phosphorylation and fatty acid  -
oxidation in mitochondrial disease. Biosci Rep 36: e00313–e00313, 2016. 
108.  O’Reilly LP, Andresen BS, Engel PC. Two novel variants of human medium chain acyl-CoA 
dehydrogenase (MCAD): K364R, a folding mutation, and R256T, a catalytic-site mutation 
resulting in a well-folded but totally inactive protein. FEBS J 272: 4549–4557, 2005. 
109.  Oezen I, Rossmanith W, Forss-Petter S, Kemp S, Voigtländer T, Moser-Thier K, Wanders RJ, 
Bittner RE, Berger J. Accumulation of very long-chain acids does not affect mitochondrial 
function in adrenoleukodystrophy protein deficiency. Hum Mol Genet 14: 1127–1137, 2005. 
110.  Ohta Shigeo IO. Contribution of dysfunction of mitochondria and oxidative stress in the 
pathogenesis of Alzheimer’s disease: On defects in the cytochrome c oxidase complex and 
aldehyde detoxification. J Alzheimer’s Dis 9: 155–166, 2006. 
111.  Ojuka E, Andrew B, Bezuidenhout N, George S, Maarman G, Madlala HP, Mendham A, Osiki PO. 
Measurement of beta-oxidation capacity of biological samples by respirometry: A review of 
110 
 
principles and substrates. Am J Physiol Endocrinol Metab 310: E715–E723, 2016. 
112.  Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell death. 
Apoptosis 12: 913–922, 2007. 
113.  Owens KM, Kulawiec M, Desouki MM, Vanniarajan A, Keshav K. Impaired OXPHOS Complex III in 
Breast Cancer. pone0023846 6: 3–118, 2011. 
114.  Palmeira CM, Moreno AJ. Mitochondrial Bioenergetics. 2nd ed. Springer New York, 2018. 
115.  Perevoshchikova I V., Quinlan CL, Orr AL, Gerencser AA, Brand MD. Sites of superoxide and 
hydrogen peroxide production during fatty acid oxidation in rat skeletal muscle mitochondria. 
Free Radic Biol Med 61: 298–309, 2013. 
116.  Pesta D, Hoppel F, Macek C, Messner H, Faulhaber M, Kobel C, Parson W, Burtscher M, Schocke 
M, Gnaiger E. Similar qualitative and quantitative changes of mitochondrial respiration 
following strength and endurance training in normoxia and hypoxia in sedentary humans. AJP 
Regul Integr Comp Physiol 301: R1078–R1087, 2011. 
117.  Phielix E, Schrauwen-hinderling VB, Mensink M, Lenaers E, Meex R, Hoeks J, Kooi ME, Moonen-
kornips E, Sels J, Hesselink MKC, Schrauwen P. Lower intrinsic ADP stimulated mitochondrial 
respirationin underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic 
patients. Diabetes 57: 2943–2949, 2008. 
118.  Porter C, Hurren NM, Cotter M V., Bhattarai N, Reidy PT, Dillon EL, Durham WJ, Tuvdendorj D, 
Sheffield-Moore M, Volpi E, Sidossis LS, Rasmussen BB, Børsheim E. Mitochondrial respiratory 
capacity and coupling control decline with age in human skeletal muscle. Am J Physiol - 
Endocrinol Metab 309: E224–E232, 2015. 
119.  Puchowicz MA, Varnes ME, Cohen BH, Friedman NR, Kerr DS, Hoppel CL. Oxidative 
phosphorylation analysis: assessing the integrated functional activity of human skeletal muscle 
mitochondria—case studies. Mitochondrion 4: 377–385, 2004. 
120.  Rana Ziadeh, Eric P. Hoffman, David N. Finegold, Rita C. Hoop, Jeffrey C. Brackett, Arnold W. 
Strauss AEWN. Medium Chain Acyl-CoA Dehydrogenase Deficiency in Pennsylvania: Neonatal 
Screening Shows High Incidence and Unexpected Mutation Frequencies. Pediatr Res 37: 675–
678, 1995. 
121.  Reis De Assis D, Maria RDC, Borba Rosa R, Schuck PF, Ribeiro CAJ, Da Costa Ferreira G, Dutra-
Filho CS, Terezinha De Souza Wyse A, Duval Wannmacher CM, Santos Perry ML, Wajner M. 
Inhibition of energy metabolism in cerebral cortex of young rats by the medium-chain fatty 
111 
 
acids accumulating in MCAD deficiency. Brain Res 1030: 141–151, 2004. 
122.  Rena E. Falk, M.D., Stephen D. Cederbaum, M.D., John P. Blass, M.D., Ph.D., Gary E. Gibson, 
Ph.D., R. A. Pieter Kark, M.D., and Robert E. Carrel MD. Ketonic Diet in the Management of 
Pyruvate Dehydrogenase Deficiency. Pediatr Res 58: 713–721, 1976. 
123.  Rinaldo P, Matern D. Disorders of fatty acid transport and mitochondrial oxidation: Challenges 
and dilemmas of metabolic evaluation. Genet Med 2: 338–344, 2000. 
124.  Rinaldo P, Matern D, Bennett MJ. Fatty Acid Oxidation Disorders. Annu Rev Physiol 64: 477–
502, 2002. 
125.  Rotig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, Munnich A RP. Aconitase and 
mitochondrial iron–sulphur protein deficiency in Friedreich ataxia. Nat Genet 17: 215–217, 
1997. 
126.  Rustin P, Bourgeron T, Parfait B, Chretien D, Munnich A, Rotig A. Inborn errors of the krebs 
cycle: a group of unusual mitochondrial diseases in human. Biochim Biophys Acta 1361: 185–
197, 1997. 
127.  S. M. S. Budde, L.P.W.J.van den Heuvel, R.J.P. Smeets, D.Skladal, J. A. Mayr, C. Boelen, V. 
Petruzzella SP and JAMS 1Nijmegen. Clinical heterogeneity in patients with mutations in the 
NDUFS4 gene of mitochondrial complex I. j.inherit.metab 26: 813–815, 2003. 
128.  Sakai C, Yamaguchi S, Sasaki M, Miyamoto Y, Matsushima Y, Goto Y ichi. ECHS1 mutations cause 
combined respiratory chain deficiency resulting in leigh syndrome. Hum Mutat 36: 232–239, 
2015. 
129.  Saks VA, Veksler VI, Kuznetsov A V., Kay L, Sikk P, Tiivel T, Tranqui L, Olivares J, Winkler K, 
Wiedemann F, Kunz WS. Permeabilized cell and skinned fiber techniques in studies of 
mitochondrial function in vivo. In: Bioenergetics of the Cell: Quantitative Aspects. 1998. 
130.  Sauer SW, Okun JG, Hoffmann GF, Koelker S, Morath MA. Impact of short- and medium-chain 
organic acids, acylcarnitines, and acyl-CoAs onmitochondrial energy metabolism. Biochim 
Biophys Acta - Bioenerg 1777: 1276–1282, 2008. 
131.  Scha¨gger H. Respiratory chain supercomplexes of mitochondria and bacteria Hermann. 
Biochim Biophys Acta 1555: 154–159, 2002. 
132.  Schlichtholz B, Turyn J, Goyke E, Biernacki M, Jaskiewicz K, Sledzinski Z, Swierczynski J. Enhanced 
citrate synthase activity in human pancreatic cancer. Pancreas 30: 99–104, 2005. 
112 
 
133.  Scholte HR, Ross JD, Blom W, Boonman AMC, van Diggelen OP, Hall CL, Huijmans JGM, Luyt-
Houwen IEM, Kleijer WJ, de Klerk JBC, Przyrembel H, Verduin MHM, Verstegen JCM. Assessment 
of deficiencies of fatty acyl-CoA dehydrogenases in fibroblasts, muscle and liver. J Inherit 
Metab Dis 15: 347–352, 1992. 
134.  Schönfeld P, Wieckowski MR, Lebiedzińska M, Wojtczak L. Mitochondrial fatty acid oxidation 
and oxidative stress: Lack of reverse electron transfer-associated production of reactive 
oxygen species. Biochim Biophys Acta - Bioenerg 1797: 929–938, 2010. 
135.  Schöpf B, Schäfer G, Weber A, Talasz H, Eder IE, Klocker H, Gnaiger E. Oxidative phosphorylation 
and mitochondrial function differ between human prostate tissue and cultured cells. FEBS J 
283: 2181–2196, 2016. 
136.  Schuck PF, Ceolato PC, Ferreira GC, Tonin A, Leipnitz G, Dutra-Filho CS, Latini A, Wajner M. 
Oxidative stress induction by cis-4-decenoic acid: Relevance for MCAD deficiency. Free Radic 
Res 41: 1261–1272, 2007. 
137.  Schuck PF, da Costa Ferreira G, Tonin AM, Viegas CM, Busanello ENB, Moura AP, Zanatta Â, 
Klamt F, Wajner M. Evidence that the major metabolites accumulating in medium-chain acyl-
CoA dehydrogenase deficiency disturb mitochondrial energy homeostasis in rat brain. Brain 
Res 1296: 117–126, 2009. 
138.  Schuck PF, Ferreira G da C, Tahara EB, Klamt F, Kowaltowski AJ, Wajner M. Cis-4-decenoic acid 
provokes mitochondrial bioenergetic dysfunction in rat brain. Life Sci 87: 139–146, 2010. 
139.  Schuck PF, Ferreira GC, Moura AP, Busanello ENB, Tonin AM, Dutra-Filho CS, Wajner M. 
Medium-chain fatty acids accumulating in MCAD deficiency elicit lipid and protein oxidative 
damage and decrease non-enzymatic antioxidant defenses in rat brain. Neurochem Int 54: 
519–525, 2009. 
140.  Schuler AM, Wood PA. Mouse models for disorders of mitochondrial fatty acid beta-oxidation. 
ILAR J 43: 57–65, 2002. 
141.  Seifert EL, Estey C, Xuan JY, Harper ME. Electron transport chain-dependent and -independent 
mechanisms of mitochondrial H2O2 emission during long-chain fatty acid oxidation. J Biol 
Chem 285: 5748–5758, 2010. 
142.  Shen JJ, Matern D, Millington DS, Hillman S, Feezor MD, Bennett MJ, Qumsiyeh M, Kahler SG, 
Chen YT, Van Hove JLK. Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-
CoA dehydrogenase deficiency and other fatty acid oxidation disorders. J Inherit Metab Dis 23: 
113 
 
27–44, 2000. 
143.  Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc 
Natl Acad Sci 91: 10771–10778, 2006. 
144.  Silberstein L, Webster SG, Travis M, Blau HM. Developmental progression of myosin gene 
expression in cultured muscle cells. Cell 46: 1075–1081, 1986. 
145.  Simon Eaton KB and MP. Mammalian mitochondrial β-oxidation. Biochem J 320: E1039-
E1044A345-357, 1996. 
146.  Sofou K, Dahlin M, Hallböök T, Lindefeldt M, Viggedal G, Darin N. Ketogenic diet in pyruvate 
dehydrogenase complex deficiency: short- and long-term outcomes. J Inherit Metab Dis 40: 
237–245, 2017. 
147.  Spiekerkoetter U. Effects of a fat load and exercise on asymptomatic VLCAD deficiency. J Inherit 
Metab Dis 30: 405, 2007. 
148.  Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, Das A, Haase C, 
Hennermann JB, Karall D, de Klerk H, Knerr I, Koch HG, Plecko B, Röschinger W, Schwab KO, 
Scheible D, Wijburg FA, Zschocke J, Mayatepek E, Wendel U. Management and outcome in 75 
individuals with long-chain fatty acid oxidation defects: Results from a workshop. J Inherit 
Metab Dis 32: 488–497, 2009. 
149.  Spiekerkoetter Ute PAW. Mitochondrial fatty acid oxidation disorders: Pathological studies in 
mouse models. 33: 539–546, 2010. 
150.  Stadlmann S, Rieger G, Amberger A, Kuznetsov A V., Margreiter R, Gnaiger E. H2O2-mediated 
oxidative stress versus cold ischemia-reperfusion: Mitochondrial respiratory defects in 
cultured human endothelial cells. Transplantation 74: 1800–18003, 2002. 
151.  Steiber A, Kerner J, Hoppel CL. Carnitine: A nutritional, biosynthetic, and functional perspective. 
Mol Aspects Med 25: 455–473, 2004. 
152.  Steinlechner-Maran R, Eberl T, Kunc M, Margreiter R, Gnaiger E. Oxygen dependence of 
respiration in coupled and uncoupled endothelial cells. Am J Physiol Physiol 271: C2053–
C2061, 1996. 
153.  Sugden MC, Holness MJ, Palmer TN. Fuel selection and carbon flux during the starved-to-fed 
transition. Biochem J 263: 313–23, 1989. 
154.  Sumegi B, Srere PA. Complex I binds several mitochondrial NAD-coupled dehydrogenases. J Biol 
114 
 
Chem 259: 15040–15045, 1984. 
155.  Tajima G, Sakura N, Yofune H, Nishimura Y, Ono H, Hasegawa Y, Hata I, Kimura M, Yamaguchi S, 
Shigematsu Y, Kobayashi M. Enzymatic diagnosis of medium-chain acyl-CoA dehydrogenase 
deficiency by detecting 2-octenoyl-CoA production using high-performance liquid 
chromatography: A practical confirmatory test for tandem mass spectrometry newborn 
screening in Japan. J Chromatogr B Anal Technol Biomed Life Sci 823: 122–130, 2005. 
156.  Taylor RW, Jackson S, Pourfarzam M, Bartlett K, Turnbull DM. Measurement of acyl-CoA 
dehydrogenase activity in cultured skin fibroblasts and blood platelets. J Inherit Metab Dis 15: 
727–732, 1992. 
157.  Taylor WA, Mejia EM, Mitchell RW, Choy PC, Sparagna GC, Hatch GM. Human Trifunctional 
Protein Alpha Links Cardiolipin Remodeling to Beta-Oxidation. PLoS One 7: e48628, 2012. 
158.  Tein I. Handbook of Clinical Neurology: Disorders of fatty acid oxidation. 3rd ed. Elsevier B.V., 
2013. 
159.  Tein I. Impact of fatty acid oxidation disorders in child neurology: From Reye syndrome to 
Pandora’s box. Dev Med Child Neurol 57: 304–306, 2015. 
160.  Tetreault M, Fahiminiya S, Antonicka H, Mitchell GA, Geraghty MT, Lines M, Boycott KM, 
Shoubridge EA, Mitchell JJ, Michaud JL, Majewski J. Whole-exome sequencing identifies novel 
ECHS1 mutations in Leigh syndrome. Hum Genet 134: 981–991, 2015. 
161.  Tonin AM, Grings M, Knebel LA, Zanatta Â, Moura AP, Ribeiro CAJ, Leipnitz G, Wajner M. 
Disruption of redox homeostasis in cerebral cortex of developing rats by acylcarnitines 
accumulating in medium-chain acyl-CoA dehydrogenase deficiency. Int J Dev Neurosci 30: 383–
390, 2012. 
162.  Tremblay LA, Fisher P, Leusch FDL, Heuvel MR Van Den, Nicolas J, Pillon A, Balaguer P. Potential 
of Sodium Fluoroacetate (1080) and Fluorocitrate to Bind to Androgen and Oestrogen 
Receptors. Australas J Ecotoxicol 1080: 155–162, 2004. 
163.  Tremblay LA, Fisher P, Leusch FDL, Heuvel MR Van Den, Nicolas J, Pillon A, Balaguer P. Potential 
of Sodium Fluoroacetate (1080) and Fluorocitrate to Bind to Androgen and Oestrogen 
Receptors. Australas J Ecotoxicol 1080: 155–162, 2005. 
164.  Turner N, Bruce CR, Beale SM, Hoehn KL, So T, Rolph MS, Cooney GJ. Excess lipid availability 
increases mitochondrial fatty acid oxidative capacity in muscle: Evidence against a role for 
reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes 56: 2085–
115 
 
2092, 2007. 
165.  Tyni T, Majander A, Kalimo H, Rapola J, Pihko H. Pathology of skeletal muscle and impaired 
respiratory chain function in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency with the 
G1528C mutation. Neuromuscul Disord 6: 327–337, 1996. 
166.  Villani G, Attardi G. In vivo control of respiration by cytochrome c oxidase in wild-type and 
mitochondrial DNA mutation-carrying human cells. Proc Natl Acad Sci U S A 94: 1166–71, 
1997. 
167.  Villarreal-Pérez JZ, Villarreal-Martínez JZ, Lavalle-González FJ, Torres-Sepúlveda MDR, Ruiz-
Herrera C, Cerda-Flores RM, Castillo-García ER, Rodríguez-Sánchez IP, Martínez de Villarreal LE. 
Plasma and urine metabolic profiles are reflective of altered beta-oxidation in non-diabetic 
obese subjects and patients with type 2 diabetes mellitus. Diabetol Metab Syndr 6: 129, 2014. 
168.  Vockley J, Whiteman DAH. Defects of mitochondrial β-oxidation: A growing group of disorders. 
Neuromuscul. Disord. 12: 235–246, 2002. 
169.  Votion DM, Gnaiger E, Lemieux H, Mouithys-Mickalad A, Serteyn D. Physical fitness and 
mitochondrial respiratory capacity in horse skeletal muscle. PLoS One 7: e34890, 2012. 
170.  Wajner M, Amaral AU. Mitochondrial dysfunction in fatty acid oxidation disorders: insights 
from human and animal studies. Biosci Rep 36: e00281–e00281, 2016. 
171.  Wanders RJ, Vreken P, den Boer ME, Wijburg F a, van Gennip  a H, IJlst L. Disorders of 
mitochondrial fatty acyl-CoA beta-oxidation. J Inherit Metab Dis 22: 442–87, 1999. 
172.  Wanders RJA, Ruiter JPN, IJlst L, Waterham HR, Houten SM. The enzymology of mitochondrial 
fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal 
screening results. J Inherit Metab Dis 33: 479–494, 2010. 
173.  Wang H, Sreenivasan U, Gong D-W, O’Connell K a, Dabkowski ER, Hecker P a, Ionica N, Konig M, 
Mahurkar A, Sun Y, Stanley WC, Sztalryd C. Cardiomyocyte-specific perilipin 5 overexpression 
leads to myocardial steatosis and modest cardiac dysfunction. J Lipid Res 54: 953–65, 2013. 
174.  Wang Y, Mohsen AW, Mihalik SJ, Goetzman ES, Vockley J. Evidence for physical association of 
mitochondrial fatty acid oxidation and oxidative phosphorylation complexes. J Biol Chem 285: 
29834–29841, 2010. 
175.  Ward PF, Peters RA. The chemical and biochemical properties of fluorocitric acid. Biochem J 78: 
661–668, 1961. 
116 
 
176.  Warren BE, Lou P-H, Lucchinetti E, Zhang L, Clanachan AS, Affolter A, Hersberger M, Zaugg M, 
Lemieux H. Early mitochondrial dysfunction in glycolytic muscle, but not oxidative muscle, of 
the fructose-fed insulin-resistant rat. AJP Endocrinol Metab 306: E658–E667, 2014. 
177.  Winterbourn CC. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol Lett 82–
83: 969–974, 1995. 
178.  Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic 
mouse muscle. Nature 270: 725–727, 1977. 
179.  Zheng J. Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (review). 
Oncol Lett 4: 1151–1157, 2012. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 
 
Appendix 
A.1 Determination of the effective concentration of inhibitors: Protocol for MTT Assay 
The purpose of this experiment is to determine the effective concentrations of inhibitors to be used as 
well as time of treatment for each. Three biological repeats to be applied for this determination.  
  Grow 3000 cells per well in a 96 well plate 
 For the two inhibitors, use the following concentrations; (0, 0.25, 0.5, 1, 2, 4, 6, 8, 10 mM). 
 Plate each concentration in triplicate; 27 wells (9 x 3) for each inhibitor; 54 wells for both 
inhibitor (see figure A.1) 
 Fill the edges of the plate with 200μL of media to prevent evaporation of media in the 
remaining wells. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A      200UL       
B             
C    FIRST INHIBITOR  90UL      
D           BLANK 200UL 
E           100UL  
F    SECOND INHIBITOR  90UL      
G             
H      200UL       
 
Figure A.1: Plate layout for MTT assay 
 
Plating of cells 
  
 
 
 
Ff4
Ff4
Ff4
 
MTT Assay 
P5 P6 
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 Use a plate per treatment time point (4, 12 & 24 hrs), hence 3 plates in total 
 The 3 plates would be plated with cells at the same time 
 Suspend cells in 90μL of Dmem++. Hence to get 3000 in 90μL; 
 
54 wells per plate; 3 plates X 54 wells = 162 wells ≈ 200 wells 
90μL in 200 wells = 18, 000μL 
Want; 3000 cells in 90μL 
Hence, 60 X 104 cells in 18000μL 
Therefore, will need to have 600, 000 cells in 18ml to get 3000 cells in 90μL of Dmem++ (Differentiation 
media). 
 
Concentration of Inhibitors 
 The inhibitors are miscible in DMEM 
 Make up 1M of main stock solution. 
 Re-dilute to 100mM 
 
Using C1V1=C2V2  : C1= 1M, C2=100mM, V2=1000μL, V1= ? 
V1= 100μL 
Therefore, 100μL of 1M stock solution into 900μL of Dmem++. 
 10μL of the inhibitor will be added to 90μL of Dmem++ (fig 1) 
 For each concentration there will be 30μL/plate (each concentration is done in triplicate). 
Hence, for the three plates, there will be 90μL/conc. To account for errors and easy pipetting, 
number would be rounded off to 150μL. 
 Hence, prepare a 150μL stock solution such that on adding 10μL of this to each well, should 
obtain the desired final concentration. See Table A.1 below. 
 Dilute 10X concentration in 150μL of Dmem++ 
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 To get 1X concentration, add 10μL of the 10X concentration into the 90μL media containing 
seeded cells. 
For example: 
For 0.25mM; 1x = 0.25mM and 10X = 2.5mM 
To make a 10X solution; Using C1V1=C2V2  : C1= 100mM, C2=2.5mM, V2=150μL, V1= ? 
V1=3.75μL 
Therefore; 3.75μL of 100mM inhibitor stock will be added to 146.25μL Dmem+. 
To make 1X solution; C1V1=C2V2  : C1= 2.5mM, C2=0.25mM, V2=100μL, V1= ? 
V1= 10μL 
Therefore; 10μL of 2.5mM 10X inhibitor solution will be added to 90μL Dmem+ cell suspension in well. 
The same calculation repeated for all the remaining concentrations and shown in table A.1. 
 
Table A.1: Concentration and volume of inhibitor 
 1XmM (final concentration 
required) 
10XmM (starting 
concentration) 
Media (μL) Inhibitor 
(μL) 
A 0 0 150 0 
B 0.25 2.5 146.25 3.75 
C 0.5 5.0 142.5 7.5 
D 1 10 135 15 
E 2 20 120 30 
F 4 40 90 60 
G 6 60 60 90 
H 8  80 30 120 
 10 100 0 150 
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6.1.2 Steps to be followed on each day of experiment 
Day 1: 
 Cell lines used- C2C12, passage number of 5 
 Defrost 1 vial of frozen cells quickly at room temperature 
 Combine with 5ml of Dmem++ in a 15ml falcon tube, centrifuge to get pellets 
 Re-suspend pellets in 1ml of Dmem++ and add to 6ml of Dmem++ in a flask 
 Return flask to the incubator 
Day 2: 
 Once the cells from day 1 have reached about 80% confluency (about 700,000cells), trypsinize 
to lift cells off tissue culture flask, re-suspend in 5ml of Dmem++ in a 15ml falcon tube, centrifuge 
to get pellets 
 Pellets will be resuspended in 18ml of fresh media. Pipette several times to obtain single cell 
suspensions. 
 Load Neubaur haemocytometer with 20 μL of cell suspension for cell counting. 
 Record and average cell counts for each of the 4 segments of the counting chamber. 
 Use average count for preparing the cell suspension to be used for plating. 
 Add Dmem++ to each well of the 96-well plate according to figure A.1 
 For wells containing cells, after thorough mixing of cell suspension, add 90 μL of this to each as 
per figure 1. 
 Return plates to the incubator 
Day 3: 
 Once the cells have reached 90% confluency, switch growth media, Dmem++ to a differentiation 
medium- Dmem+. 
Day 5-9: 
 Change differentiation media every second day till the cells have differentiated for 7 days. 
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Day 9: 
 Treat cells with the respective inhibitor concentrations as per table A.1 
 Add 150 μL of the inhibitor solution into a new 96-well plate; this would ensure ease of transfer 
of the solution by multi pipetting into each well as detailed in figure A.1 and table A.1. 
 
 
0.0mM 
(150μL) 
0.25mM 
(150μL) 
0.5mM 
(150μL) 
1mM 
(150μL) 
2mM 
(150μL) 
4mM 
(150μL) 
6mM 
(150μL) 
8mM 
(150μL) 
10mM 
(150μL) 
 
 Add 10 μL of inhibitor solution to each well of the three 96-well plates and note the time of 
treatment 
 Treat Each plate for the next step after its incubation period is over 
 Plate 1: 4 hrs, Plate 2: 12 hrs, Plate 3: 24 hrs. 
 
E.G after 24 hours: 
 Add 10μL of MTT solution to each of the wells containing cells as well as the blank well  
 4 hours later, add 100μL of solubilisation solution to the wells and incubate overnight 
 The next morning, read the absorbance using a microplate reader at 595nm, analyse with 
Graph pad Prism software 
 
Solubilisation solution (250ml) 
25g of SLS (Sodium lauryl Sulphate) 
250ml of distilled water 
76.6ul Conc. HCL 
 Follow the same steps for all the other time points.  
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A.2 Optimization of digitonin for permeabilizing cells  
 
The purpose of this is to get the effective concentration of digitonin that would completely permeabilize 
cells. Digitonin concentration for permeabilization of cells must be optimized for each cell type/cell line 
and cell concentration used in respirometry. A single experiment is sufficient to determine this 
concentration. 
 Grow myotubes for 6 days and collect pellets 
 Place pellets (106 cells) in two Oxygraphy-2K chambers 
 The following protocol will be used; 
SUIT Protocol 
i. First, observe routine respiration after cells have been placed into the O2K 
ii. Add rotenone, 1μg/ml (inhibitor of complex I) to block respiration 
iii. Add Substrates; 20μl succinate (10mM) and 10μl ADP (2.5mM). These do not stimulate 
respiration in intact cells, slight increase will represent damaged cells 
iv. Digitonin (5mg/ml) is add in 1μl steps up to 10μg/ml. This is to progressively permeabilize the 
plasma membrane up to an optimum allowing access of substrates to the mitochondria, while 
leaving the membrane intact. 
Respiration is expected to increase with progressive addition of digitonin, once a decrease begins to 
occur, it signifies over titration of digitonin and thus the maximum concentration needed to 
permeabilize the cells can be determined.  
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A.3 Aconitase assay Methodology 
Principle  
This assay monitors the activity of aconitase indirectly by monitoring the reduction of NAD-dependent 
isocitrate dehydrogenase. Citrate is converted by aconitase into isocitrate, which is further broken into 
α-ketoglutarate by isocitrate dehydrogenase. The reduction of NADP at 340nm is monitored kinetically 
over an hour. 
 
 
Chemicals 
Tri-sodium citrate (Uviv AR 58225000), β-NADP+ (Sigma N050), MgCl2 (Merck), isocitrate 
dehydrogenase (ICDH) (Sigma 94596), MgCl2 (Merck), Tris-Cl (Sigma 77861) 
Stock solutions 
Tris-buffer                   0.2 M, Mw = 121.14 g/mol (1.21 g in 50ml dH2O) pH 7.4 
Tri-sodium citrate      0.5 M, Mw = 294.10 g/mol (1.47 g in 10 ml DH2O) 
MgCl2                            0.5 M, Mw = 203.3 g/mol (2.03 g in 20 ml dH2O) 
Β-NADP+                       0.1 M, Mw = 743.4 g/mol (74.34 mg in 1 ml dH2O) 
ICDH                              100 Units/ml  
Table A.2: Aconitase assay reagent solutions: 
Reagents Stock 
Concentration 
1 ml 10 ml 25 ml Final 
Concentration 
Tris-Buffer                    0.2 M 250 μl 2.5 ml 6.25 ml 50 mM 
Tri-sodium citrate       0.5 M 4 μl 40 µl 100 µl 2 mM 
MgCl2 0.5 M 1 μl 10 µl 25 µl 0.5 mM 
Β-NADP+                        0.1 M 2 μl 20 µl 50 µl 0.2 mM 
ICDH 100 U/ml 15 µl 150 µl 375 µl 1.5 U/ml 
Fill up with DH2O, pH 7.4 
 
Citrate                                      Isocitrate                                  α-ketoglutarate 
Aconitase 
NAD+ NADH + H+ 
Isocitrate dehydrogenase 
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Generating NADPH standard 
Chemicals: 
NADPH Sigma  N7505 
Na2CO3 Merck 6392 
NaHCO3 Merck 6329 
Buffer: 
 
Na2CO3 0.08 M Mw 105.99 0.848 g 
NaHCO3 0.02 M Mw 84.01 0.168 g 
 Make up to 100 ml dH20 
NADPH ± 5 mM Mw 833.4 25 mg 
 Dissolve in 6 ml buffer 
 Heat NADPH solution for 10 min in a water bath at 60°C to destroy NADP+ 
 
Standardising NADPH: 
 Add 1 ml 0.1 M TRIS buffer pH 8.0 (or any other buffer between pH 8 – 12) to 4 quarts cuvettes. 
 Read the blanks at 340 nm and write down the values. (NB remember which cuvette is which) 
 Pipette 20 µl NADH or NADPH solution into 2 of the cuvettes, invert to mix and read. 
 
 Correction factor: Reading 2 – Reading 1 
 NADH        X Total volume    = mM NADH or NADPH 
6270  Volume NADH         
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Generating NADPH standard curve:  
1. Using clear 96-well plates; make sure the microplate reader is switched on for at least 20 
minutes. Set the wavelength to 340nm. 
2. Make a solution of 50mM Tris Buffer from 0.2M stock, pH 7.4 
3. Dilute the original NADPH standard whose concentration has been measured above serially to 
get concentrations for a standard curve.  
4. By using the table below, pipette the required volumes in duplicate into each well.  
5. Add 250 µl 0.05 M (Tris or Imidazole) buffer to each well and read.  
6. Subtract the blank value from the rest of the measurements.  
7. Draw a graph with the absorbance values on the Y-axis and NADPH concentration (μM) on the 
X-axis.  
8. Determine the slope, expressed as absorbance units / μM 
 
NADPH Stock Solution: 4.89mM. 
Doing 1:1 serial dilutions; e.g. 50 μl 4.89 mM in 50 μl DH2O; this gives 2.44 mM. For three serial dilutions 
the concentrations of stock solutions are: 4.89 mM, 2.44 mM, 1.22 mM, 0.61 mM 
 
Table A.3: NADPH Standard Curve 
Standard Initial concentration 
(mM) 
Vol. 
Stock 
Vol. 0.5 Mm Tris Final concentration (μM) 
Blank - 0 250 - 
1 0.61 10 240 24.4 
2 1.22 10 240 48.8 
3 2.44 10 240 97.6 
4 4.89 10 240 195.6 
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Procedure for kinetic determination for aconitase activity 
1. Under “Protocol”, Open Aconitase-protocol 
2. SETTINGS: wavelength (340 nm), shaking duration 5secs before measurements, 25oC, Kinetics: 
read every min for 2 hrs. 
3. Add 15μl of each sample; 240 μl complete reaction Mix to each well 
4. Place the plate on the plate reader and Start readings immediately 
5. Repeat procedure until all samples are done. 
Export raw data to Aconitase template on excel sheet 
 
 
A.4 MCAD activity assay Methodology 
Principle 
This is a sensitive assay that detects the activity of FAD-dependent MCAD by monitoring the transfer of 
electrons from FAD to electron transferring flavoprotein (ETF) of the electron transport system (ETS). 
Octanoyl-CoA is the substrate that binds tightly to the enzyme active site and is oxidized to trans-Δ2-
enoyl-CoA. The organometallic oxidant ferricenium hexafluorophosphate (Fe+PF6-) is an excellent 
alternative electron acceptor that mimics the activity of physiology ETF. Fe+PF6- is reduced during this 
reaction and the rate of its reduction is measured at 300nm. 
 
 
 
 
 
 
 
 
                    Oct-CoA 
                                         FAD                     FADH2 
                                       MCAD                  ETF (Fe+PF6-)                                   
                                       FADH2                      FAD 
          Trans-Δ2-enoyl-CoA 
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Chemicals 
KH2PO4 (Sigma P5379), EDTA (Sigma E5134), Sodium tetrathionate (Sigma S5758), ferrocenium 
hexafluorophosphate (Sigma 388297), Octanoyl-CoA (Sigma 06877)    
Reaction Mix/Buffer: KH2PO4 + EDTA + Sodium tetrathionate + ferrocenium hexafluorophosphate 
Stock solutions     
Each component of the reaction mix except Fe+PF6- is measured and added together; made up to 100ml 
DH2O (pH 7.4). Complete reaction mix is made after determining FE+PF6-. 
                                                                                           
 KH2PO4                                100mM, Mw 136.086g/mol (1.36g in 100ml DH2O) 
EDTA                                     1mM, Mw 372.24g/mol (0.0372g in 100ml DH2O) 
Sodium tetrathionate        0.5mM, Mw 306.27g/mol (0.0153g in 100ml DH2O) 
Octanoyl-CoA                      0.5mM, Mw 898.73g/mol (5mg in 11.19 DH2O)  
Fe+PF6-                                  71.6μM, Mw 330.999g/mol (determined in spectrophotometer) 
 
In the spectrophotometer 
To make up a solution of Fe+PF6- that contains 71.6 μM, add a spatula (~10 mg) of Fe+PF6- powder in a 
1.5 ml microfuge tube, to this add 50 ml con HCL. Allow to dissolve for about 10minutes on bench, 
thereafter vortex vigorously for ~ 30 seconds then centrifuge at 10000 g X for 10minutes, 4oC. Collect 
the supernatant into a clean microfuge tube. Blank a cuvette containing 996.8 μl DH2O then add 3.25 
μl Fe+PF6-. Based on the extinction coefficient for Fe+PF6- a 71.6 μM concentration should read 0.308 Au 
at 300 nm. The method formula indicates how much Fe+PF6- to add to bring up to 1 ml.  
In the microplate reader 
The same steps as in the above for spectrophotometric reading of the absorbance are followed; 
however, the absorbance of 71.6 μM should read as 0.230 Au. 
In order to perform subsequent experiments using the microplate reader, a standard curve for Fe+PF6- 
should be generated according to the table below. 
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Table A.4: Determination of Ferrocenium (Fe+PF6-) standard 
Vol Concentrated Fe+PF6- 
(μl) 
Vol of reaction mix - Fe+PF6- (μl) Concentration (μM) 
0 290 0 
40 250 9.88 
90 200 22.2 
140 150 34.6 
190 100 46.9 
240 50 59.3 
290 0 71.6 
 
Procedure 
1. Turn on the BIOTEK Synergy (microplate reader), select Gen5 on the computer 
2. Under “Protocol”, Open Ferrocenium standard-protocol 
3. SETTINGS: wavelength (340 nm), shaking duration 5secs before measurements, 35oC 
4. Pipette volumes in table above to generate standard curve 
5. Read the plate 
6. Under “Protocol”, Open MCAD-protocol 
7. SETTINGS: wavelength (340 nm), shaking duration 5secs before measurements, 35oC, Kinetics: 
read every 5 mins for 30 mins. 
8. Add 20 μl of each sample; 220 μl complete reaction Mix to each well 
9. Place the plate on the plate reader and immediately add 50 μl Oct-CoA to each well using a 8-
channel pipette 
10. Start readings immediately 
11. Repeat procedure until all samples are done. 
12. Export raw data to MCAD template on excel sheet. 
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A.5 Citrate synthase Assay Methodology 
Principle 
This assay monitors the activity of citrate synthase indirectly by monitoring the reduction of NAD+-
dependent conversion of malate to oxaloacetate. Oxaloacetate condenses with acetyl-CoA to form 
citrate, a reaction catalysed by citrate synthase. This is a fluorometric assay that measures the 
production of NADH at known time intervals for 10 mins.  
 
 L-malate                                                              Oxaloacetate                                               Citrate 
 
 
Chemicals 
Tris Base                                                                                         Sigma T-1503 
Ethylenediaminetetraacetic acid (EDTA)                                 Sigma E-5134 
NAD+                                                                                               Roche 127 965 
L-Malate                                                                                         Sigma M-1125 
Malate dehydrogenase (MDH)                                                   Roche 127 256 
Acetyl-CoA                                                                                      Sigma A-2056 
NADH                                                                                               Roche 107 735 
 
Stock solutions 
Tris-buffer: Mw 121.1, 0.2 M pH 8.0, 12.11 g/100 ml dH2O 
EDTA: MW 372.2, 0.1 M, 3.722 g/100 ml dH2O 
NAD+: MW 663.4, 69 mg/1 ml dH2O, freeze at -800C in aliquots 
L-malate: MW 156.1, 78 mg/5 ml dH2O, freeze at -800C in aliquots 
Acetyl-CoA: MW 809.6, 3 mM, 5 mg/2 ml dH2O 
Malate dehydrogenase 
NAD+ NADH 
Acetyl-CoA 
Citrate synthase 
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NADH: MW 709.3, 36 mg/10 ml buffer, heat NADH solution for 10 min in a water bath at 600C to destroy 
NAD+ 
 
Reagent solutions: 
 Initial 
concentration 
25 ml: 50 ml: 120 ml: Final 
concentration 
Tris buffer 1 M 2.5 ml 5 ml 12 ml 0.1 M 
EDTA 0.1 M 625 μl 1.25 ml 3 ml 2.5 M 
NAD+ 0.1 M 125 μl 250 μl 600 μl 0.5 M 
L-malate 0.1 M 250 μl 500 μl 1.2 ml 1.0 mM 
MDH 5 mg/ml 40 μl 80 μl 192 ml 8 μg/ml 
Fill up with dH2O to desired volume; pH 8.0 
Standardising NADH 
 Add 1ml 0.1 M Tris buffer pH8 to 4 quarts cuvettes 
 Read the blanks at 340 nm and write down the values 
 Pipette 20 μl NADH solution into 2 of the cuvettes, invert to mix and read. 
Correction factor: Reading 2 – reading 1 
𝑁𝐴𝐷𝐻
6270
 𝑋 
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
𝑉𝑜𝑙𝑢𝑚𝑒 𝑁𝐴𝐷𝐻
= 𝑚𝑀 𝑁𝐴𝐷𝐻 
 
Generating NADH standard curve 
1. Use black plates; make sure the fluorometer is switched on for at least 20 minutes. Set 
the excitation wavelength to 340/11 nm and the emission wavelength to 460/40 nm. 
2. Read the background fluorescence of each well 
3. Dilute the original NADH standard 11 times (1:10) with dH2O 
4. By using the table below, pipette the required volumes in duplicate into each well. 
5. Add 250 μl 0.05 M tris buffer to each well and read 
6. Subtract the blank value from each NADH read 
7. Subtract the blank volume from the rest of the measurements 
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8. Draw a graph with the fluorescence values on the Y-axis and NADH concentration (μM) 
on the X-axis 
9. Determine the slope, expressed as fluorescent units/μM 
 
Table A.5: Development of NADH standards 
Standards Vol. NADH (μl) 
A 0 
B 2 
C 4 
D 6 
E 8 
F 10 
 
Procedure 
1. Turn on the BIOTEK synergy and start Gen5 on the computer 
2. Under “protocol”, open the citrate synthase-protocol 
3. Settings: 
a. Excitation wavelength: 340/11 
b. Emission wavelength: 460/40 
c. Optics position: top; sensitivity:100 
d. Shaking intensity = 3, shaking duration = 3 seconds before measurements 
e. Temperature: 250C 
f. Kinetics: read every 30seconds for 3 minutes 
4. Into the side of the plate, pipette 5 μl sample; 5 μl acetyl-CoA in the other side 
5. Place the plate on the reader and add 250 μl reagent solution to each using a 8-channel 
pipette 
6. Start the readings 
7. After completion, export to Microsoft excel 
8. Repeat procedure until all samples are done 
 
 
